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Abstract 
 
In recent years, the relationship between chirality and biological activity has been 
of increasing importance in Pharmaceutical Medicinal Chemistry. Actually, chirality can 
now be considered as one of the majors topics in the design, discovery, development and 
marketing of new drugs. Considering a particular biological activity we find frequently that 
one of the enantiomers is more potent than the other. The differences normally exhibited 
by the enantiomers in pharmacodynamics, pharmacokinetics and toxicity, makes the 
therapeutics with single enantiomers, comparing with racemates, of unquestionable 
advantages.  
Xanthones (9H-xanthon-9-ones) are privileged structures with a large range of 
biological and pharmacological activities. Among them, carboxyxanthone derivatives 
(XCars) are considered not only interesting bioactive compounds but they are also very 
important chemical substrates to obtain new compounds, such as chiral derivatives. Even 
though there is a large structural multiplicity of bioactive xanthonic compounds, there are 
only a few reports in literature about synthetic chiral derivatives of xanthones (CDXs). 
Moreover, CDXs represent an attractive area of chemical research, since they exhibit 
important biological/pharmacological activities. In some cases the biological activities are 
dependent on the stereochemistry of the CDXs.  
This dissertation reports the synthesis of new CDXs in enantiomerically pure form 
and the evaluation of their growth inhibitory effect on three human tumor cell lines. The 
evaluation of the enantiomeric purity of the synthesized CDXs by enantioselective liquid 
chromatography using (S,S)-Whelk-O1 chiral stationary phase was also considered. 
Three XCars were also successfully synthesized by a multi-step synthetic pathway. 
The CDXs were synthesized by coupling two XCars as chemical substrates with a 
variety of commercially available enantiomerically pure building blocks, using the reagent 
O-(benzotriazol-1-yl)-N-N-N’-N’-tetramethyluronium tetrafluoroborate (TBTU), with short 
reactions times (20 min to 1.5 h), excellent yields (from 95 to 99%) and very high 
enantiomeric purity (enantiomeric excess higher than 99%). 
Considering biological activity evaluation, some CDXs exhibited interesting results 
with enantioselectivity. Furthermore, the nature and positions of substituents on the 
xanthonic scaffold of CDXs demonstrate to have great influence on the growth inhibitory 
effect. 
 
Keywords: Chirality; Enantiomeric Purity; Single enantiomer; Chiral derivatives of 
xanthones; Enantioselectivity. 
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Resumo 
 
Nos últimos anos, a relação entre quiralidade e atividade biológica tem sido cada 
vez mais importante na área farmacêutica, com especial destaque para a Química 
Farmacêutica Medicinal. Atualmente, a quiralidade pode ser considerada como um dos 
grandes temas, no design, descoberta, desenvolvimento e comercialização de novos 
fármacos. Considerando as atividades biológicas frequentemente se constata que um dos 
enantiómeros é mais potente do que outro. As diferenças normalmente exibidas pelos 
enantiómeros, quer na farmacodinâmica, farmacocinética e toxicidade, reforçam a 
importância da utilização dos enantiómeros puros comparativamente com os racematos. 
Os derivados xantónicos são considerados estruturas privilegiadas com uma 
grande variedade de atividades biológicas e farmacológicas. Além disso, os derivados 
xantónicos carboxilados (XCars) são considerados não apenas interessantes compostos 
bioativos, mas também são substratos químicos muito importantes para a obtenção de 
novos compostos, como derivados xantónicos quirais (DXQs). Apesar da grande 
multiplicidade estrutural de compostos xantónicos bioativos, estão apenas descritos 
alguns exemplos na literatura sobre DXQs. Estes representam uma área de investigação 
muito apelativa, uma vez que estudos descritos têm demonstrado que exibem actividades 
biológicas/farmacológicas importantes. Além disso, em alguns casos as atividades 
biológicas são dependentes da estereoquímica do DXQ. 
Esta dissertação descreve a síntese de novos DXQs na forma 
enantiomericamente pura e a avaliação do efeito inibidor do crescimento de três linhas 
celulares tumorais humanas. Também foi considerada a avaliação da pureza 
enantiomérica dos DXQs sintetizados através de cromatografia líquida enantiosseletiva, 
utilizando a fase estacionária quiral (S,S)-Whelk-O1. Foram também sintetizadps com 
sucesso três XCars por uma via de síntese em múltiplos passos. 
Os DXQs foram sintetizados por acoplamento de dois XCars como substratos 
químicos com uma grande variedade de blocos moleculares enantiomericamente puros, 
disponíveis comercialmente, utilizando o reagente tetrafluoroborato de  O-(benzotriazol-1-
il)-N-N-N’-N’-tetrametilurónio (TBTU), com tempos reacionais curtos (20 min a 1,5 h), 
rendimentos excelentes (95 a 99%) e excesso enantiomerico normalmente maior que 
99%. 
Considerando a avaliação da atividade biológica, alguns DXQs apresentaram  
resultados interessantes de enantioseletividade. Além disso, a natureza e as posições 
dos substituintes no núcleo xantónico demonstraram ter influência sobre o efeito de 
inibição do crescimento celular. 
xiv 
 
Tanto quanto é do nosso conhecimento os vinte e quatro novos DXQs e um XCar 
são descritos pela primeira vez nesse trabalho. 
 
Palavra-chave: Quiralidade; Pureza enantiomérica; Enantiómeros puros; 
Derivados xantónicos quirais; Enantioseletividade.  
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General and Specific Objectives 
 
The general objective of this dissertation was the synthesis of new bioactive chiral 
derivatives of xanthones (CDXs) in enantiomerically pure form.  
Considering that this dissertation concerns Pharmaceutical Medicinal Chemistry 
biological evaluation was also considered. 
 
The specific objectives of this dissertation were: 
 Total synthesis of suitable functionalized xanthone derivatives as chemical 
substrates by multi-step pathways; 
 Optimizatione of the synthetic procedures using other reaction conditions; 
 Synthesis of a library of CDXs in enantiomerically pure form by using 
efficient, and mild coupling reactions of carboxyxanthone derivatives 
(XCars) with chiral building blocks; 
 Structure elucidation of the CDXs, as well as the xanthonic chemical 
subtracts and intermediates; 
 Evaluation of the enantiomeric purity of CDXs by liquid chromatography 
using a chiral stationary phase; 
 Screening the inhibitory effect of growth of human tumor cell lines in order 
to evaluate the in vitro behaviour for both enantiomers. 
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Structure and Organization of the Dissertation 
 
The present dissertation is structured in six chapters. 
 
Chapter 1 - Introduction 
 The first chapter deals with the theoretical background that supports the developed 
work, and is sub-divided into six subchapters. A brief introduction of chirality, 
enantioselectivity, trends in development of chiral drugs, enantiomeric purity, xanthones, 
with emphasis on both natural and synthetic chiral derivatives of xanthones (CDXs) are 
referred.  
 
Chapter 2 – Results and Discussion 
 This chapter focuses on the results and discussion of the developed research 
work, being sub-divided into three subchapters, concerning the synthesis, structure 
elucidation, determination of enantiomeric purity and biological evaluation of CDXs. 
 
Chapter 3 – Experimental  
 The third chapter describes the experimental methodologies used in this work 
related to the synthesis, determination of the enantiomeric purity and inhibition of growth 
of human tumor cell lines. 
 
Chapter 4 – Conclusions 
 The fourth chapter focuses on the main conclusions of the developed work, based 
on the proposed objectives. 
 
Chapter 5 – References 
 In this chapter, the references cited throughout the dissertation as well as the 
browsers used are presented. 
 
Chapter 6 – Appendixes 
 The chapter 6 is composed by two tables: Table 24 comprises the chemical 
structures of natural and synthetic CDXs and their biological activities described in 
literature. Table 25 comprises the chemical structures of the synthesized 
carboxyxanthone derivatives and CDXs 
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1. Chirality: basic principles  
Molecules are termed chiral when can exist in two enantiomeric forms, which are 
mirror images of each other and are non-superimposable in three dimensions (Figure 1). 
The words chiral and enantiomer are derived from Greek words cheir, meaning “hand" 
and enantios meaning “opposite", respectively.1 
Usually, enantiomerism is a result of a different configuration of four substituents 
(atoms or groups of atoms) arising from an atom, normally carbon. Such atom is called a 
stereogenic center or stereocenter. In addition to carbon, nitrogen, phosphorus, sulphur, 
selenium and boron can also produce stereogenic centers.2 Chirality is a property of the 
entire molecule, whereas a stereocenter is one of the causes of chirality. Although most of 
the chiral molecules show central chirality, with one or more stereogenic centers, there 
are also chiral molecules possessing axial or planar chirality.3 
 
 
Figure 1:  A chiral molecule and its mirror image in a tetrahedral configuration. Letters (a, b, c, and 
d) represent four different groups attached to a stereogenic center (adapted from4). 
 
Configuration can be assigned by the system Cahn-Ingold-Prelog, which 
expresses the configurations as (R) and (S) (from the Latin words rectus and sinister 
which means right and left, respectively) by a set of priority rules.5 
Chemically, enantiomers possess the same chemical formula and identical 
physicochemical properties when they are in an achiral environment, such as density, 
melting point, boiling point, among others. However, their ability to rotate plane-polarized 
light is different, and is a property commonly used to identify and characterize two 
enantiomeric forms: one enantiomer rotates the light to clockwise (dextrorotatory) and the 
other to counterclockwise (levorotatory), referred by the symbols (+) and (-), respectively. 
As a consequence, the enantiomers are frequently called optical isomers.6  
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2. Enantioselectivity 
It is well know that enantiomers of chiral drugs may possess differences in their 
pharmacodynamic and pharmacokinetic properties as a consequence of stereoselectivity 
in drug action and/ or disposition.6,7 In fact, the biotargets such as receptors and enzymes 
comprises chiral units being able to recognize and discriminate between enantiomers with 
high levels of selectivity (Figure 2). The enantioselectivity observed in drugs, causes 
different effects depending on the mode of interaction of the chiral small molecules with 
the biological macromolecules involved.8  
 
 
Figure 2: Only one of the two enantiomers shown can achieve three-point binding with the 
hypothetical binding site of the biotarget (adapted from9). 
 
Considering biological activities, when one enantiomer is responsible for the 
activity of interest, the other enantiomer could be inactive, or possess lower activity, or the 
some activity, or to be an antagonist or have a different activity that could be desirable or 
undesirable.10 Some examples illustrating the referred situations are presented in Table 
1.2,11-14 
Regarding a particular biological activity we find frequently that one of the 
enantiomers is more potent (eutomer) than the other (distomer), being the ratio of the 
potencies termed eudismic ratio.15  
 
 
Enantiomers 
Binding sites 
of the biotarget 
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Table 1: Examples of different biological activities regarding a pair of enantiomers. 
Drug (R)-enantiomer (S)-enantiomer 
 
Ketamine 
Hallucinogen 
Analgesic  
Hypnotic 
 
 
Ibuprofen 
Inactive Antiinﬂammatory 
 
Methyldopa 
Inactive Antihypertensive 
 
Penicillamine 
Mutagenic Antirheumatic 
 
Promethazine 
Antihistaminic Antihistaminic 
 
 
 
 
 
 
Propranolol 
Antiarrhythmic 
 
Antiarrhythmic 
(100X  more 
active) 
 
Methadone 
 
Analgesic 
25-50 X  more 
potent 
Analgesic 
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Besides these examples many others demonstrate that enantiomers of chiral 
drugs should be treated as independent entities rather than just different forms of the 
same drug. 
Considering pharmacokinetics, the distribution, metabolism and excretion 
processes usually favour one enantiomer over the other.16 The use of racemic mixtures 
typically results in stereoselective drug metabolism and may also contribute to the toxicity 
or adverse effects.17 Drug absorption is frequently a passive process which depends on 
properties such as lipophilicity and pKa, and therefore, in this case, the rate extend of 
absorption usually does not differ for enantiomers.18 On the other hand, active transport 
through membranes mediated by a protein transporter may be stereoselective. Regarding 
the distribution of the drug in plasma, if the plasma protein binding of enantiomers is 
different at the same total concentration, the active concentration at the site of action will 
differ.18 Biotransformation by drug-metabolizing enzymes exhibits the greatest degree of 
stereoselectivity of all processes contributing to drug disposition.19 For example, two 
enantiomers can be metabolized either at different rates or by different routes leading to 
the preferential metabolism of one enantiomer.18,19  
Thus, it can be stated that the enantioselectivity plays an essential role in 
pharmacodynamic, pharmacokinetic and toxicological events. Thus, it is essential to take 
into account the stereochemistry in drug development to obtain more therapeutic beneﬁts, 
namely more effective and safer drugs.20 
Accordingly, there are several advantages in using enantiomeric pure drugs 
compared to racemates as showed in Figure 3.21 
 
 
Figure 3: Advantages of enantiomeric pure drugs. 
 
Reduction of the total administered dose
Less side effects
Larger therapeutic window
Better estimation of dose-response
Less complex pharmacokinetics and 
drug interation
More selective pharmacological profile
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3. Trends in development of chiral drugs 
During a large period of time, many of the chiral drugs used in clinical practice 
were administered as racemates.10 In 1992, the Food and Drug Administration (FDA)22 
announced a set of guidelines addressing stereochemical topics concerning the 
submission of new drugs. Moreover, in 1993, the European Union Committee for 
Proprietary Medical Products (CPMP),23 issued formal guidelines called "Investigation of 
Chiral Active Substance". Considering guidelines for Japan, they are essentially 
consistent with the recommended by the USA and EU.24  
Since then, there was a large tendency to develop single enantiomeric drugs 
rather than racemates.25 The number of worldwide new molecular entities (NMEs) 
approved from 2001 to 2010 is presented in Figure 4 indicating that single enantiomers 
exceeded achirals while racemic drugs represented the minority category.26 
 
 
Figure 4: Number of worldwide-approved new molecular entities (NMEs) according to the chirality 
of the NME for the 2001–2010 period (adapted from 26). 
 
In addition to the regulatory requirements, also the advances in asymmetric 
syntheses and chiral separation methodologies, as well as the “chiral switch” 
phenomenum contributed to the increasing development of enantiomerically pure drugs 
rather than racemates.10 Accordingly, for several years, the pharmaceutical industry has 
invested in the "chiral switch", developing single enantiomers from chiral drugs that have 
been developed, claimed, approved and marketed previously as racemates. These new 
enantiomeric drugs received additional patent protection and a new generic name.2,27 
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In recent years, most of the blockbuster drugs in the pharmaceutical market were 
single enantiomers. In fact, in 2015, according to IMS Health, three single enantiomeric 
drugs were on the top ten best-selling drugs.28 The antiepileptic drug Lyrica® (pregabalin, 
Pfizer) was the sixth-most prescribed brand-name drug in that year, with about 10.1 
million prescriptions. The antihyperglycemic drug Januvia® (sitagliptin, Merck) afforded 
9.2 million prescriptions in USA, making it the eighth-most prescribed drug overall. The 
proton pump inhibitor Nexium® (esomeprazole, AstraZeneca), often indicated to treat acid 
reflux and heartburn, was the third-most prescribed drug in the USA, with 13.2 million 
prescriptions in that year.28   
 
4. Enantiomeric purity 
 
The need to generate both enantiomers in high enantiomeric purity for biological 
and pharmacological assays is crucial since the majority of the individual enantiomers 
exhibit distinct pharmacological profiles.29 
The enantiomerically pure drugs can be obtained either by preparative resolution 
of a racemate or by enantioselective synthesis of the desired enantiomer.30 While the 
enantioselective synthesis is useful when a large amount of one enantiomer is required, 
the enantioresolution more adequate to produce both enantiomers in the early stages of 
drug discovery process.31,32 Enantioresolution by chromatography usually furnishes both 
enantiomers with high enantiomeric purity that is required for biological, pharmacological 
or toxicological evaluations.25,33,34  
Regardless the strategy used to obtain the single enantiomers, it is crucial to 
evaluate their enantiomeric purity. The enantiomeric purity can be measured in a mixture 
of enantiomers. The composition is given by the enantiomeric excess (e.e.), which is an 
indicator of the enantiomeric purity.  
There are several methods of measuring e.e. including nuclear magnetic 
ressonance (NMR) spectroscopy, optical rotation, liquid chromatography (LC), gas 
chromatography (GC), capillary electrophoresis (CE), among others (Figure 5). 
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Figure 5: Common methods used to assess the enantiomeric purity. 
 
Comparatively with the other methods, LC using chiral stationary phases (CSPs) is 
the most common method employed for the determination of e.e. (Figure 6)25,35,36 
 
 
 
Figure 6: Distribution of the methods used for the determination of e.e., appeared in Journal of the 
American Chemical Society (2005) (adapted from 37). 
 
The e.e. can be measured by the percentage excess of the major enantiomer (E1) 
over the minor enantiomer (E2), determined by the relative percentages of the peak areas 
according to the following formula, where [E1] and [E2] are the peak area of each 
enantiomer.38  
 
% Enantiomeric excess =
[E1] − [E2] 
[E1] + [E2]
× 100          
 
Enantiomeric 
Purity NMR 
Optical 
Rotation
LC GC
CE
Others
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The closer the value is to 100%, the greater the enantiomeric purity. 
Alternatively the e.e. can be expressed in terms of molar fraction of each 
enantiomer: 
 
% Enantiomeric excess =
moles of one enantiomer − moles of other enantiomer
total moles of both enantiomers
× 100         
 
Over the last few decades, a growing number of different types of CSPs became 
available namely Pirkle-type, ion- and ligand-exchange type, based on proteins, 
polysaccharides, macrocyclic antibiotics, synthetic polymers, cyclodextrins, crown ethers, 
cyclofructans, among others.35 Nowadays, polysaccharide-based, macrocyclic antibiotics-
based and Pirkle-type CSPs are pointed out as the most useful and broadly applied.39,40  
 
5. Xanthone: a privileged structure 
 
Chemically, xanthone (9H-xanthon-9-ones) is a symmetrical compound possessing 
a dibenzo-ɣ-pyrone framework (Figure 7). Most of derivatives of this oxygen-containing 
heterocyclic scaffold exhibit fluorescence which can be an advantage since they can be 
used as fluorescence probes.30,41,42  
 
 
Figure 7: Xanthonic scaffold and numbering. 
This family of compounds is very appealing in Medicinal Chemistry, being 
classified as privileged structures, because different patterns of substitution have been 
found leading to a considerable variety of compounds that are able to interact with several 
biological targets.43-46 The xanthonic scaffold is not merely restricted to a pharmacophoric 
moiety role. In fact, it can also be a substituent group to modulate biological responses.43  
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Natural xanthones have been found in fungi, lichens and higher plants.47,48 Most 
natural xanthones from higher plants are associated with the families Clusiaceae  and 
Gentianaceae.47 Natural xanthones can be classified in six groups, depending on the 
nature of the substituents in their scaffold: simple oxygenated xanthones, xanthone 
glycosides, prenylated xanthones, xanthonolignoids, xanthone dimers and 
miscellaneous.41,47,49,50 
The biosynthetic pathway of xanthones only allows the presence of certain groups 
in specific positions of the xanthonic scaffold, which is a limiting factor for the structural 
natural variation. For this reason, it was considered using total synthesis. Total synthesis 
allows the access to structures that otherwise could not be reached if it is used the natural 
product, as a launching platform for molecular modification. Moreover, a greater amount 
of compounds is obtained. The total synthesis can also help to rationalize the structure-
activity relationship (SAR).42,51,52   
Considering synthetic xanthones, they can have simple groups as substituents in 
the dibenzo-γ-pirone scaffold like hydroxyl, methoxyl, methyl, carboxyl, but can also have 
more complex substituents such as epoxide, azole, aminoalcohol, sulfamoyl, 
methylthiocarboxylic acid, and dihydropyridine.43 A main objective of the synthesis of new 
derivatives is to develop more diverse and complex xanthones for biological activity even 
for SAR studies. The traditional methods to synthesize simple xanthones include: (I) via 
benzophenone intermediate - (a) the Grover, Shah, and Shah (GSS) reaction, and (b) 
condensation by Friedel-Crafts acylation, and (II) via diaryl ether intermediate (Ullman 
synthesis) (Figure 8).51 Additionally, other several routes with higher yields and less 
drastic experimental conditions have been developed.51,53  
 
 
Figure 8: General methods for the synthesis of xanthone derivatives. 
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6. Chiral derivatives of xanthones 
Recently, there has been an increase in the interest in new bioactive xanthones 
particularly in chiral derivatives of xanthones (CDXs). The importance of this class of 
compounds in Medicinal Chemistry, the promising biological/pharmacological activities of 
some chiral members of this family, the clinical advantages of a single enantiomer than a 
racemate, the scarce examples of synthetic CDXs described, are some of the reasons 
that can justify this trend. 
 
6.1. Natural chiral xanthones 
It is well known that many naturally occurring xanthones are chiral and present 
interesting biological activities. Some of them have been exhaustively studied, and have 
also been subsequently obtained by synthesis.47 Historically, the ﬁrst total synthesis of a 
naturally occurring xanthone was a euxanthone, described by Ullmann and Panchaud in 
1906.54  
Considering the large number of natural chiral xanthones, only some examples of 
compounds recently isolated will be presented highlighting their biological activities. The 
chemical structures of the natural CDXs and the associated biological activities are 
represented in Appendix (Table 24). 
 
6.1.1. Sterigmatocystin and derivatives 
Sterigmatocystin (1) was first isolated from the fungus Aspergillus versicolor in 
1953,55 and then from several other species over the years.54 Its structure was only 
subsequently determined by a combination of spectral and chemical degradation 
techniques. Over the last fifty years, various derivatives of sterigmatocystin were isolated 
and characterized.54 Among them, dihydrosterigmatocystin (2) and secosterigmatocystin 
(3) were isolated from the mangrove endophytic fungus ZSUH-36 in South China Sea.56 In 
the same year, sterigmatocystin (1) and these two derivatives (2,3) were also found in 
fungus of Kandelia candel.57 
The antitumor activity of sterigmatocystin (1) was first reported in 1975.58 The 
results demonstrated that this compound has inhibitory effect of the growth of transplanted 
leukemias P-388 and L1210 in mice. In 2007, the biological activity of sterigmatocystin (1) 
and its derivatives dihydrosterigmatocystin (2) and secosterigmatocystin (3) against 
human DNA topoisomerase type (hTOP) was tested, and none of the three xanthones 
exhibited significant inhibitory effect.57 
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6.1.2. Asperxanthone 
Asperxanthone (4) was isolated from the cultures of a marine-derived Aspergillus 
sp. collected in China sea water, in 2009.59 This natural xanthone is structurally related to 
the difuranoxanthones (1) and (2), in the sterigmatocystin series. This compound was 
identified using 2D NMR techniques and FAB-MS (fast atom bombardment mass 
spectrometry) and was shown to have inhibitory activity against the tobacco mosaic 
virus.54,59 
 
6.1.3. Chaetoxanthones 
Chaetoxanthones A (5), B (6), and C (7) were isolated from the marine-derived 
fungus Chaetomium sp. in 2008.60 Chaetoxanthones A (5) and B (6) are xanthones 
substituted with a dioxane/tetrahydropyran moiety rarely found in natural products. 
Chaetoxanthone C (7) is a chlorinated xanthone substituted with a tetrahydropyran ring. 
These chiral xanthones were tested in a series of in vitro bioassays for antiprotozoal 
activities and cytotoxic potency. Chaetoxanthone B (6) was found to be active against 
Plasmodium falciparum in the mid micromolar range, whereas Chaetoxanthone C (7) was 
active in low micromolar range against Trypanosoma cruzi, the causative organism of 
Chaga’s disease.54,60 
 
6.1.4. Psorospermin and derivatives 
Psorospermin (8) was isolated from the bark and roots of the African plant 
Psorospermum febrifugum in 1980.61,62 It is a natural fused tetracyclic xanthone containing 
two stereogenic centers with (2R,3’R)-stereochemistry and a reactive epoxide. The 
importance of the configuration and the functionality of the epoxydihydrofuran group for 
the in vivo activity have also been evaluated.43,63 The total synthesis of psorospermin (8) 
was reported for the first time in 2005, by obtaining the xanthone skeleton by the method 
of Grover et al.62 Psorospermin (8) was synthesized in thirteen steps with an overall yield 
of 1.7%. Psorospermin (8) revealed interesting biological activities showing antileukaemic, 
and also antitumor activity in several human cell lines.43,62 
Additionally, the (R,R)-stereochemistry of psorospermin (8) gave optimum DNA 
alkylation and antitumor activity, although all four possible stereoisomers show 
topoisomerase II-dependent alkylation.64 Molecular modeling rationalized this activity in 
terms of the energy of interaction with DNA and proximity of the epoxide ring CH2 to N7 of 
guanine.43,64 
Psorospermum febrifugum has yielded other compounds structurally similar to 
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psorospermin (8), without alkylating moieties, but with moderate activity against human 
tumor cell lines, such as psorofebrin (9) and isohydroxy-psorofebrin (10). Two ring-
constrained analogues of psorospermin were also synthesized, namely, stereoisomer 11,  
a ring-constrained (2R,3R)-form, and 12, a ring-constrained (2R,3S)-compound.64 
The chlorohydrin (13) retains the psorospermin-like DNA alkylation characteristics 
despite its rigid structure and high affinity for DNA. The chlorohydrin (13) and epoxide (12) 
showed increased cytotoxicity against a range number of human tumor cell lines, 
compared to isohydroxy-psorofebrin (10).64 
Another study described the synthesis of two diastereisomeric pairs of O-5-methyl 
psorospermin and evaluation of in vitro activity against a range of solid and hematopoietic 
tumors. The diastereisomeric pair having the naturally occurring enantiomer (2R,3R) (14) 
was the most active across all the cell lines tested. In subsequent studies using all four 
isomers of O-5-methyl psorospermin, the order of biological potency was (2R,3R) > 
(2R,3S) = (2S,3R) > (2S,3S).65 The compound (2R,3R) psorospermin (14) showed to be 
as effective as gemcitabine (chemotherapeutic drug) in slowing tumor growth in vivo in 
pancreatic cancer model.65   
 
6.1.5. Xanthonolignoids 
Xanthonolignoids are a natural class of compounds isolated from the plants of 
Clusiaceae family (Guttiferae).66 They possess a phenylpropane skeleton linked to a 
xanthonic scaffold by a dioxane ring, formed by radical oxidative coupling.67,68 Natural 
xanthonolignoids include kielcorins, cadensins, subalatin, calophyllumins and 
gemixanthone.68 The first xanthonolignoid described was based in 2,3,4-trioxygenated 
xanthone isolated in 1969 from Kielmeyera species.63 
Considering that xanthonolignoids are very interesting templates for molecular 
modifications, several xanthonolignoids were synthesized.63,68,69 Initially the main goal for 
synthesis was to help in structure elucidation of this class of compounds but, then, also to 
improve biological and physicochemical properties.68 
Both classic synthesis and biomimetic approaches have been used to obtain 
xanthonolignoids mainly kielcorin derivatives.68 The total synthesis of kielcorin derivatives 
requires several steps and drastic reaction conditions while the biomimetic way is based 
on natural building blocks and is achieved by an oxidative coupling of a suitable 
dihydroxyxanthone and a cinnamyl alcohol derivative, in the presence of an oxidizing 
agent at room temperature.68 
Pinto et al. have reported the first biomimetic synthesis of xanthonolignoids of the 
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kielcorin group. To obtain related bioactive compounds with a kielcorin framework, other 
constitutional isomers were synthesized by the same group (15-19). Once again, the 
synthetic approach was based on a biomimetic pathway as a model, by oxidative coupling 
of coniferyl alcohol, with an appropriate xanthone.69 In order to investigate the oxidative 
coupling reaction different oxidizing agents were used (e.g., Ag2O, Ag2CO3, and 
K3[Fe(CN)6]).  
Kielcorins (15-19) were evaluated for their in vitro effect on the growth of three 
human tumor cell lines, MCF-7 (breast), TK-10 (renal), UACC-62 (melanoma), and on the 
proliferation of human lymphocytes.69 The growth inhibitory effect was moderate but dose-
dependent, and influenced by the isomerism of the tested compounds. The compounds 
15, 16 were the most active. The inhibition of human lymphocyte proliferation induced by 
phytohemagglutinin (PHA) was detected.69 The high potency and selectivity observed for 
these compounds suggested that kielcorins may be an important model for developing 
potent and isoform-selective protein kinase C (PKC) inhibitors.43 Accordingly, the 
kielcorins 15-19 revealed an effect compatible with PKC inhibition similar to that exhibited 
by the well-established PKC inhibitor chelerythrine.70 Kielcorins 15 and 18 were evaluated 
and demonstrated protectives effects against tert-butylhydroperoxide-induced toxicity in 
freshly isolated rat hepatocytes.71 
In order to study if the growth inhibitory effects of these kielcorins (15-19) were 
depended on the stereochemistry, analytical LC methods using four carbamate of 
polysaccharide derivative CSPs and multimodal elution conditions were developed for 
their enantioresolution.72 The amylose tris-3,5-dimethylphenylcarbamate CSP was chosen 
to scale-up to the preparative resolution considering not only the highest enantioselectivity 
obtained for these chiral compounds but also due to low retention factors.72 Consequently, 
the enantiomers of the kielcolins 15–18 were efficiently separated by chiral LC in 
multimilligram scale. A solid-phase injection system was developed and combined with a 
closed loop recycling system to increase the productivity and recovery of the preparative 
process.31 The e.e. was also measured and was greater than 99% for each enantiomer, 
except for compound 15.31 
The inhibitory activity of the racemates 15-18 as well as of the corresponding 
enantiomers on in vitro growth of the human breast adenocarcinoma cell line MCF-7 was 
evaluated and compared. The most evident enantioselectivity was noticed between the 
racemate 16 (inactive) and the active enantiomers (+)-16 and (−)-16.31 
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6.1.6. Tajixanthones 
The tajixanthone family, curiously biosynthesized from a combination of xanthone 
and terpenoid-derived carbon units, includes the compound 20 and highly structurally 
related species shamixanthone (21) and their derivatives. Tajixanthone (20) and 
shamixanthone (21) were isolated for the first time in 1970, from cultures of Aspergillus 
variecolor, and then reisolated along the years.54,73 Their structures were determinate by 
several techniques including NMR spectroscopy and chemical degradation.73 The 
biosynthetic pathway to tajixanthone (20) and shamixanthone (21) was originally proposed 
based upon 13C and 1H feeding experiments.54,74,75 Subsequently, shamixanthone (21) 
was synthesized by the epoxidation of tajixanthone (20) with triphenylphosphine selenide 
and trifluoroacetic acid.74,75  
Tajixanthone (20) and shamixanthone (21) were tested against several tumor cell 
lines, including gastric, colon, lung and human hepatocarcinoma, in comparison with 
doxirubicin. Tajixanthone (20) showed widespread activity against all the tested cell 
lines.76 
6.2. Synthetic chiral xanthones 
Even though there is a large structural multiplicity of bioactive xanthonic 
compounds, there are only a few reports in literature about chiral synthetic derivatives. 
However, these CDXs seem to represent an attractive area of chemical research, since 
the described studies have shown that these xanthonic compounds exhibit important 
biological/pharmacological activities. Moreover, in some cases the biological activities are 
dependent on the stereochemistry of the CDXs.  
For the last years, searching of new synthetic CDXs with potential biological 
activities has remained in the area of interest particularly of two research groups, 
Madalena Pinto’s and Henry Marona’s groups. 
The chemical structures of the synthetic CDXs and the biological activities 
evaluated are included in Appendix (Table 24). 
 
6.2.1. DMXAA analogues 
DMXAA or dimethylxanthenone-4-acetic acid (Figure 9) is a simple carboxylated 
xanthone discovered in a SAR study involving a series of xanthone-4-acetic acids related 
to the parent compound flavone acetic acid.77 DMXAA is a tumor vascular-disrupting 
agent leading to a fast vascular collapse and tumor necrosis by immunomodulation and 
cytokines induction, particularly of tumor necrosis factor-α (TNF-α). DMXAA  also 
demonstrated a synergic effect when combined with chemotherapeutic agents.78 
43 
 
 
Figure 9: Chemical structure of DMXAA. 
 
DMXAA is not a chiral xanthone, but its analogues 22 and 23 are. Both 
enantiomers of the DMXAA analogue 5-methyl-α-methyl-xanthone acetic acid, (22a and 
22b), were separated and tested in vitro and in vivo tumor assays. Both were active, but 
the S-(+)-enantiomer (22b) was much more dose-dependent than the R-(-)-enantiomer 
(22a). Rewcastle et al. suggested that the enantiomers have different intrinsic activities, 
rather than differing in their metabolism.43,79  
 
 
6.2.2. Alkanolic chiral derivatives of xanthones 
Pinto et col. have a vast experience in synthesis and biological evaluation of 
xanthone derivatives30,80-82, and recently reported the synthesis of a library of CDXs in an 
enantiomerically pure form (24-38).30,34,72 Among the synthesized CDXs, the compounds 
25-30 and 33-38 are alkanolic, with the exception of CDXs 24, 31 and 32. 
The synthesis of all the CDXs (24-38) were achieved through the coupling of two 
carboxyxanthone derivatives, with both enantiomers of eight commercially available chiral 
building blocks, using O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 
(TBTU) as coupling reagent. TBTU has been widely used as efficient reagent for the 
synthesis of different classes of compounds such as peptides,83 amides, 
phenylhydrazides,84 esters. However, it was used for the first time to synthesize CDXs. 
The coupling reactions with the chiral blocks were performed at room temperature, 
showing short reactions times and excellent yields (ranging from 94% to 99%).30,82 
Carboxyxanthone derivatives demonstrated to be suitable molecular  basis to perform 
molecular modifications to obtain chiral derivatives. The commercial chiral blocks used, 
such as amines, amino alcohols, and amino esters, included both enantiomers of 
enantiomerically pure building blocks with no tendency towards racemization or 
enantiomeric interconversion, and having a primary amine as reactive group for amide 
formation.30 The synthetic methodology used to obtain the referred CDXs provided to be 
very efficient, broad-scope applicability, inexpensive and operationally simplest. Moreover, 
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the synthesis of CDXs may be easily scaled-up for both enantiomers in order to obtain 
available quantities for biological and pharmacological assays.30 
LC using different types of CSPs namely polysaccharide-based,34 macrocyclic 
antibiotics,85  and Pirkle-type82 was used to determine the enantiomeric purity of the 
synthesized CDXs. The enantioselective LC method using polysaccharide-based CSPs 
under multimodal elution conditions afforded very high resolutions with short 
chromatographic runs. The best performances were achieved on amylose tris-3,5-
dimethylphenylcarbamate stationary phase under polar organic elution conditions. The 
resolution achieved allowed the determination of the e.e. for all CDXs, affording values 
higher than 99%. This study also explored the influence of different mobile phases as well 
as of the structural features of the CDXs on their chiral discrimination by the 
polysaccharide-based CSPs.34  
Considering the macrocyclic antibiotic CSPs, the best enantioselectivity and 
resolution were achieved on Chirobiotic R and Chirobiotic T CSPs under normal elution 
conditions. The optimized chiral LC conditions were successfully employed for the 
accurate determination of the enantiomeric purity of eight enantiomeric mixtures of CDXs 
(25-28), always higher than 99%. Under these elution conditions the (R)-enantiomer of all 
the CDXs evaluated was the first to elute.85 
Regarding the Pirkle-type CSPs, the (S,S)-Whelk-O1 CSP showed the best 
performance for the resolution of the CDXs evaluated, presenting very high 
enantioselectivity for CDXs with aromatic group linked to the chiral moiety.86 Polar organic 
elution mode presented the best chromatographic parameters allowing good resolutions 
and lower run time. 
Both enantiomers of the synthesized CDXs (24-38) were evaluated for their effect 
on the in vitro growth of three human tumor cell lines, namely A375-C5 (melanoma), MCF-
7 (breast adenocarcinoma), and NCI-H460 (non-small cell lung cancer).30 The results 
obtained demonstrate that some CDXs exhibited interesting growth inhibitory effects on 
the tumor cell lines. The most active CDX in all human tumor cell lines was compound 
30c.30 Furthermore, it is important to highlight that the effects on the growth of the human 
tumor cell lines were attributed not only to the nature and positions of substituents on the 
xanthonic scaffold, but also, in some cases, were associated with the stereochemistry of 
the CDXs concerning enantioselectivity results. Interesting examples of enantioselectivity 
were observed between the enantiomeric pairs of CDXs 24a and 24b, 26a and 26b, 30c 
and 30d.30 These promising results were an inspiration for our group to enlarge the library 
of bioactive CDXs. 
Taking into account that these CDXs have molecular moieties structurally very 
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similar to local anesthetics, the ability to block compound action potentials (CAP) at the 
isolated rat sciatic nerve was also investigated. In fact, these compounds are structurally 
similar to dibucaine, lidocaine, bupivacaine with which they might share common 
molecular moieties, and, consequently, the same pharmacophore. The absence of a 
tertiary amine is the most significant difference regarding the pharmacophoric descriptors 
for local anesthetics. The CDXs 24b, 25b and 26b were chosen for biological evaluation 
and the results suggested that the nerve conduction blockade might result predominantly 
from an action on Na+ ionic currents. It was also investigated if the CDXs could prevent 
hypotonic haemolysis on rat erythrocytes. However, data suggested that CDXs 24b, 25b 
and 26b caused no significant protection against hypotonic when applied in 
concentrations high enough to block the sciatic nerve conduction in the rat.82  
Considering the inspiring evolution of CSPs based on small molecules developed 
by Pirkle and co-workers,20 Pinto et col. selected three CDXs (25b, 27a, 31b) and 
developed and patented new CSPs.87 The CSPs obtained are based on a completely 
different type of small molecules from those commercial available. Accordingly, the CDXs 
when being connected to a chromatographic support may consist of good CSPs for LC 
due to the structural features of the xanthonic scaffold which gives the possibility to 
perform different types of interactions (hydrogen, dipole–dipole and π–π), and the intrinsic 
enantioselectivity of the chiral moiety substituent.20 The enantioselective capability of 
these CSPs was evaluated by LC under multimodal elution conditions using several 
chemical classes of chiral compounds, showing promising results. 
As referred before, Marona et col. also described the synthesis and biological 
activity evaluation of a series of alkanolic CDXs (39-75, 102-107).44,88-93 CDXs 39-54, 64-
69 were synthesized by condensation of an appropriate 2-bromomethylxanthone or 2-
bromomethyl-7-chloroxanthone with the corresponding aminoalkanol in toluene, in the 
presence of anhydrous potassium carbonate.44,88,94 Some of them were isolated, 
characterized and examined as salts. The exchange of secondary amino group of 
compounds 48, 48a and 48b for a tertiary amino group (53, 53a and 53b) was generated 
by reductive N-methylation.44   
Compounds 55-63 were synthesized by the amination of (+-)-3-(2,3-epoxy)-
propoxy)-xanthone in n-propanol, or 2-methyl-6-hydroxyxanthone using propylene 
epichlorohydrin, in the presence of sodium hydroxide and water.91 
The synthesis of compounds 70-75 evolved as a multi-step process. At first, 
substituted benzoic acid reacted with 2- or 4-methylphenol in two steps involving Ullmann 
condensation and electrophylic addition. The intermediate methyl derivatives of 
substituted xanthone were used in the reaction with N-bromosuccinimide giving 
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appropriate bromide derivatives. The last step comprised an aminolysis by means of 
appropriate aminoalkanol carried out in toluene in the presence of anhydrous K2CO3.95 
All the synthesized CDXs (39-75, 102-107) were evaluated for anticonvulsant 
activity.44,88-91,93,94,96-98 The studies involved three kind of tests: maximal electroshock-
induced seizerus (MES), subcutaneous pentetrazole seizure threshold (scMet), and 
neurological toxicity (TOX).  
In one of the first MES assays in mice, 2-amino-1-propanol-, 1-amino-2-propanol 
and 1-amino-2-butanol derivatives of 6-methoxy- or 6-chloroxanthone were the most 
interesting compounds. In fact, the results indicated that compound 43 was the most 
active.44 Further study compared the anticonvulsant activity of CDX 43 (racemate) with the 
single enantiomers (43a, 43b). All the compounds showed excellent results, and no 
significant differences were observed in the anticonvulsant activity of the single 
enantiomers compared with the racemate.99 
Additionally, the enantiomeric purity of 43a and 43b was determined by liquid 
chromatography–mass spectrometry method with an electrospray ionization interface 
(ESI-LC/MS). The separation of the two enantiomers (43a and 43b) was carried out on 
the commercially available cellulose tris-(3,5-dimethylphenyl carbamate) CSP, Chiralcel® 
OD-RH, giving e.e. values higher than 99.9%.90 
Interesting anticonvulsant results were also observed with alkanolic chiral 
derivatives of 7-chloroxanthone (48 and 53) which displayed anti-MES activity 
corresponding with that for phenytoin, carbamazepine and valproate.88 Moreover, it is 
important to highlight that in this study some cases of enantioselectivity were observed. 
For example, although enantiomers 48a and 48b showed anticonvulsant activity, the (S)-
enantiomer (48b) was more neurotoxic. Furthermore, considering the compound 53 
(racemate), the (R)-enantiomer (53a) in comparison to (S)-enantiomer (53b) showed 
higher anticonvulsant activity.88,96 A further study including chiral aminoalkanol derivatives 
substituted in position 2 of xanthonic scaffold (structures not shown) also emphasized the 
importance to examine biologically enantiomers rather racemates.97  
Additionally, a structure-anticonvulsant activity relationship study was described 
including series of aminoalkanol derivatives of 6-methoxy- or 7-chloro-2-methylxanthone 
as well as 6-methoxy-4-methylxanthone (71-75).95 All the compounds showed activity in 
the MES screen which is recognized as one of the two most widely used seizures models 
for early identification of candidate anticonvulsants. The tested compounds were 
evaluated in the form of racemic mixture and some additionally in the form of single 
enantiomers to determine stereochemistry and activity relationship. In fact, as 
demonstrated before,95 stereochemistry is one of the factors that can potentially 
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influenced anticonvulsant activity of the CDXs. However, considering anti-MES activity it 
was not possible to establish relationship between stereochemistry and anticonvulsant 
properties because all sets of compound gave different results. Racemate and 
enantiomers showed either similar results or diverged in duration of activity or lower 
effective doses. However, the anticonvulsant activity was associated with both 
aminoalkanol type and respective configuration as well as the place of substitution in the 
xanthonic scaffold.95  
The overall results from several studies of Marona et col. 44,88-91,94,96-98 are quite 
encouraging and suggested that in the group of xanthone derivatives new potential 
anticonvulsants might be found. 
Some of alkanolic CDXs were also evaluated for cardiovascular activity,91,94,98,100 
including antiarrhythmic, hypotensive, 1- and β1-adrenergic blocking activities, effect on 
the normal electrocardiogram and influence on central nervous system (CNS). Among the 
investigated compounds, some of them exhibited significant antiarrhythmic and/or 
hypotensive activity. For example, compounds 105 and 106 revealed the strongest anti-
arrhythmic activity in the adrenaline-induced model of arrhythmia. Additionally, compound 
106 was also the most potent concerning hypotensive activity.93  
The effects on platelet aggregation of some racemic CDXs 39-41, 55 and 56, and 
the enantiomeric pure CDX 53a were evaluated and showed interesting results. The most 
active and promising compound was 53a which nearly completely inhibited the thrombin 
aggregation concentration (TAC).101 The results indicate that the presence of the 2-N-
methylamino-1-butanol at position 2 and the chloride atom at the 7-position of the 
xanthonic scaffold promotes antiplatelets activity.    
Alkanolic CDXs 39, 42, 43, and 64 were used to assess mutagenic and 
antimutagenic activity in assays using the Vibrio Harvey.102 According to the results 
obtained, the most beneficial mutagenic and antimutagenic profiles were observed for 
compound 64. A modification of the chemical structure of compound 64 by the 
replacement of the hydroxyl group by a chloride improved considerably the antimutagenic 
activity. Thus, antimutagenic potency reached a maximum with the presence of tertiary 
amine and one chloride atom in the side chain. Minimal activity was showed to compound 
43 and no antimutagenic activity was observed for compound 39.102 
 
6.2.3. Chiral xanthones containing piperazine moieties and analogues 
Several CDXs containing piperazine moieties (78-81, 83-101) and analogues (76, 
77, 82) were synthesized and their biological activity evaluated by Marona’s 
group.45,46,89,91,92,101,103-105 
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The 2-hydroxyxanthone was the building block to synthesize compounds 78-85 
using epichorhydrin in presence of pyridine.89 Compounds 86-92 were synthesized by 
amination of 2-(2-bromoethoxy)-9H-xanthen-9-one and derivatives in n-propanol or 
toluene in the presence of K2CO3.103 The compounds 93-95 were obtained by amination of 
4-[(2,3-epoxy)propoxy]xanthone  with appropriate 1-piperazine derivatives in n-propanol.45 
Chiral compounds 96-101 were obtained by amination of respective parent compounds 105 
with appropriate amines in n-propanol. In addition, compound 98 was obtained from 
compound 96 by acetylation. In order to optimize synthetic methodologies, CDX 96 was 
obtained using an alternative method including (R,S)-4-(3-chloro-2-hydroxypropoxy)-9H-
xanthen-9-one as intermediate.105 
CDXs 78-85 were evaluated for anticonvulsant activity in the MES- and 
subcutaneous pentylenetrazole-induzed seizures in mice and rats.89 Among them, the 
most promising compound was CDX 79 which was active in both the anticonvulsant tests. 
Moreover, the influence on the platelet aggregation of CDXs 76, 77, 80 and 82 
was evaluated by using adenosine-5'-diphosphate (ADP), sodium arachidonate (AA) or 
thrombin as the aggregating agents.101 CDXs 77 and 82 were active, inducing 80-90% 
inhibition of thrombin-stimulated platelet aggregation. 
Considering that the xanthone itself proved to possess vasorelaxating properties in 
thoracic aorta isolated from rats 106 and the strongest hypotensive effects were observed 
for compounds containing piperazine moiety,105 several compounds that combining 
xanthone nucleus and piperazine rings (86-101) were evaluated for anti-arrhythmic and/or 
antihypertensive activities.45,46,103,105 It is important to emphasize that CDXs 86 and 89 
demonstrated to possess significant anti-arrhythmic activity in the adrenaline-induced 
model of arrhythmia.103 The strongest hypotensive activity which persisted for 60 minutes 
was also associated to compound 86. 
Additionally, in another study related to the some biological activities, compounds 
93 was the most promising in its effect on circulatory system. Moreover, this CDX 
diminished arterial blood pressure by about 40% during one hour.45 
A recent cardiovascular activity study of several CDXs (96-101) was described 
including the following pharmacological experiments: the binding affinity for 
adrenoceptors, the influence on the normal electrocardiogram, the effect on the arterial 
blood pressure and prophylactic antiarrhythmic activity in adrenaline induced model of 
arrhythmia (rats, iv).105 The CDXs 96 and 97 revealed to act as potential antiarrhythmics in 
adrenaline induced model of arrhythmia in rats after intravenous injection. The results 
obtained were quite promising and suggested that in the group of xanthone derivatives 
new potential antiarrhythmics and hypotensives might be found. 
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A series of some chiral derivatives of 2-xanthone with piperazine moiety (78-85) 
was evaluated for their activity against M. tuberculosis. The highest level of activity 
against M. tuberculosis was observed for compound 81, which exhibited 94% growth 
inhibition. This compound was also examined for its anti- M. avium activity as well as 
cytotoxicity, showing insignificant anti M. avium activity and cytotoxic effects.104 
In summary, CDXs, from both natural and synthetic origin, represent an attractive 
area of in Pharmaceutical Medicinal Chemistry concerning their broad spectrum of 
biological/pharmacological activities. Natural products may undoubtedly correspond to an 
important novel source of bioactive chiral xanthones of great interest, with synthetic 
methodologies also furnishing interesting CDXs, particularly single enantiomers. 
Moreover, naturally occurring chiral xanthones have been subsequently obtained by 
synthesis. CDXs revealed interesting biological activities, such as antitumor, 
antiarrhythmic, anticonvulsant, antibacterial, antiplatelet, and antihypertensive, among 
others. The results are encouraging and suggested that in the group of xanthone 
derivatives new potential antitumor, anticonvulsant and antiarrhythmic agents might be 
found. Moreover, interesting examples showed that biological activities were dependent 
on the stereochemistry of the CDXs. The referred cases highlight the essential role of 
development of efficient methodologies to synthesize bioactive chiral xanthonic 
derivatives in high yields and with high enantiomeric purity.  
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1. CHEMISTRY  
 
1.1. Synthesis of carboxyxanthone derivatives  
Carboxyxanthone derivatives (XCars) are not only interesting bioactive 
compounds 79,107 but they are also very important chemical substrates to obtain new chiral 
derivatives.90 Herein, the total synthesis of three different XCars (Figure 10 and Erro! A 
origem da referência não foi encontrada. of Appendix), namely 6-methoxy-9-oxo-9H-
xanthene-2-carboxylic acid (XCar-2, 108), 8-methoxy-9-oxo-9H-xanthene-2-carboxylic 
acid (XCar-3, 109) and 5,7-dimethyl-9-oxo-9H-xanthene-2-carboxylic acid (XCar-5, 110), 
was carried out by a multi-step pathway. To our knowledge, XCar-5 (110) is described 
here for the first time. All the XCars were obtained via modified Ullmann reaction with the 
formation of diaryl ether intermediates starting from an aryl bromide and a phenol.  
 
 
 
Figure 10: Chemical structures of XCar-2 (108), XCar-3 (109) and XCar-5 (110). 
 
 
1.1.1. Synthesis of 6-methoxy-9-oxo-9H-xanthene-2-carboxylic acid (XCar-2, 
108) and XCar-3 (109)  
The multi-step pathway for synthesis of XCar-2 (108) and XCar-3 (109) is 
illustrated on Scheme 1. 
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Scheme 1:  Total synthesis of 6-methoxy-9-oxo-9H-xanthene-2-carboxylic acid (XCar2, 108) and 
8-methoxy-9-oxo- 9H-xanthene-2-carboxylic acid (XCar3, 109). 
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The two carboxyxanthones, XCar-2 (108) and XCar-3 (109), were synthesized via 
Ullmann reaction, with the formation of the diaryl ether intermediate 114 from dimethyl 4-
bromoisophthalate (112) and 3-methoxyphenol (113). The aryl bromide 112 was 
previously prepared from the corresponding carboxylic acid (111) by Fisher esterification 
(reaction a). 
The Ullmann condensation (reaction b) between 112 and 113 under the catalytic 
action of CuI and picolinic acid in combination with K3PO4 in dimethyl sulfoxide (DMSO) 
provided the diaryl ether 114. This coupling reaction was carried out at 80
 
°C under 
nitrogen atmosphere for 28 h to give the compound 114 in excellent yield (96%).  The 
K3PO4/DMSO was used as a base/solvent combination and picolinic acid as a ligand for 
copper.  
In a previous work, our group used N,N-dimethyl glycine and the stronger base 
Cs2CO3 to promote the Ullmann coupling reaction between the same building blocks using 
higher reaction temperature, in shorter reaction time but with lower yield.82 As expected, 
this reaction had also better yield than the traditional method using copper-catalyzed in 
polar solvents typically pyridine and K2CO3 at high reaction temperature as described 
before.107  
The reaction conditions, time and yield of the three Ullmann reactions are shown in 
Table 2. Consequently, the optimization performed on Ullmann reaction using a different 
solvent, catalysts and reaction conditions was effective due to the lower reaction 
temperature and remarkable yield. Additionally, picolinic acid is economically more 
attractive.  
The diaryl ether (114) was dissolved in a mixture of tetrahydrofuran/methanol and 
5M NaOH solution in order to hydrolyse the methyl esters (reaction c), affording the 
compound 115. An intramolecular acylation of diaryl ether 115 (reaction d), using 
phosphorus pentoxide and methane sulfonic acid (Eaton’s reagent) at room temperature 
afforded two compounds, the XCar-2 (108) and its isomer XCar-3 (109) in different yields. 
The separation of the two isomers was achieved through a Fisher esterification (reaction 
e) followed by flash column chromatography. After separation, the methyl esters of 
compounds 116 and 117 were hydrolysed (reactions f and g, respectively) in alkaline 
medium yielding the carboxyxanthones XCar-2 (108) and XCar-3 (109), respectively. This 
synthetic pathway has already been described,82 but here was modified regarding reaction 
conditions and purification techniques. 
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Table 2: Optimization of Ulmann reaction. 
Reagents Time and temp. Yield 
CuI, Pyridine, K2CO3  24 h, 115 0C 32% 107 
N,N-Dimethyl glycine, 
CuI, Cs2CO3, Dioxane, N2  
14 h, 90 0C 54% 82 
CuI, K3PO4, Picolinic 
Acid, DMSO, N2 
24 h, 80 0C 96% 
 
 
1.1.2. Synthesis of 5,7-dimethyl-9-oxo-9H-xanthene-2-carboxylic acid (XCar-5, 
110) 
The multi-step pathway for synthesis of XCar-5 (110) is illustrated on Scheme 2. 
The first step to synthesize XCar-5 (110) comprised a Fisher esterification reaction 
(reaction a), common to the synthetic pathway of XCar-2 (108) and XCar-3 (109) 
(Scheme 1).  
The Ullmann condensation between the synthesized aryl bromide (112) and 2,4-
dimethylphenol (118) (reaction h), under the catalytic action of CuI and picolinic acid in 
combination with K3PO4 in DMSO, provided the diaryl ether 119 (Scheme 2). Once again, 
the coupling reaction was carried out at 80
 
°C under nitrogen atmosphere for 28 h to give 
the compound 119.  
The diaryl ether 119 was dissolved in a mixture of tetrahydrofuran/methanol and 
5M NaOH solution to hydrolyze the methyl esters (reaction i), affording the compound 
120.  
An intramolecular acylation of the diaryl ether 120, using phosphorus pentoxide 
and methane sulfonic acid at room temperature (reaction j) afforded the XCar 5 (110). 
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Scheme 2: Total synthesis of 5,7-dimethyl-9-oxo-9H-xanthene-2-carboxylic acid (XCar-5, 110). 
 
1.2. Structure elucidation of carboxyxanthone derivatives and their 
intermediates 
All the XCars and their intermediates were characterized by IR, 1H and 13C NMR. 
(108,109,112,114-117 also characterized by MS). XCar 5 (110) was also characterized by 
HMBC and HSQC techniques. 
 
HOOC COOH
Br
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H3COOC COOCH3
Br
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CH3
CH3
COOCH3
H3COOC
OH
CH3
CH3
(118)
(119)
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O
CH3
CH3
COOH
HOOC
(120)
j)
O
CH3
H3C COOH
O
(110)
Reagents and conditions:  a) Methanol, H2SO4, reflux, 17 h; h) CuI, K3PO4, Picolinic 
acid, Dimethyl sulfoxide, N2, 80 ºC, 28 h;  i) Methanol/Tetrahydrofuran (1:1 v/v), 5M NaOH, 
room temp., 18 h; j) P2O5, CH3SO3H, room temp., 48 h.
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1.2.1. Structure elucidation of dimethyl 4-bromoisophthalate (112) 
 
 
(112) 
 
Dimethyl 4-bromoisopthalate (112) resulted from the esterification of 4-
bromoisophthalic acid (111). The IR, 1H and 13C NMR, and MS allowed the structure 
elucidation of compound 112.  
Comparing the IR spectra of compounds 112 and 111 (Table 3), it is important to 
highlight that two broad bands at 2625 and 2880 cm-1, corresponding to O-H bond of 
carboxylic acids, are only observed on spectrum of compound 111. Moreover, the shift of 
the band at 1687 cm-1 (C=O bond of carboxylic acid) to 1754 cm-1 (C=O bond of ester) 
confirmed that ocurred transformation from COOH to COOCH3. 
 
 
Table 3: IR data of 4-bromoisophthalic acid (111) and dimethyl 4-bromoisophthalate (112). 
Bond 
 (cm-1) 
(111) (112) 
C=O 1687 1754 
C-O 1255 1309 and 1253   
O-H  2625 and 2880 -- 
C=C (aromatic) 930 929 
 
Considering the 1H NMR spectrum of compound 112 (Figure 11) it is important to 
highlight the presence of two singlets, at 3.95 ppm and 3.93 ppm, with integration for three 
protons each, corresponding to the protons of two COOCH3. In the 13C NMR spectrum of 
compound 112 it is possible to observe the presence of two signals at 52.7 and 52.5 ppm 
corresponding to the carbons C(1’’)OOCH3 and C(1’)OOCH3, respectively.  
 
H3COOC COOCH3
Br
1
2
3
4
5
6
1' 1''
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Figure 11: 1H NMR (CDCl3, 300.13 MHz) and 13C NMR (CDCl3, 75.47 MHz) of dimethyl 4-
bromoisopthalate (112). 
 
MS spectra of compound 112 showed the following peaks and m/z values: 273 
[M]+. (100), 256 (9), 240 (13), 221 (6), 209 (8), 203 (11). The presence of the respective 
molecular ion peak at the expected m/z values, confirmed the success of the reaction. 
 
1.2.2. Structure elucidation of dimethyl 4-(3’-methoxyphenoxy)isophthalate 
(114) and 4-(3’-methoxyphenoxy)isophthalic acid (115)  
 
                       
                                      (114)                                                             (115) 
 
Dimethyl 4-(3’-methoxyphenoxy)isophthalate (114) resulted from the Ullmann 
diaryl ether coupling of dimethyl 4-bromoisophthalate (112) and 3-methoxyphenol (113). 
The compound 4-(3’-methoxyphenoxy)isophthalic acid (115) resulted from the hydrolysis 
of the methyl esters of compound 114. The IR, 1H and 13C NMR, and MS allowed the 
structure elucidation of compounds 114 and 115. 
Comparing the IR spectrum of compound 114 (Table 4) with the spectrum of its 
precursor 112 (Table 3) showed the presence of the absortion bands corresponding to the 
C=O and to aromatic C=C in both spectra. The main difference important to highlight is 
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the presence of the absorption band C-O-C corresponding to the ether bond (1229 cm-1 ) 
the IR spectra of both compounds (112 and 114).  
Comparing the IR spectra of compounds 114 and 115 (Table 4), it can be seen the 
presence of the absorption bands corresponding to the C=C aromatic ring bond and to C-
O-C ether bond in both spectra, with IR frequencies not significantly different. The 
presence of a broad absorption band at 2907 cm-1, corresponding to the of O-H carboxyl 
acid bond, on spectrum of compound 115 confirmed that the reaction occurred 
successfully. Moreover, the shift of the band at 1719 cm-1 and 1724 cm-1 (C=O of 
COOCH3) to 1680 cm-1 and 1694cm-1 (C=O of COOH) confirmed that occurred 
transformation from COOCH3 to COOH. 
 
Table 4: IR data of dimethyl 4-(3’-methoxyphenoxy)isophthalate (114) and 4-(3’-  
methoxyphenoxy)isophthalic acid (115). 
Bond 
 (cm-1) 
(114) (115) 
C=C (aromatic) 1613 and 1488 1601 and 1486 
C=O  1724 and 1719 1694 and 1680 
O-H  --- 2907 
C-O (ester) 1153 --- 
Ar-OCH3 1274 1271 
C-O-C 1229 1265 
 
The 1H and 13C NMR data obtained for compounds 114 (Figure 12) and 115 
(Figure 13) presented 𝜹 values consistent to their proposed structures. 
The 1H NMR spectrum of compound 114, compared to the spectrum of its 
precursor (112) (Figure 11), presented new signals such as one singlet at 𝜹 3.79 ppm, 
integration for three protons, corresponding to Ar-OCH3, which confirmed the desired 
transformation. 
Compounds 114 and 115 showed similar NMR profiles with respect to the 
aromatic protons with similar chemical shifts and coupling constants. The most significant 
difference in the 1H NMR spectra is to the absence in compound 115 spectrum of two 
singlets at 𝜹 3.89 ppm and 𝜹 3.93 ppm, with the integration for three protons each, 
corresponding to the protons of the two COOCH3 methyl groups of compound 114. This 
difference confirmed the success of the desired transformation.  
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The 13C NMR spectrum of compound 114 compared to the spectrum of its 
precursor (112), presented a signal at 𝜹 55.4 ppm, corresponding to the carbon of Ar-
OCH3 group, and associated to the signals of aromatic carbons, confirmed the desired 
transformation.  
The most significant differences between the 13C NMR spectra of compounds 114 
and 115 correspond to the shift of carbons signals from 𝜹 165.3 and 165.7 ppm (ester) to 
𝜹 179.3 ppm (carboxylic acid), and the absence, in the spectrum of compound 115, of two 
signals at 𝜹 52.2 and 52.3 ppm, corresponding to the carbons of the two COOCH3 methyl 
groups.  
The referred differences confirmed the success of the transformation. 
 
 
Figure 12: 1H NMR (CDCl3, 300.13 MHz) and 13C NMR (CDCl3, 75.47 MHz) of dimethyl 4-(3’-
methoxyphenoxy)isophthalate (114). 
 
 
Figure 13: 1H NMR (CDCl3, 300.13 MHz) and 13C NMR (CDCl3, 75.47 MHz) of 4-(3’-
methoxyphenoxy)isophthalic acid (115). 
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MS spectra of compound 114 showed the following peaks and m/z values: 316 
[M]+. (100), 285 [M-OCH3]+. (55), 253 (54), 242 (10), 225 (16), 213 (12), 198 (25), 138 
(15), 127 (10), 92 (15), 83 (14), 64 (11). The intense signal at 316 corresponding to the 
peak of the molecular ion, the base peak is consistent with the proposed structure. 
MS spectra of compound 115 showed the following peaks and m/z values: 288 
[M]+. (100), 271 (10), 257 [M-OCH3] +. (12), 227 (11), 199 (23), 165 (61), 124 (63), 92 
(23), 77 (20), 64 (19). The molecular ion peak at 288, which also corresponded to the 
most intense peak of the spectrum is consistent with the proposed structure. 
 
 
1.2.3. Structure elucidation of methyl 6-methoxy-9-oxo-9H-xanthene-2-
carboxylate (116) and 6-methoxy-9-oxo-9H-xanthene-2-carboxylic acid 
(XCar2, 108)  
 
 
                          (116)                                                           (108) 
 
The 6-methoxy-9-oxo-9H-xanthene-2-carboxylic acid (XCar-2, 108) resulted from an 
intramolecular acylation reaction of the 4-(3’-methoxyphenoxy)isophthalic acid (115). 
Methyl 6-methoxy-9-oxo-9H-xanthene-2-carboxylate (116) resulted from the esterification 
of XCar-2 (108). The IR, 1H and 13C NMR, and MS allowed the structure elucidation of 
compounds 108 and 116. 
The IR spectra of compounds 108 and 116 (Table 5) showed the presence of the  
absorption bands corresponding to the of C=O and aromatic C=C bonds associated with 
the xanthonic sccafold. It is also important to point out the presence of the absorption 
band corresponding to of the Ar-OCH3 bond at 1271 cm-1 for compound 108 and at 1270 
cm-1 for compound 116. 
Tha main changes are: the shift of the band at 1610 cm-1 (C=O of COOH) to 1730 
cm-1 (C=O of COOCH3). As well as the absence of a broad band at 2901 cm-1 (OH of 
COOH) in IR spectrum of compound 116. Considering that occurred transformation from 
COOH to COOCH3. 
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Table 5: IR data of 6-methoxy-9-oxo-9H-xanthene-2-carboxylic acid (XCar-2, 108) and 
methyl 6-methoxy-9-oxo-9H-xanthene-2-carboxylate (116). 
Bond 
 (cm-1) 
(108) (116) 
O-H  2901 --- 
C=O (ester)  --- 1730 
C=O (ketone) 1687 1663 
C=O (carboxylic acid)  1610 --- 
C=C (aromatic) 1575,1500, 1433 1581, 1467, 1438 
Ar-OCH3  1271 1270 
C-O (ester)  --- 1117 
C-H (aromatic) 766 764 
 
The 1H and 13C NMR spectra data of the xanthones 108 (Figure 14) and 116 
(Figure 15) are consistent to the proposed structure for these compounds, and allowed 
not only to confirm the success of the transformation, but also to structurally elucidate 
them. 
The analysis of 1H NMR data of compounds 108 and 116 revealed that both 
compounds showed similar NMR profiles with respect to the six aromatic protons of the 
xanthonic scaffold and to the three protons of methoxyl group, with similar chemical shifts 
and coupling constants. Moreover, it is also important to note the presence in compound 
116 spectrum of a singlet at 𝛿 3.95 ppm, with the integration for three protons, 
corresponding to the COOCH3 protons, which are absent in compound 108.  
The most significant differences between the 13C NMR spectra of compounds 108 
and 116 were associated to the signals of the carbons of the groups COOH and COOCH3. 
The presence in the spectrum of compound 116 of the signal at 𝛿 52.3 ppm corresponding 
to COOCH3, confirmed the desired transformation from COOH to COOCH3. 
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Figure 14: 1H NMR (DMSO-D6, 300.13 MHz) and 13C NMR (DMSO-D6, 75.47 MHz) of 6-methoxy-
9-oxo-9H-xanthene-2-carboxylic acid (XCar-2, 108). 
 
 
 
 
Figure 15: 1H NMR (CDCl3, 300.13 MHz) and 13C NMR (CDCl3, 75.47 MHz) of methyl 6-methoxy-
9-oxo-9H-xanthene-2-carboxylate (116). 
 
The MS spectra of the compound 108 showed the following peaks and m/z values: 
270 [M]+. (100), 253 [M-OH]+. (26), 226 (27), 199 (15), 182 (15), 169 (8), 154 (7), 139 (7), 
126 (17), 115 (10), 63 (16). The strong signal at 284, corresponding to the peak of the 
molecular ion obtained is consistent with the proposed structure. 
The MS spectra of the compound 116 showed the following peaks and m/z values: 
284 [M]+. (89), 253 [M-OCH3] +. (100), 225 (32), 197 (14), 182 (30), 169 (17), 154 (16), 
142 (14), 126 (28), 111 (12), 75 (12), 63 (14). The intense signal at 270, corresponding to 
the peak of the molecular ion obtained is consistent with the proposed structure. 
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1.2.4. Structure elucidation of 8-methoxy-9-oxo-9H-xanthene-2-carboxylic acid 
(XCar3, 109) and methyl 8-methoxy-9-oxo-9H-xanthene-2-carboxylate 
(117) 
 
         
                          (109)                                                              (117)   
 
The 8-methoxy-9-oxo-9H-xanthene-2-carboxylic acid (XCar-3, 109) resulted from an 
intramolecular acylation reaction of the 4-(3’-methoxyphenoxy)isophthalic acid (115). 
Methyl 8-methoxy-9-oxo-9H-xanthene-2-carboxylate (117) resulted from the esterification 
of XCar-3 (109). The IR, 1H and 13C NMR, and MS allowed the structure elucidation of 
compounds 109 and 117. 
The IR spectra of compounds 109 and 117 (Table 6) presented absorption bands 
characteristic of C=O and C=C bonds from the carbonyl group and aromatic rings, 
respectively, of the xanthonic scaffold.  It is also important to point out the presence of the 
absorption band characteristic of the Ar-OCH3 bond at 1266 cm-1 for compound 109 and 
at 1264 cm-1 for compound 117. 
 
Table 6: IR data of 8-methoxy-9-oxo-9H-xanthene-2-carboxylic acid (XCar-3, 109) and 
methyl 8-methoxy-9-oxo-9H-xanthene-2-carboxylate (117). 
Bond 
 (cm-1) 
(109) (117) 
O-H  3460 --- 
C=O (ester) --- 1726 
C=O (ketone) 
1687 
 
1668 
C=O (carboxylic acid) 1663 --- 
C=C (aromatic) 1420, 1469, 1603 1431, 1480, 1611 
Ar-OCH3  1266 1264 
C-O (ester) --- 1079 
C-H (aromatic) 763 760 
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The comparison of IR spectra of both xanthones (109 and 117) revealed the shift of 
the band at 1668 cm-1 (C=O of COOCH3) to 1687 cm-1 (C=O of COOH). It is also 
important to highlight the presence of large band at 3460 cm-1 corresponding to O-H 
(carboxylic acid) in xanthone 109. 
 
The 1H and 13C NMR spectra data are in agreement with the proposed structure for 
compounds 109 and 117 (Figure 16 and Figure 17).  
The analysis of 1H NRM data of compounds 109 and 117 revealed that both 
compounds presented a singlet at 𝜹 3.94-3.98 ppm, with integration for three protons, 
corresponding to the group Ar-OCH3 protons. Moreover, it is also important to note the 
presence in compound 117 spectrum of a singlet at 𝜹 4.05 ppm, with the integration for 
three protons, corresponding to the group COOCH3 protons, which are absent in 
xanthone 109. 
The most significant differences between the 13C NMR spectra of compounds 109 
and 117 were related to the signals of the carbons of the groups COOH and COOCH3. 
The presence in the spectrum of compound 117, a signal at 𝛿 52.4 ppm corresponding to 
COOCH3, and lower 𝜹 of signal to the carbonyl group of COOH compared to C=O from 
ester bond, confirmed the desired transformation. 
 
 
 
Figure 16: 1H NMR (CDCl3, 300.13 MHz) and 13C NMR (CDCl3, 75.47 MHz) of methyl 8-methoxy-
9-oxo-9H-xanthene-2-carboxylate (117). 
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Figure 17: 1H NMR (DMSO-D6, 300.13 MHz) and 13C NMR (DMSO-D6, 75.47 MHz) of 8-methoxy-
9-oxo-9H-xanthene-2-carboxylic acid (XCar-3, 109). 
 
The xanthone 8-methoxy-9-oxo-9H-xanthene-2-carboxylic acid (109) showed the 
following values for HRMS (ESI) m/z: calcd for (C15H10O5 + H): 271.16994, found: 
271.06010. 
The MS spectra of the compound 117 showed the following peaks and m/z values: 
284 [M]+. (100), 255 (56), 253 (30), 197 (14), 238 (56), 223 (47), 195 (27), 139 (33), 126 
(20), 111 (18), 70 (15), 63 (12). 
 
 
1.2.5. Structure elucidation of dimethyl 4-(2,4-dimethylphenoxy)isophthalate 
(119) and dimethyl 4-(2,4-dimethylphenoxy)isophthalic acid (120) 
 
                                       
                                          (119)                                                          (120) 
 
Dimethyl 4-(2,4-dimethylphenoxy)isophthalate (119) resulted from the Ullmann 
diaryl ether coupling of dimethyl 4-bromoisophthalate (112) and 2,4-dimethylphenol (118). 
The compound 4-(2,4-dimethylphenoxy)isophthalic acid (120) resulted from the hydrolysis 
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of the methyl esters of compound 119. The data obtained from IR, 1H and 13C NMR 
allowed the structure elucidation of compounds 119 and 120. 
Comparing the IR spectrum of the compound 119 (Table 7) with the spectrum of 
its precursor (112) (Table 3) showed the presence of the absortion bands corresponding 
to the C=O and to aromatic C=C in both spectra. The main difference important to 
highlight is the presence of the absorption band C-O-C corresponding to the ether bond at 
(1259 cm-1) the IR spectra of both compounds (112 and 119). 
Comparing the IR spectra of compounds 119 and 120 (Table 7) it can be seen the 
presence of the absorption bands corresponding to the C=C aromatic ring bond and to   
C-O-C ether bond in both spectra, with IR frequencies not significantly different. The 
presence of a broad absorption bands at 2923 cm-1 corresponding to the O-H carboxyl 
acid bond, on spectrum of compound 120 confirmed that the reaction occurred 
successfully. Moreover, the shift of the band at 1717 cm-1 (C=O of COOCH3)  to 1613 cm-1 
(C=O of COOH) confirmed that occurred transformation from COOCH3 to COOH. 
 
Table 7: IR data of dimethyl 4-(2,4-dimethylphenoxy)isophthalate (119) and dimethyl 4-
(2,4-dimethylphenoxy)isophthalic acid (120). 
Bond 
 (cm-1) 
(119) (120) 
C=O  1717 1613 
C=C (aromatic) 1436 1491 and 1604 
C-O-C (ether) 1259 1257 
O-H  --- 2923 
 
 
The 1H and 13C NMR spectra data obtained for compounds 119 (Figure 18) and 
120 (Figure 19) are consistent to the proposed structure for these compounds, and 
allowed not only to confirm the success of the transformation, but also to structurally 
elucidate them. 
The 1H NMR spectrum of compound 119, compared to the spectrum of its 
precursor (112) (Figure 11), presented new signals such as two singlets at 𝜹 2.29 ppm 
and 2.07 ppm, with the integration for three protons each, corresponding to the two Ar-
CH3, confirming the desired transformation. 
Compounds 119 and 120 showed similar NMR profiles with respect to the 
aromatic protons with similar chemical shifts and coupling constants. The most significant 
difference in the 1H NMR spectra is the absence in compound 120 spectrum of two 
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singlets at 𝜹 3.84 ppm, with the integration for three protons each, corresponding to the 
protons of the two COOCH3 methyl groups of compound 120. This difference confirmed 
the success of the desired transformation. 
The 13C NMR spectrum of compound 119 compared to the spectrum of precursor 
(112) (Figure 11), presented new spectrum signals at 𝜹 20.4 and 21.0 ppm, 
corresponding to the carbons of Ar-CH3 groups, and associated to the signals of aromatic 
carbons, confirmed the desired transformation.  
 The most significant differences between the 13C NMR spectra of the compounds 
119 and 120 are the shift of carbon signals from 𝜹 166.1 and 166.0 ppm (COOCH3) to   
166.3 and 166.2 ppm (COOH), and the absence, in the spectrum of compound 120, of 
two signals at 𝜹  52.3 and 52.2 ppm, corresponding to the carbons of COOCH3 methyl 
groups. The referred differences confirmed the success of the chemical modification. 
 
Figure 18: 1H NMR (DMSO-D6, 300.13 MHz) and 13C NMR (DMSO-D6, 75.47 MHz) of dimethyl 4-
(2,4-dimethylphenoxy)isophthalate (119). 
 
 
Figure 19: 1H NMR (DMSO-D6, 300.13 MHz) and 13C NMR (DMSO-D6, 75.47 MHz) of dimethyl 4-
(2,4-dimethylphenoxy)isophthalate acid (120)). 
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1.2.6. Structure elucidation of 5,7-dimethyl-9-oxo-9H-xanthene-2-carboxylic 
acid (XCar-5, 110) 
 
The 5,7-dimethyl-9-oxo-9H-xanthene-2-carboxylic acid (XCar-5, 110)  resulted from an 
intramolecular acylation reaction of the dimethyl 4-(2,4-dimethylphenoxy)isophthalic acid 
(120). The IR, 1H and 13C NMR data allowed the structure elucidation of XCar-5 (110). 
 
 
 
(110) 
The IR spectrum of XCar-5 (110) (Table 8) showed the presence of the absorption 
bands corresponding to the C=O and aromatic C=C bonds associated with the xanthonic 
scaffold. It is important to point out the presence of the absorption bands at 680 and 768 
cm -1 corresponding to the Ar-CH3 methyl groups. 
 
Table 8: IR data of 5,7-dimethyl-9-oxo-9H-xanthene-2-carboxylic acid (XCar-5, 110). 
Bond 
 (cm-1) 
(110) 
O-H  2920 
C=O (ketone)  1667 
C=O (carboxylic acid) 1611 
C=C (aromatic) 1475 and 1421 
Ar-CH3 680 and 768 
 
The 1H and 13C NMR spectra data of compound 110 (Figure 20) is consistent to 
the proposed structure for this compound, and allowed not only to confirm the success of 
the transformation, but also to structurally elucidate it. 
 
 
The 1H NMR spectrum of compound 110 showed signals corresponding to the five 
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aromatic protons of the xanthonic scaffold and to the six protons of the two methyl groups. 
Comparing of 13C NMR spectra of the compound 110 and its precursor (120) 
(Figure 19) it is important to point out the presence of a new signal at 𝜹 176.8 ppm 
corresponding to the carbonyl group, characteristic of the xanthonic scaffold, confirming 
the desired transformation. The carbon shifts were assigned with the help of HSQC and 
HMBC techniques. 
 
 
 
 
Figure 20: 1H NMR (DMSO-D6, 300.13 MHz) and 13C NMR (DMSO-D6, 75.47 MHz) of 5,7-
dimethyl-9-oxo-9H-xanthene-2-carboxylic acid (XCar-5, 110). 
 
1.3. Synthesis of chiral xanthone derivatives  
Twenty four new chiral derivatives of xanthones (CDXs) were synthesized by 
coupling reaction of the carboxyxanthones 6-methoxy-9-oxo-9H-xanthene-2-carboxylic 
acid (XCar-2, 108) and 5,7-dimethyl-9-oxo-9H-xanthene-2-carboxylic acid (XCar-5, 110) 
with a variety of a commercially available enantiomerically pure building blocks (121-136) 
through an amide bond (Scheme 3). 
The chosen enantiomerically pure building blocks included the amines and amino 
alcohols used in a previous work,30 which CDXs afforded the most interesting results 
considering not only the growth inhibitory effects on the human tumor cell lines tested but 
also enantioselectivity. Other analogue amines were also selected. Regardless the 
enantiomerically pure building block, the primary amine was the reactive group for the 
amide formation. 
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Scheme 3: General scheme of coupling reaction of carboxyxanthone derivatives (108 and 110) 
with enantiomerically pure building blocks (121-136). 
 
Therefore, eight new CDXs, namely, (S)-XEA-3-MET (137), (R)-XEA-3-MET (138), 
(S)-XEA-4-MET (139), (R)-XEA-4-MET (140), (S)-XEA-4-CLO (141), (R)-XEA-4-CLO 
(142), (S)-XEA-4-FLU (143), (R)-XEA-4-FLU (144), (Table 9 and Table 25 of Appendix) 
were synthesized by coupling the XCar-2 (108) with (S)-3-methoxy-α-methylbenzylamine, 
(R)-3-methoxy-α-methylbenzylamine, (S)-4-methoxy-α-methylbenzylamine, (R)-4-
methoxy-α-methylbenzylamine, (S)-4-chloro-α-mehtylbenzylamine, (R)-4-chloro-α-
mehtylbenzylamine, (S)-4-fluoro-α-methylbenzylamine and (R)-4-fluoro-α-
methylbenzylamine, respectively. 
Moreover, twelve new CDXs, namely, (S)-XEA5-3-MET (145), (R)-XEA5-3-MET 
(146), (S)-XEA5-4-MET (147), (R)-XEA5-4-MET (148), (S)-XEA5-4-CLO (149), (R)-XEA5-
4-CLO (150), (S)-XEA5-4-FLU (151), (R)-XEA5-4-FLU (152), (S)-XEA5 (153), (R)-XEA5 
(154), (S)-XEA5-DES (155), (R)-XEA5-DES (156), (Table 9 and Table 25 of Appendix) 
were synthesized by coupling the XCar-5 (110) with both enantiomers of the same four 
amines mentioned above as well as both enantiomers of  α-dimethylbenzylamine and α-
methylbenzylamine. 
Furthermore, with the same xanthonic chemical substrate (XCar-5, 110) four new 
CDXs were synthesized, namely (S,S)-X2ADF5 (157), (R,R)-X2ADF5 (158), (S,R)-
X2ADF5 (159) and (R,S)-X2ADF5 (160) (Table 9 and Table 25 of Appendix) using the 
four isomers of the aminoalcohol 2-amino-1,2-diphenylethanol as building blocks. 
The activation of the carboxylic acid group attached to the xanthonic scaffold of both 
xanthonic chemical substrates (108 and 110) was carried out with O-(benzotriazol-1-yl-)-
N,N,N’,N’-tetramethylluronium tetrafluoroborate (TBTU) (Figure 21), in the presence of a 
catalytic amount of triethylamine (TEA) in dry tetrahydrofuran (THF) (Scheme 3). Despite 
a high number of coupling reagents described in the literature, TBTU is one of the most 
used due to its higher efficiency and lower tendency towards racemization.82  
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Figure 21: The chemical structure of TBTU. 
 
Table 9 and Table 10 summarize the results obtained with the coupling reactions 
for the synthesis of CDXs by using XCar-2 (108) and XCar-5 (110), respectively, as 
chemical substrates. 
All the reactions were carried out at room temperature and, as demonstrated in 
Table 9 and Table 10, showed good yields (above 95%) and short reaction times (20 min 
– 1.5 h). As expected, the syntheses worked equally well with both carboxyxanthones 
affording the desired amides. The purification procedures were easy, involving liquid-liquid 
extraction followed by crystallization. 
 
 
Table 9: Results obtained for the synthesis of CDXs using XCar-2 (108) as chemical substrate. 
Enantiomerally pure 
building block 
Product (CDX) Yield 
Reaction 
time 
[α]D25°C 
(c)* 
 
 
(121) 
 
 
 
(S)-XEA-3-MET (137) 
96.8% 30 min 
-36.4°  
(5.5 x 10-3) 
 
 
(122) 
 
 
(R)-XEA-3-MET (138) 
97.2% 30 min 
+39.2° 
(5.5 x 10-3) 
 
 
 
(123) 
 
 
 
 
(S)-XEA-4-MET (139) 
98.4% 30 min 
+26.5° 
(5.6 x 10-3) 
 
 
(124) 
 
 
 
(R)-XEA-4-MET (140) 
96.7% 30 min 
-28.5° 
(5.6 x 10-3) 
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Table 9 : ContinuationTa 
 
 
 
 
(125) 
 
 
 
 
 
(S)-XEA-4-CLO (141) 
 
 
98.9% 
 
 
 
 
20 min 
 
 
+136.7° 
(5.3 x 10-3)*1 
 
 
 
(126) 
 
 
 
(R)-XEA-4-CLO (142) 
 
97.9% 20 min 
-135.9° 
(5.3 x 10-3)*1 
 
(127) 
 
 
 
(S)-XEA-4-FLU (143) 
96.4% 20 min 
+45.5° 
(5.7 x 10-3) 
 
 
(128) 
 
 
 
(R)-XEA-4-FLU (144) 
97.1% 20 min 
-52.5° 
(5.7 x 10-3) 
* Specific rotation in acetone except *1(in chloroform) with c = concentration in g/mL. 
 
 
Table 10: Results obtained for the synthesis of CDXs using XCar-5 (110) as chemical substrate. 
Enantiomeracally pure 
building block 
Product (CDX) Yield 
Reaction 
time 
[α]D25°C 
(c)* 
 
 
 
 
(121) 
  
 
(S)-XEA5-3-MET (145) 
 
97.2% 1 h 
+183.7° 
(3.7 x 10-3) 
 
 
 
(122) 
 
 
 
(R)-XEA5-3-MET (146) 
 
96.2% 1 h 
-173.5° 
(3.7 x 10-3) 
 
 
 
(123) 
 
 
 
 
 
 
 
(S)-XEA5-4-MET (147) 
 
95.8% 1 h 
+179.3° 
(4.3 x 10-3) 
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(124) 
 
 
 
(R)-XEA5-4-MET (148) 
 
98.7% 
1 h 
-177.6° 
(4.4 x 10-3) 
 
 
(125) 
 
 
 
 
(S)-XEA5-4-CLO (149) 
 
96.8% 1 h 
+204.2° 
(4.7 x 10-3) 
 
 
 
 
(126) 
 
 
 
 
(R)-XEA5-4-CLO (150) 
 
 
97.9% 
 
 
1 h 
 
 
-203.4° 
(4.7 x 10-3) 
 
 
 
(127) 
 
 
 
 
(S)-XEA5-4-FLU (151) 
 
95.8% 1.5 h 
+167.4° 
(4.3 x 10-3) 
 
 
 
(128) 
 
 
 
(R)-XEA5-4-FLU (152) 
 
96.3% 1.5 h 
-166.7° 
(4.2 x 10-3) 
 
 
 
(129) 
 
 
(S)-XEA5 (153) 
 
97.9% 1.5 h 
+130.7° 
(3.9 x 10-3) 
 
 
 
(130) 
 
 
(R)-XEA5 (154) 
99.1% 1 h 
-125.8° 
(3.9 x 10-3) 
 
 
 
(131) 
 
 
(S)-XEA5-DES (155) 
 
 
98.9% 
 
 
1 h 
 
 
+132.5° 
(4.0 x 10-3) 
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(132) 
 
 
 
 
 
(R)-XEA5-DES (156) 
97.7% 1 h 
-131.5 
(4.0 x 10-3) 
 
 
 
 
(133) 
 
 
(S,S)-X2ADF5 (157) 
 
 
97.3% 
 
 
1.5 h 
 
 
-30.2° 
(4.3 x 10-3) 
 
 
 
 
(134) 
 
 
 
(R,R)-X2ADF5 (158) 
96.9% 1.5 h 
 
+52.8° 
(4.3 x 10-3) 
 
 
 
 
 
(135) 
 
 
 
 
(S,R)-X2ADF5 (159) 
97.0% 1.5 h 
 
+32.2° 
(4.3 x 10-3) 
 
 
 
 
(136) 
 
 
 
(R,S)-X2ADF5 (160) 
97.5% 1.5 h 
 
-39.0° 
(4.3 x 10-3) 
* Specific rotation in chloroform with c = concentration in g/mL. 
 
1.4. Structure elucidation of chiral derivatives of xanthones 
The IR, 1H and 13C NMR allowed the structure elucidation of all CDXs. 
The data obtained by analysis of IR spectra of CDXs obtained from XCar-2 (108) 
and XCar-5 (110) are listed on Table 11 and Table 12, respectively. 
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  Table 11: IR data of CDXs obtained from XCar-2 (108). 
  (cm-1) 
C=O 
ketone  
C-H 
aromatic  
C=C  
aromatic 
Ar-OCH3  
C=O 
amide 
N-H 
(S)-XEA-3-MET 
(137) 
1663 833 
1440, 1469, 1482, 
1533 
1270 1631 3319 
(R)-XEA-3-MET 
 
(138) 
1666 833 
1440, 1470, 1482, 
1533 
1271 1633 3319 
(S)-XEA-4-MET 
 
(139) 
1655 831 
1443, 1478, 1513, 
1539 
1272 1629 3318 
(R)-XEA-4-MET 
 
(140) 
1658 831 1443, 1479, 1537 1272 1636 3319 
(S)-XEA-4-CLO 
 
(141) 
1651 826 
1445,1480, 
1540, 1589 
1275 1635 3290 
(R)-XEA-4-CLO 
 
(142) 
1652 827 
1445,1481, 
1540, 1590 
1274 1635 3296 
(S)-XEA-4-FLU 
 
(143) 
1665 833 1443, 1476, 1511 1274 1634 3316 
(R)-XEA-4-FLU 
 
(144) 
1665 834 1443, 1539 1274 1630 3317 
 
 
  Table 12: IR data of CDXs obtained from XCar-5 (110). 
  (cm-1) 
C=O 
ketone  
C-H 
aromatic  
C=C  
aromatic 
O-H  
C=O 
amide 
N-H 
(S)-XEA5-3-MET 
(145) 
1664 791, 837 
1473, 1540 
1606 
--- 1633 3289 
(R)-XEA5-3-MET 
 
(146) 
1664 792, 837 
1470, 1540 
1605 
--- 
1634 3297 
(S)-XEA5-4-MET 
 
(147) 
1662 792, 829 
1466, 1515, 
1539, 1614 
--- 
1634 3303 
(R)-XEA5-4-MET 
 
(148) 
1662 793, 829 
1467, 1540, 
1610 
--- 
1633 3300 
(S)-XEA5-4-CLO 
 
(149) 
1667 791, 825 
1474, 1536, 
1611 
--- 
1629 3297 
(R)-XEA5-4-CLO 
 
(150) 
1666 791, 828 
1470, 1540, 
1611 
--- 
1631 3299 
(S)-XEA5-4-FLU 
 
(151) 
1673 790, 824 
1473, 1555, 
1609 
--- 
1637 3304 
(R)-XEA5-4-FLU 
 
(152) 
1672 792, 829 
1463, 1555, 
1608 
--- 
1637 3303 
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Table 12: Continuation 
(S)-XEA5 
 
(153) 
1667 790, 834 
1466, 1547, 
1609 
--- 
1632 3298 
(R)-XEA5 
 
(154) 
1667 791, 832 
1466, 1542, 
1612 
--- 
1634 3300 
(S)-XEA5-DES 
 
(155) 
1666 791, 833 
1475, 1536, 
1611 
--- 
1630 3303 
(R)-XEA5-DES 
 
(156) 
1665 791, 837 
1475, 1536, 
1612 
--- 
1632 3304 
(S,S)-X2ADF5 
 
(157) 
1669 701, 792 
1475, 1529, 
1613 
3421 1634 3320 
(R,R)-X2ADF5 
 
(158) 
1668 702, 801 
1475, 1489,  
1533 
3389 1635 3302 
(S,R)-X2ADF5 
 
(159) 
1673 701, 755 1474, 1533 3385 1635 3311 
(R,S)-X2ADF5 
 
(160) 
1674 700, 754 
1474, 154-0, 
1614 
3418 1636 3311 
 
The IR spectra of all CDXs (Table 11 and Table 12) showed the presence of 
absorption bands corresponding to the C=O relative the ketone bond, at 1651-1674 cm-1 
and to aromatic C=C at 1440-1614 cm-1, associated with the xanthonic scaffold. 
Moreover, the presence of a band at 1270-1275 cm-1 corresponding to the Ar-OCH3 bond 
was observed for all the CDXs obtained from XCar-2 (108) (Table 11). For the CDXs 
obtained by coupling XCar-5 (110) with chiral aminoalcohols a broad band at 3385-3421 
cm-1, corresponding to O-H bond of the alcohol was also present. 
Comparing the IR spectra of xanthonic chemical substrates, namely XCar-2 (108) 
(Table 5) and XCar-5 (110) (Table 8) and CDXs the main changes that are important to 
highlighted are the presence of strong bands corresponding to N-H around 3300 cm-1 and 
C=O of amine around 1630 cm-1,  
 The 1H and 13C NMR data of CDXs obtained from XCar-2 (108) are reported in 
Table 13 and Table 14, respectively.  
The 1H NMR data of CDXs obtained by coupling XCar-5 (110) with amines are 
shown in Table 15 and Table 16, and with aminoalcohols in Table 17.  
Table 18 and Table 19 presented the 13C NMR data of CDXs obtained by coupling 
XCar-5 (110) with amines; and Table 20 with aminoalcohols. 
 The 1H NMR and the 13C NMR spectra of all CDXs showed chemical shifts 
corresponding to the aromatic protons and carbons of the xanthonic scaffold. 
The more significant differences of 1H NMR and the 13C NMR spectra of all CDXs, 
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comparing with the spectrum of their precursors, namely XCar-2 (108) (Figure 14) and 
XCar-5 (110) (Figure 20) correspond to the presence of new spectral signals that confirm 
the success of the coupling reactions. For example, it is important to point out the 
presence in 1H NMR spectra of the chemical shift around 6.60 ppm corresponding to the 
proton of amide group, and the presence in 13C NMR spectra of the chemical shift around 
165.5 ppm corresponding to the carbonyl of amide group. 
For compounds (137, 147) were provided spectral data from HSQC and HMBC 
experiments to clarify the structural elucidation of these compounds.  
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Table 13: 1H NMR (CDCl3 or DMSO-D6, 300.13 MHZ), chemical shift values, δ, in ppm, and J in Hz, for CDXs (137-144) obtained from XCar-2. (108).  
 (S)-XEA-3-MET 
(137) 
(R)-XEA-3-MET 
(138) 
(S)-XEA-4-MET 
(139) 
(R)-XEA-4-MET 
(140) 
(S)-XEA-4-CLO 
(141) 
(R)-XEA-4-CLO 
(142) 
(S)-XEA-4-FLU 
(143) 
(R)-XEA-4-FLU 
(144) 
H1 
8.58 
(d, J=2.2) 
8.58 
(d, J=2.2) 
8.56 
(d, J=2.3) 
8.56 
(d, J=2.3) 
8.59 
(d, J=2.2) 
8.59 
(d, J=2.2) 
8.57 
(d, J=2.3) 
8.57 
(d, J=2.3) 
H3 
8.32 
(dd, J=2.3, 8.8) 
8.32 
(dd, J=2.3, 8.8) 
8.32 
(dd, J=2.3, 8.8) 
8.32 
(dd, J=2.3,  8.8) 
8.30 
(dd, J=2.3, 8.8) 
8.30 
(dd, J=2.3, 8.8) 
8.32 
(dd, J=2.3, 8.8) 
8.32 
(dd, J=2.3, 8.8) 
H4 
7.54 
(d, J=8.8) 
7.54 
(d, J=8.8) 
7.54 
(d, J=8.8) 
7.54 
(d, J=8.8) 
7.53 
(d, J=8.8) 
7.53 
(d, J=8.8) 
7.55 
(d, J=8.8) 
7.55 
(d, J=8.8) 
H5 
6.93 
(d,  J=2.3) 
6.93 
(d, J=2.3) 
6.93 
(d, J=2.7) 
6.93 
(d, J=2.7) 
6.91 
(d, J=2.3) 
6.91 
(d, J=2.3) 
6.93 
(d, J=2.3) 
6.93 
(d, J=2.3) 
H7 
6.97 
(dd, J=2.3, 8.9) 
6.97 
(dd, J=2.3, 8.9) 
6.99 
(dd, J=2.4, 8.9) 
6.99 
(dd, J=2.4, 8.9) 
6.98 
(dd, J=2.4, 8.9) 
6.98 
(dd, J=2.4, 8.9) 
6.99 
(dd, J=2.3, 8.9) 
6.99 
(dd, J=2.3, 8.9) 
H8 
8.26 
(d, J=8.9) 
8.26 
(d, J=8.9) 
8.26 
(d, J=8.9) 
8.26 
(d, J=8.9) 
8.24 
(d, J=8.9) 
8.24 
(d, J=8.9) 
8.26 
(d, J=8.9) 
8.26 
(d, J=8.9) 
NH 
6.59 
(d, J=7.8) 
6.58 
(d, J=7.7) 
6.59 
(d, J=7.8) 
6.56 
(d, J=7.8) 
6.71 
(d, J=7.4) 
6.67 
(d, J=7.4) 
6.58 
(d, J=7.4) 
6.58 
(d, J=7.4) 
H1' 
5.37 - 5.28 
(m) 
5.37 - 5.28 
(m) 
5.37 - 5.28 
(m) 
5.37 - 5.28 
(m) 
5.37 - 5.28 
(m) 
5.37 - 5.28 
(m) 
5.37-5.28 
(m) 
5.37-5.28 
(m) 
H2' 
1.64 
(d, J=6.9) 
1.64 
(d, J=6.9) 
1.63 
(d, J=7.0) 
1.63 
(d, J=7.0) 
1.62 
(d, J=7.0) 
1.62 
(d, J=7.0) 
1.63 
(d, J=7.0) 
1.63 
(d, J=7.0) 
H2'' 
7.30 
(d, J=7.9) 
7.30 
(d, J=7.9) 
7.35 
(d, J=8.5) 
7.35 
(d, J=8.5) 
7.36 - 7.26 
(m) 
7.36 - 7.26 
(m) 
7.41 - 7.37 
(m) 
7.41 - 7.37 
(m) 
H3'' - - 
6.89 
(d, J=2.1) 
6.89 
(d, J=2.1) 
7.36 - 7.26 
(m) 
7.36-7.26 
(m) 
7.08 - 7.03 
(m) 
7.08 - 7.03 
 (m) 
H4'' 
6.83 
(ddd, J=0.7, 2.5, 
8.0) 
6.83 
(ddd, J=0.7, 2.5, 
8.0) 
- - - - - - 
H5'' 
7.00 – 6.98 
(m) 
7.00 – 6.98 
(m) 
6.89 
(d, J=2.1) 
6.89 
(d, J=2.1) 
7.36 - 7.26 
(m) 
7.36 - 7.26 
(m) 
7.08 - 7.03 
 (m) 
7.08 - 7.03 
 (m) 
H6'' 
7.00 – 6.98 
(m) 
7.00 – 6.98 
(m) 
7.35 
(d, J=8.5) 
7.35 
(d, J=8.5) 
7.36 - 7.26 
(m) 
7.36 - 7.26 
(m) 
7.41 - 7.37 
(m) 
7.41 - 7.37 
(m) 
OCH3 
xanthone 
3.96 (s) 3.96 (s) 3.96 (s) 3.96 (s) 3.95 (s) 3.95 (s) 3.96 (s) 3.96 (s) 
OCH3  
aromatic 
amine 
3.82 (s) 3.82 (s) 3.81 (s) 3.81 (s) - - - - 
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Table 14: 13C NMR (CDCl3 or DMSO-D6, 300.13 MHZ), chemical shift values, δ, in ppm, for CDXs (137-144) obtained from XCar-2 (108). 
 (S)-XEA-3-MET 
(137) 
(R)-XEA-3-MET 
(138) 
(S)-XEA-4-MET 
(139) 
(R)-XEA-4-MET 
(140) 
(S)-XEA-4-CLO 
(141) 
(R)-XEA-4-CLO 
(142) 
(S)-XEA-4-FLU 
(143) 
(R)-XEA-4-FLU 
(144) 
C1 124.0 124.0 124.0 124.0 124.0 124.0 123.9 123.9 
C2 129.8 129.9 130.0 130.1 129.8 129.8 129.8 129.8 
C3 134.3 134.3 134.3 134.3 134.3 134.3 134.4 134.3 
C4 118.5 118.6 118.5 118.5 118.6 118.6 118.7 118.6 
C4a 157.9 157.9 157.9 157.9 157.9 157.9 157.9 157.9 
C5 100.4 100.4 100.3 100.3 100.3 100.3 100.4 100.3 
C6 164.8 164.6 164.8 164.8 165.0 164.9 164.8 164.8 
C7 113.8 113.8 113.8 113.8 113.8 113.8 113.9 113.8 
C8 128.4 128.4 128.3 128.3 128.3 128.3 128.4 128.3 
C8a 115.5 115.5 115.5 115.5 115.5 115.5 115.6 115.6 
C9 175.9 175.9 175.9 175.9 175.9 175.9 175.9 175.9 
C9a 121.1 121.1 121.1 121.0 121.0 121.0 121.0 121.0 
C10a 158.0 158.0 158.0 158.0 158.0 158.0 158.0 158.0 
C=O amide 165.5 165.5 165.5 165.6 165.5 165.5 165.5 165.5 
C1' 49.6 49.6 49.0 49.0 49.0 49.0 48.9 48.9 
C2' (CH3) 21.8 21.8 21.6 21.6 21.8 21.8 21.8 21.8 
C1'' 144.5 144.5 135.0 135.0 133.1 133.1 138.7 138.7 
C2'' 130.0 130.0 127.5 127.5 127.6 127.6 127.9 127.9 
C3'' 159.9 159.9 114.1 114.1 117.8 117.8 115.5 115.5 
C4'' 112.7 112.7 159.0 159.0 141.6 141.6 161.1 161.1 
C5''  112.3 112.3 114.1 114.1 117.8 117.8 115.5 115.5 
C6''  118.6 118.6 127.5 127.5 127.6 127.6 127.9 127.9 
OCH3 
xanthone 
55.9 55.9 55.9 55.9 55.9 55.9 55.9 55.9 
OCH3 
aromatic 
amine 
55.3 55.3 55.3 55.3 - - - - 
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Table 15: 1H NMR (CDCl3 or DMSO-D6, 300.13 MHZ), chemical shift values, δ, in ppm, and J in Hz, for CDXs (145-150) obtained from XCar-5. (110). 
 (S)-XEA5-3-MET 
(145) 
(R)-XEA5-3-MET 
(146) 
(S)-XEA5-4-MET 
(147) 
(R)-XEA5-4-MET 
(148) 
(S)-XEA5-4-CLO 
(149) 
(R)-XEA5-4-CLO 
(150) 
H1 
8.60 
 (d, J=2.3) 
8.59  
(d, J=2.3) 
8.57  
(d, J=2.3) 
8.57 
 (d, J=2.3) 
8.60  
(d, J=2.3) 
8.60  
(d, J=2.3) 
H3 
8.33 
 (dd, J=2.3,8.8) 
8.33  
(dd, J=2.3,8.8) 
8.33 
 (dd, J=2.3,8.8) 
8.33  
(dd, J=2.3,8.8) 
8.33 
 (dd, J=2.3,8.8) 
8.33 
 (dd, J=2.3,8.8) 
H4 
7.59  
(d, J=8.8) 
7.59  
(d, J=8.8) 
7.59  
(d, J=8.8) 
7.59  
(d, J=8.8) 
7.60  
(d, J=8.8) 
7.60  
(d, J=8.8) 
H6 
7.43  
(d, J=0.8) 
7.43  
(d, J=0.8) 
7.43 
 (d, J=0.8) 
7.43  
(d, J=0.8) 
7.43  
(d, J=0.8) 
7.43  
(d, J=0.8) 
H8 
7.95  
(d, J=0.8) 
7.95 
(d, J=0.8) 
7.96  
(d, J=0.8) 
7.96  
(d, J=0.8) 
7.95  
(d, J=0.7) 
7.95  
(d, J=0.7) 
NH 
6.63  
(d, J=7.6) 
6.63  
(d, J=7.6) 
6.60  
(d, J=7.5) 
6.60  
(d, J=7.5) 
6.65  
(d, J=7.5) 
6.65  
      (d, J=7.5) 
H1' 
5.37–5.27  
(m) 
5.37–5.27 
(m) 
5.37–5.27  
(m) 
5.37–5.27 
 (m) 
5.37–5.27  
(m) 
5.37–5.27  
(m) 
H2' (CH3) 
1.64  
(d, J=6.9) 
1.64  
(d, J=6.9) 
1.64  
(d, J=6.9) 
1.64  
(d, J=6.9) 
1.63  
(d, J=6.9) 
1.63  
(d, J=6.9) 
H2'' 
7.27  
(d, J=7.9) 
7.27  
(d, J=7.9) 
7.35  
(d, J=8.7) 
7.35  
(d, J=8.7) 
7.36  
(d, J=8.8) 
7.36  
(d, J=8.8) 
H3'' - - 
6.90  
(d, J=8.7) 
6.90  
(d, J=8.7) 
7.31  
(d, J=8.8) 
7.31 
 (d, J=8.8) 
H4'' 
6.82 
(ddd, J=8.0, 2.6, 0.8) 
6.82 
(ddd, J=8.0, 2.6, 0.8) 
- - - - 
H5'' 
7.02 – 6.96 
(m) 
7.02 – 6.96 
(m) 
6.90  
(d, J=8.7) 
6.90  
(d, J=8.7) 
7.31 
 (d, J=8.8) 
7.31 
 (d, J=8.8) 
H6'' 
7.02 – 6.96 
(m) 
7.02 – 6.96 
(m) 
7.35 
 (d, J=8.7) 
7.35 
 (d, J=8.7) 
7.36  
(d, J=8.8) 
7.36  
(d J=8.8) 
CH3 (C5 xanthone) 2.54 (s) 2.54 (s) 2.54 (s) 2.54 (s) 2.54 (s) 2.54 (s) 
CH3 (C7 xanthone) 2.44 (s) 2.44 (s) 2.44 (s) 2.44 (s) 2.44 (s) 2.44 (s) 
Ar-OCH3   3.81 (s) 3.81 (s) 3.80 (s) 3.80 (s) - - 
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Table 16: 1H NMR (CDCl3 or DMSO-D6, 300.13 MHZ), chemical shift values, δ, in ppm, and J in Hz, for CDXs (151-156) obtained from from XCar-5 (110). 
 (S)-XEA5-4-FLU 
(151) 
(R)-XEA5-4-FLU 
(152) 
(S)-XEA5 
(153) 
(R)-XEA5 
(154) 
(S)-XEA5-DES 
(155) 
(R)-XEA5-DES 
(156) 
H1 
8.58  
(d, J=2.3) 
8.58  
(d, J=2.3) 
8.58 
 (d, J=2.3) 
8.58 
 (d, J=2.3) 
8.59  
(d, J=2.3) 
8.59 
(d, J=2.3) 
H3 
8.33 
 (dd, J=2.3,8.8) 
8.33  
(dd, J=2.3,8.8) 
8.33 
 (dd, J=2.3, 
8.8) 
8.33 
 (dd, J=2.3, 8.8) 
8.33 
 (dd, J=2.3, 
8.8) 
8.33  
(dd, J=2.3, 
8.8) 
H4 
7.60  
(d, J=8.8) 
7.60 
 (d, J=8.8) 
7.60 
(d, J=8.8) 
7.60  
(d, J=8.8) 
7.60  
(d, J=8.8) 
7.60  
(d, J=8.8) 
H6 
7.43 
 (d, J=0.8) 
7.43  
(d, J=0.8) 
7.43  
(d, J=0.9) 
7.43  
(d, J=0.9) 
7.43-7.27  
(m) 
7.43-7.27  
(m) 
H8 
7.98 
 (d, J=0.7) 
7.98  
(d, J=0.7) 
7.97  
(d, J=0.9) 
7.97  
(d, J=0.9) 
7.97 
 (d, J=0.9) 
7.97  
(d, J=0.9) 
NH 
6.58  
(d, J=7.5) 
6.68  
(d, J=7.5) 
6.60  
(d, J=7.6) 
6.60  
(d, J=7.6) 
6.65  
(d, J=7.6) 
6.65  
(d, J=7.6) 
H1' 
5.38–5.28 
 (m) 
5.38–5.28 
 (m) 
5.37–5.27  
(m) 
5.37–5.27  
(m) 
5.41–5.32  
(m) 
5.41–5.32  
(m) 
H2' (CH3) 
1.64  
(d, J=6.9) 
1.64  
(d, J=6.9) 
1.64  
(d, J=6.9) 
1.64  
(d, J=6.9) 
1.66  
(d, J=6.9) 
1.66 
 (d, J=6.9) 
H2'' 
7.41 
 (d, J=8.7) 
7.39  
(d, J=8.7) 
7.33  
(d, J=8.0) 
7.33 
(d, J=8.0) 
7.43-7.27 
 (m) 
7.43-7.27  
(m) 
H3'' 
7.07  
(d, J=8.7) 
7.07 
 (d, J=8.7) 
7.18  
(d, J=8.0) 
7.18  
(d, J=8.0) 
7.43-7.27  
(m) 
7.43-7.27  
(m) 
H4'' - - - - 
7.43-7.27  
(m) 
7.43-7.27 
 (m) 
H5'' 
7.07 
 (d, J=8.7) 
7.07 
 (d, J=8.7) 
7.18  
(d, J=8.0) 
7.18  
(d, J=8.0) 
7.43-7.27  
(m) 
7.43-7.27  
(m) 
H6'' 
7.41  
(d, J=8.7) 
7.39  
(d, J=8.7) 
7.33  
(d, J=8.0) 
7.33 
(d, J=8.0) 
7.43-7.27  
(m) 
7.43-7.27  
(m) 
CH3 (C5 xanthone) 2.54 (s) 2.54 (s) 2.54 (s) 2.54 (s) 2.54 (s) 2.54 (s) 
CH3 (C7 xanthone) 2.44 (s) 2.44 (s) 2.44 (s) 2.44 (s) 2.44 (s) 2.44 (s) 
Ar-CH3   - - 2.34 (s) 2.34 (s) - - 
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Table 17: 1H NMR (CDCl3 or DMSO-D6, 300.13 MHZ), chemical shift values, δ, in ppm, and J in 
Hz, for CDXs (157-160) obtained from from XCar-5 (110). 
 
(S,S)-X2ADF5 
(157) 
(R,R)-X2ADF5 
(158) 
(S,R)-X2ADF5 
(159) 
(R,S)-X2ADF5 
(160) 
H1 
8.55 
(d, J=2.1) 
8.76 
(d, J=2.1) 
8.64 
(d, J=2.1) 
8.64 
(d, J=2.1) 
H3 
8.09 
(dd, J=2.1, 8.8) 
7.76 
(dd, J=2.1, 8.8) 
8.20 
(dd, J=2.1, 8.8) 
8.29 
(dd, J=2.1, 8.8) 
H4 
7.68 
(d, J=8.8) 
7.76 
(d, J=8.8) 
7.56 
(d, J=8.8) 
7.59 
(d, J=8.8) 
H6 
7.57 
(d, J=0.8) 
7.61 
(d, J=0.8) 
7.42 
(d, J=0.8) 
7.44 
(d, J=0.8) 
H8 
7.82 
(d, J=0.8) 
7.86 
(d, J=0.8) 
7.97 
(d, J=0.8) 
7.97 
(d, J=0.8) 
NH 
9.01 
(d, J=8.3) 
9.18 
(d, J=8.3) 
9.18 
(d, J=8.3) 
9.18 
(d, J=8.3) 
H1' 
5.21 – 5.15 
(m) 
5.26 – 5.21 
(m) 
5.46 – 5.42 
(m) 
5.53 – 5.49 
(m) 
H2' (OH) 
4.99 
(d, J=5.1) 
4.99 
(d, J=5.1) 
5.16 
(d, J=5.1) 
5.16 
(d, J=5.1) 
Aromatics 
(chiral moiety) 
7.33 – 7.16 
(m) 
7.32 – 7.14 
(m) 
7.38 – 7.24 
(m) 
7.38 – 7.22 
(m) 
CH3 (C5 
xanthone) 
2.51 (s) 2.51 (s) 2.53 (s) 2.53 (s) 
CH3 (C7 
xanthone) 
2.48 (s) 2.48 (s) 2.45 (s) 2.45 (s) 
OH 
5.70 
(d, J=5.1) 
5.70 
(d, J=5.1) 
5.70 
(d, J=5.1) 
5.70 
(d, J=5.1) 
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Table 18: 13C NMR (CDCl3 or DMSO-D6, 300.13 MHZ), chemical shift values, δ, in ppm, for CDXs (145-150) obtained from XCar-5 (110). 
 (S)-XEA5-3-MET 
(145) 
(R)-XEA5-3-MET 
(146) 
(S)-XEA5-4-MET 
(147) 
(R)-XEA5-4-MET 
(148) 
(S)-XEA5-4-CLO 
(149) 
(R)-XEA5-4-CLO 
(150) 
C1 124.2 124.1 124.1 124.0 124.1 124.1 
C2 129.8 129.8 129.9 129.9 129.6 129.5 
C3 134.5 134.5 134.5 134.5 134.5 134.5 
C4 118.9 118.9 118.9 118.9 119.0 119.0 
C4a 157.7 157.7 157.7 157.7 157.8 157.8 
C5 127.1 127.1 127.1 127.1 127.2 127.2 
C6 137.6 137.6 137.6 137.6 137.7 137.7 
C7 133.8 133.8 133.7 133.7 133.8 133.8 
C8 123.6 123.6 123.6 123.6 123.6 123.6 
C8a 121.1 121.1 121.1 121.1 121.1 121.1 
C9 177.3 177.3 177.3 177.3 177.3 177.3 
C9a 120.6 120.6 120.6 120.6 120.6 120.6 
C10a 152.7 152.7 152.7 152.7 152.7 152.7 
C=O amide 164.9 164.9 164.8 164.8 165.0 164.9 
C1' 49.5 49.5 49.0 49.0 49.0 49.0 
C2' (CH3) 21.7 21.8 21.6 21.6 21.8 21.8 
C1'' 144.6 144.6 135.0 135.0 133.2 133.2 
C2'' 112.3 112.3 127.5 127.5 128.8 128.8 
C3'' 159.8 159.8 114.1 114.1 127.7 127.7 
C4'' 112.3 112.3 158.9 158.9 141.6 141.6 
C5''  118.5 118.5 114.1 114.1 127.7 127.7 
C6''  112.7 112.7 127.5 127.5 128.8 128.8 
CH3 (C5 xanthone) 15.7 15.7 15.7 15.7 15.7 15.7 
CH3 (C7 xanthone) 20.8 20.8 20.8 20.8 20.8 20.8 
Ar-OCH3   55.2 55.2 55.3 55.3 - - 
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Table 19: 13C NMR (CDCl3 or DMSO-D6, 300.13 MHZ), chemical shift values, δ, in ppm, for CDXs (151-156) obtained from XCar-5 (110). 
 (S)-XEA5-4-FLU 
(151) 
(R)-XEA5-4-FLU 
(152) 
(S)-XEA5 
(153) 
(R)-XEA5 
(154) 
(S)-XEA5-DES 
(155) 
(R)-XEA5-DES 
(156) 
C1 124.0 124.0 124.1 124.4 124.1 124.1 
C2 129.7 129.7 129.9 129.9 129.8 129.8 
C3 134.5 134.5 134.5 134.5 134.5 134.5 
C4 119.0 119.0 118.9 118.9 118.9 118.9 
C4a 157.8 157.8 157.7 157.9 157.7 157.7 
C5 127.2 127.2 127.1 127.1 127.1 127.1 
C6 137.7 137.7 137.6 137.6 137.6 137.6 
C7 133.9 133.9 133.8 133.8 133.8 133.8 
C8 123.6 123.6 123.6 123.6 123.6 123.6 
C8a 121.1 121.1 121.1 121.1 121.1 121.1 
C9 177.3 177.3 177.3 177.3 177.3 177.3 
C9a 120.6 120.6 120.6 120.6 120.6 120.6 
C10a 152.7 152.7 152.7 152.7 152.7 152.7 
C=O amide 165.0 165.0 164.8 164.8 164.9 164.9 
C1' 48.9 48.9 49.4 49.4 49.5 49.5 
C2' (CH3) 21.8 21.8 21.1 21.1 21.7 21.7 
C1'' 135.0 135.0 137.2 137.2 142.9 142.9 
C2'' 128.0 128.0 129.4 129.4 126.3 126.3 
C3'' 115.6 115.6 126.2 126.2 128.7 128.8 
C4'' 138.8 138.8 139.9 139.9 127.5 127.5 
C5''  115.6 115.6 126.2 126.2 128.7 128.8 
C6''  128.0 128.0 129.4 129.4 126.3 126.3 
CH3 (C5 xanthone) 15.7 15.7 15.7 15.7 15.7 15.7 
CH3 (C7 xanthone) 20.8 20.8 20.8 20.8 20.8 20.8 
Ar-CH3   - - 21.7 21.7 - - 
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Table 20: 13C NMR (CDCl3 or DMSO-D6, 300.13 MHZ), chemical shift values, δ, in ppm, for CDXs 
(157-160) obtained from XCar-5 (110). 
 (S,S)-X2ADF5 
(157) 
(R,R)-X2ADF5 
(158) 
(S,R)-X2ADF5 
(159) 
(R,S)-X2ADF5 
(160) 
C1 125.2 125.5 125.5 124.5 
C2 130.1 130.2 129.6 129.6 
C3 134.0 134.2 134.3 134.4 
C4 118.5 118.5 118.9 118.9 
C4a 156.9 156.9 157.8 157.8 
C5 127.0 127.0 127.1 127.1 
C6 137.6 137.6 137.6 137.6 
C7 133.5 133.5 133.8 133.8 
C8 122.9 122.9 123.6 123.6 
C8a 120.6 120.7 121.1 121.1 
C9 176.1 176.2 177.2 177.2 
C9a 120.1 120.2 120.6 120.7 
C10a 152.7 152.7 152.7 152.7 
C=O amide 163.8 164.6 166.0 165.6 
C1' 59.25 59.25 60.24 59.85 
CHOH 74.54 75.55 74.90 74.90 
C1'' 143.6 143.0 140.7 140.7 
C2'' and C6’’ 127.6 127.7 127.9 128.1 
C3'' and C5’’ 128.4 127.8 127.8 128.2 
C4'' 126.9 126.8 127.0 127.8 
C1’’’ 141.3 141.2 139.4 139.7 
C2’’’ and C6’’’ 127.0 127.0 127.8 128.0 
C3’’’ and C5’’’ 127.7 127.7 127.4 128.2 
C4’’’ 126.7 126.6 126.1 126.5 
CH3 (C5 
xanthone) 
15.19 15.24 15.72 15.72 
CH3 (C7 
xanthone) 
20.34 20.36 20.86 20.86 
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2. Enantiomeric purity  
LC has proven to be one of the best methods for the separation and analysis of 
enantiomers.108,109 Moreover, the LC using CSPs is the most helpful between the currently 
analytical methods to determine the enantiomeric purity.85 
The chiral separation method should take only a short analysis time and preferably 
use inexpensive and “green” solvents. Herein, we explored the LC enantioseparation of 
the synthesized CDXs based on a recent study using Pirkle-type CSPs.86  The (S,S)-
Whelk-O1 CSP (Figure 22) was chosen since it demonstrated a very good 
enantioresolution performance for CDXs possessing an aromatic moiety linked to the 
stereogenic center with excellent separation (α) and resolution (Rs) factors, under polar-
organic conditions.86 
 
 
                               
 
Figure 22: The chemical structure of (S,S)-Whelk-O1 CSP. 
 
The mixture of two polar-organic solvents, specifically acetonitrile (ACN) and 
methanol (MeOH) (50:50 v/v), as mobile phase has been tested in our group and showed 
excellent results with outstanding enantioselectivity, resolution and shorter retention time. 
The polar-organic conditions proved to be a best alternative to the normal-phase 
conditions.86  
Consequently, and based on described work,86 enantiomeric mixtures of the 
synthesized CDXs were prepared and separated using the following chromatographic 
conditions: (S,S)-Whelk-O1 CSP, MeOH:ACN (50:50 v/v) as mobile phase, flow rate at 
1.0 mL/min and U.V detection at 254nm. The chromatographic data obtained for all the 
enantiomeric mixtures of CDXs is shown in Table 21. 
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 Table 21: Chromatographic results obtained on (S,S)-Whelk-O1 CSP, under polar organic 
elution condition, for the enantiomeric mixtures of synthesized CDXs. 
Enantiomeric 
mixtures of CDXs 
k1 k2 α RS 
XEA-3-MET  0.61 3.20 5.27 10.55 
XEA-4-MET 0.67 3.32 4.92 15.09 
XEA-4-FLU 0.49 2.01 4.07 11.46 
XEA-4-CLO 0.66 3.91 5.91 16.59 
X2ADF5 – RR,SS 0.48 0.82 1.69 2.42 
X2ADF5 -RS,SR 0.44 0.68 1.53 2.12 
XEA5 0.64 3.23 5.01 11.55 
XEA5-DES 0.61 2.58 4.22 11.73 
XEA5-3-MET 0.66 3.96 5.97 16.84 
XEA5-4-MET 0.79 4.65 5.84 17.20 
XEA5-4-FLU 0.54 2.54 4.65 11.87 
XEA5-4-CLO 0.67 4.20 6.25 16.22 
 
Mobile phase conditions: MeOH:ACN (50:50 v/v), flow rate 1.0 mL/min. k = retention factor, α = separation 
factor, Rs = resolution factor. 
 
All enantiomeric mixtures of CDXs were enantioseparated with excellent 
enantioselectivity on (S,S)-Whelk-O1 CSP, with α ranging from 1.53 to 6.25 and 
resolutions ranging from 2.12 to 17.20. The (R)-enantiomer of all enantiomeric pairs of 
CDXs was the first to elute in the tested conditions. 
The same chromatographic conditions were used to determine the enantiomeric 
excess (e.e.) for both enantiomers of all CDXs (Table 22). The e.e. values were 
determined by injecting the solutions of enantiomeric mixtures prepared mixing equal 
aliquots of each enantiomer and then each enantiomer separately. Solutions of each 
enantiomer contaminated with 1% of the opposite enantiomer were also prepared. 
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Table 22: Enantiomeric excess (e.e) of CDXs. 
CDXs e.e CDXs e.e 
(S)-XEA-3-MET 
(137) 
>99.9% (S)-XEA5-4-CLO 
(149) 
99.6% 
(R)-XEA-3-MET 
(138) 
99.8% (R)-XEA5-4-CLO 
(150) 
99.5% 
(S)-XEA-4-MET 
(139) 
99.9% (S)-XEA5-4-FLU 
(151) 
99.8% 
(R)-XEA-4-MET 
(140) 
99.9% (R)-XEA5-4-FLU 
(152) 
>99.9% 
(S)-XEA-4-CLO 
(141) 
>99.9% (S)-XEA5 
(153) 
99.2% 
(R)-XEA-4-CLO 
(142) 
99.5% (R)-XEA5 
(154) 
99.3% 
(S)-XEA-4-FLU 
(143) 
99.7% (S)-XEA5-DES 
(155) 
>99.9% 
(R)-XEA-4-FLU 
(144) 
99.2% (R)-XEA5-DES 
(156) 
>99.9% 
(S)-XEA5-3-MET 
(145) 
99.6% (S,S)-X2ADF5 
(157) 
99.1% 
(R)-XEA5-3-MET 
(146) 
99.3% (R,R)-X2ADF5 
(158) 
99.2% 
(S)-XEA5-4-MET 
(147) 
>99.9% (S,R)-X2ADF5 
(159) 
99.2% 
(R)-XEA5-4-MET 
(148) 
99.4% (R,S)-X2ADF5 
(160) 
99.2% 
Mobile phase conditions: MeOH:ACN (50:50 v/v), flow rate 1.0 mL/min,.e.e = enantiomeric excess. 
As shown in Table 22 the e.e. values were higher than 99%. These results 
emphasize that do not occur racemization in the course of the synthesis. Figure 23 - 
Figure 27 show an example of characteristic chromatograms obtained during the 
determination of the elution order and measuring of the e.e. XEA-4-FLU enantiomers. 
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Figure 23: Chromatogram of enantiomeric mixture of XEA-4-FLU. Chromatographic conditions: 
column, (S,S)-Whelk-O1 CSP; mobile phase: MeOH:ACN (50:50 v/v); flow rate, 1.0 mL/min 
detection, 254 nm. 
 
 
 
Figure 24: Chromatogram of (R)-enantiomer of XEA-4-FLU (144). Chromatographic conditions: 
column, (S,S)-Whelk-O1 CSP; mobile phase: MeOH:ACN (50:50 v/v); flow rate, 1.0 mL/min 
detection, 254 nm. 
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Figure 25: Chromatogram of (S)-enantiomer of XEA-4-FLU (143). Chromatographic conditions: 
column, (S,S)-Whelk-O1 CSP; mobile phase: MeOH:ACN (50:50 v/v); flow rate, 1.0 mL/min 
detection, 254 nm. 
 
 
 
 
Figure 26: Chromatogram of (R)-enantiomer of XEA-4-FLU (144) spiked with 1% of (S)-
enantiomer. Chromatographic conditions: column, (S,S)-Whelk-O1 CSP; mobile phase: 
MeOH:ACN (50:50 v/v); flow rate, 1.0 mL/min detection, 254 nm. 
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Figure 27: Chromatogram of (S)-enantiomer of XEA-4-FLU (143) spiked with 1% of (R)-
enantiomer. Chromatographic conditions: column, (S,S)-Whelk-O1 CSP; mobile phase: 
MeOH:ACN (50:50 v/v); flow rate, 1.0 mL/min detection, 254 nm. 
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3. Biological activity 
 
3.1. Effect on the growth of human tumor cell lines 
The library of twenty-four new synthesized CDXs, in enantiomerically pure form, 
and the two xanthonic chemical substrates (Xcar-2, 108 and XCar-5, 110) were tested in 
order to evaluated their effect on the in vitro growth of three human tumor cell lines: A375-
C5 (melanoma), MCF-7 (breast adenocarcinoma), and NCI-H460 (non-small cell lung 
cancer). The biological activity of the compounds was evaluated by Professor Hassan 
Bousbaa and co-workers. in Instituto Superior de Ciências da Saúde – Norte (ISCS-N) – 
CESPU. 
This drug-screening procedure, adopted from the National Cancer Institute (NCI, 
USA), uses the protein binding dye sulforhodamine B, SRB,,to assess cell growth.110 For 
each compound, a dose–response curve was established. The results, expressed as the 
concentration that was able to cause 50% cell growth inhibition (GI50), are summarized in 
Table 23. 
Table 23: Growth inhibitory activity of synthezised CDXs and XCars on the growth of three human 
tumor cell lines. 
Compounds 
GI50 (μM) 
A375-C5 MCF-7 NCI-H460 
XCar-2  
(108) 
113.75 ± 23.55 134.32 ± 10.34 >150 
(S)-XEA-3-MET 
(137) 
54.84 ± 46.02 92.55 ± 14.54 68.63 ± 5.91 
(R)-XEA-3-MET 
(138) 
>150 >150 >150 
(S)-XEA-4-MET 
(139) 
40.46 ± 6.02 37.35 ± 4.56 37.02 ± 4.75 
(R)-XEA-4-MET 
(140) 
59.99 ± 4.79 37.00 ± 7.67 38.80 ± 8.35 
(S)-XEA-4-CLO 
(141) 
72.72 ± 52.17 50.35 ± 40.02 86.55 ± 75.23 
(R)-XEA-4-CLO 
(142) 
89.31 ± 11.26 59.63 ± 4.91 87.24 ± 7.91 
(S)-XEA-4-FLU 
(143) 
>150 81.64 ± 13.43 104 ± 2.83 
(R)-XEA-4-FLU 
(144) 
137.5 ± 2.12 42.34 ± 31.61 70.33 ± 10.20 
XCar-5 
(110) 
102.97 ± 22.24 90.51 ± 1.07 112.67 ± 12.34 
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Table 23: Continuation 
(S)-XEA5-3-MET 
(145) 
>150 >150 >150 
(R)-XEA5-3-MET 
(146) 
>150 >150 >150 
(S)-XEA5-4-MET 
(147) 
>150 99.69 ± 6.12 75.31 ± 5.36 
(R)-XEA5-4-MET 
(148) 
>150 85.89 ± 10.60 85.52 ± 16.47 
(S)-XEA5-4-CLO 
(149) 
63.44 ± 15.86 53.35 ± 0.43 48.41 ± 1.60 
(R)-XEA5-4-CLO 
(150) 
86.47 ± 6.04 69.35 ± 13.98 49.60 ± 9.74 
(S)-XEA5-4-FLU 
(151) 
>150 >150 >150 
(R)-XEA5-4-FLU 
(152) 
>150 133.50 ± 10.10 >150 
(S)-XEA5 
(153) 
>150 93.59 ± 2.26 
 
83.05 ± 13.16 
 
(R)-XEA5 
(154) 
>150 >150 122.68 ± 21.00 
(S)-XEA5-DES 
(155) 
>150 >150 >150 
(R)-XEA5-DES 
(156) 
>150 >150 >150 
(S,S)-X2ADF5 
(157) 
109.01 ± 8.20 75.28 ± 17.86 75.31 ± 18.13 
(R,R)-X2ADF5 
(158) 
>150 84.35 ± 12.04 61.40 ± 21.32 
(S,R)-X2ADF5 
(159) 
72.17 ± 7.60 38.75 ± 4.54 36.65 ± 7.58 
(R,S)-X2ADF5 
(160) 
111.11 ± 21.52 50.38 ± 7.24 42.36 ± 5.63 
*Results are expressed as mean ± SD of data obtained from three independent experiments. 
 
The overall results obtained demonstrate that some CDXs exhibited interesting 
growth inhibitory effects on the tested human tumor cell lines. Actually, the most active 
CDX in all human tumor cell lines was compound (S)-XEA-4-MET (139) presenting values 
of GI50 = 37.02 ± 4.75 μM, GI50 = 37.35 ± 4.56 μM and GI50 = 40.46 ± 6.02 μM for NCI-
H460, MCF-7 and A375-C5, respectively. Moreover, its antipode (R)-XEA-4-MET (140) 
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also revealed interesting inhibitory effects with values of GI50 = 38.80 ± 8.35 μM, GI50 = 
37.00 ± 7.67 μM and GI50 = 59.99 ± 4.79 μM for NCI-H460, MCF-7 and A375-C5, 
respectively. 
Others CDXs synthesized by coupling the xanthonic chemical substrate XCar-2 
(108) with chiral amines as building blocks were also able to inhibit the growth of cell lines, 
such as (R)-XEA-4-FLU (144) with GI50 value of 42.34 ± 31.61 μM for MCF-7. 
Among the synthesized CDXs obtained from XCar-5 (110), compound (S,R)-
X2ADF5 (159) presented the higher tumor cell growth inhibitory effect with values of GI50 
= 36.65 ± 7.58 μM, and GI50 = 38.75 ± 4.54 μM in the cell lines NCI-H460 and MCF-7, 
respectively. Both enantiomers of XEA5-4-MET also revealed interesting results. For 
example, for the cell lines NCI-H460 and MCF-7 the (S)-enantiomer (149) showed values 
of GI50 = 75.31 ± 5.36 μM, and GI50 = 99.69 ± 6.12 μM, respectively; the values of GI50 for 
(R)-enantiomer (150) in the same cell lines were 85.52 ± 16.47 μM, and 85.89 ± 10.6 μM, 
respectively. 
XCar-5 (110) possessing two methyl groups showed better results (although 
presenting a weaker activity) in all human tumor cell lines tested than XCar-2 (108) 
possessing one methoxy group. However, in general, the CDXs synthesized from XCar-2 
(108) showed better results than the CDXs obtained from XCar-5 (110). 
Furthermore, the evaluation of the growth inhibitory effect of the series of CDXs 
synthesized by coupling the carboxyxanthones XCar-2 (108) or XCar-5 (110) with different 
chiral amines allowed taking some considerations regarding structure–activity relationship.  
For example, comparing the results obtained with the CDXs (S)-XEA-4-MET (139) 
and its enantiomer (R) (140) and (S)-XEA5-4-MET (147) and its enantiomer (R) (148), 
possessing the same chiral moiety while the xanthonic chemical substrates is the XCar-2 
(108) and XCar-5 (110), respectively, it can be seen that: the first pair of compounds 
exhibited the highest growth inhibitory effects on the three human tumor cell lines, while 
the second pair was practically inactive. Therefore, it is interesting to emphasise that the 
nature of the substituents and their positions on the xanthonic chemical substrate also 
have an important role in growth inhibitory effect and enantioselectivity. 
Concerning the influence of the configuration on the activity, several examples of 
enantioselectivity occurred between the enantiomeric pairs of CDXs obtained from XCar-2 
on human tumor cell lines tested. For example, the CDX (R)-XEA-3-MET (138) was 
inactive for all cell lines tested (GI50 > 150 μM), while its enantiomer, (S)-XEA-3-MET 
(137) was more active presenting values of GI50 = 92.55 ± 14.54 μM, GI50 = 68.63 ± 
5.91μM and GI50 = 54.84 ± 46.02 μM for MCF-7, NCI-H460 and A375-C5, respectively. 
 
98 
 
Another interesting example of enantioselectivity was observed between the 
enantiomers (S)-XEA-4-FLU (143) and (R)-XEA-4-FLU (144) in MCF-7 human tumor cell 
line. In fact, (S)-XEA-4-FLU (143) presented a slight inhibitory activity (GI50 = 81.64 ± 
13.43 μM), while (R)-XEA-4-FLU (144) was able to inhibit the growth of this cell line with a 
GI50 = 42.34 ± 31.61μM. Considering these results as well as the incapacity of both 
enantiomers to inhibit the growth of the human tumor cell line A375-C5, it can be 
emphasized that cell-type selectivity also occurred. 
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Chapter 3:  
                  Experimental 
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1. Chemistry 
 
1.1. General Methods 
 
All the synthesis were performed in Laboratory of Organic and Medicinal Chemistry of 
the Faculty of Pharmacy of the University of Porto. 
The commercial available reagents and solvents were purchased from Sigma Aldrich 
Co and were used without purification. 
All the reactions were monitored by thin-layer chromatography (Merck silica gel, 60 
(GF254 plates), with appropriate mobile phases, and UV detection at 245 and 365 nm. 
Purifications of compounds were carried out by flash chromatography using 
Macherey-Nagel silica gel 60 (0.04-0.063 mm), liquid-liquid extraction and crystallization.  
Solvents were evaporated on a rotary evaporator under reduced pressure (rotative 
evaporator Büchi). 
Optical rotation measurements were carried out on a Polartronic Universal 
polarimeter (ADP 410 polarimeter).  
Melting points were obtained in a Köfler microscope and are uncorrect.  
IR spectra were obtained in KBr microplate in a FTIR spectrometer Nicolet iS10 from 
Thermo Scientific (Waltham, MA, USA) with Smart OMNI-Transmisson accessory 
(Software 188 OMNIC 8.3). 
1H and 13C NMR spectra were performed in the Department of Chemistry of the 
University of Aveiro and were taken using CDCl3 or DMSO as solvent at room temperature, 
on Bruker Avance 300 and 500 instruments (300.13 MHz for 1H and 75.47 MHz for 13C). 
Chemical shifts are expressed in 𝜹 (ppm) values relative to tetramethylsilane (TMS) used 
as an internal reference; 13C NMR assignments were made by 2D (HSQC and HMBC) 
NMR experiments (long-range 13C-1H coupling constants were optimized to 7 Hz).  
MS spectra were recorded as electronic impact mode on a VG Autospec Q 
spectrometer (m/z) and HRMS mass spectra were measured on a Bruker Daltonics 
micrOTOF Mass Spectrometer, recorded as electrospray modein Centro de Apoio 
Científico e Tecnológico á Investigation (C.A.C.T.I.), University of Vigo, Spain. 
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1.2. Synthesis of 6-methoxy-9-oxo-9H-xanthene-2-carboxylic acid (XCar-2, 108) 
and 8-methoxy-9-oxo- 9H-xanthene-2-carboxylic acid (XCar-3, 109) 
 
1.2.1. Esterification of 4-bromoisophthalic acid (111). Dimethyl 4-
bromoisophthalate (112)      
To a solution of 4-bromoisophthalic acid (111) (19.78 g, 79.62 mmol) in methanol 
(600 mL) was added 12 mL of concentrated H2SO4. Then, the reaction mixture was 
refluxed for 20 h. After evaporation of the methanol, water (65 mL) was added and the 
crude product was extracted with diethyl ether (3 x 70 mL).  The organic layer was washed 
with water (100 mL), saturated NaHCO3 solution (3 x 120 mL) and water (2 x 100 mL), 
successively. After drying with anhydrous sodium sulfate and filtered, the solvent was 
evaporated under reduced pressure. During overnight at room temperature the dimethyl 4-
bromoisophthalate (112) appeared as a white solid. Yield: 92.3%; m.p. 56-58oC; IR max 
(cm-1) (KBr): 1754, 1309, 1253, 929, 565; 1H NMR (CDCl3, 300MHz) δ: 8.43 (1H, d, J= 2.2 
Hz, H-2), 7.95 (1H, dd, J= 8.3 and 2.2 Hz, H-6),  7.75 (1H, d, J= 8.3 Hz, H-5), 3.95 (3H, s, 
C(1’’)OOCH3), 3.93 (3H,s, C(1’)OOCH3); 13C NMR (CDCl3, 75.47 MHz) δ: 165.7 (C-1’’), 
165.5 (C-1’), 134.7 (C-4), 133.0 (C-6), 132.3 (C-2), 132.2 (C-5), 129.3 (C-3), 127.0 (C-1), 
52.7 (C(1’’)OOCH3), 52.5 (C(1’)OOCH3); MS (El) m/z (%): 273 [M]+. (100), 256 (9), 240 (13), 
221 (6), 209 (8), 203 (11). 
 
1.2.2. Ullmann diaryl ether coupling. Dimethyl 4-(3-methoxyphenoxy) 
isophthalate (114) 
A mixture of dimethyl 4-bromoisophthalate (112) (8.28 g, 30.33 mmol), 3-
methoxyphenol (113) (4.5 mL, 36.39 mmol), CuI (0.29 g, 3.70 mmol), K3PO4 (12.86 g, 
73.94 mmol) picolinic acid (1.14 g, 11.09 mmol) the sealed flask was then evacuated and 
backfilled with nitrogen. The evacuation/backfill sequence was repeated two additional 
times. Under nitrogen atmosphere remaining liquid reagents were added, followed by 3-
methoxyphenol and dimethyl sulfoxide (61 mL). 
The sealed flask was placed in a preheated oil bath at 80 °C and the reaction 
mixture was stirred vigorously with a magnetic stirrer for 28h. The reaction mixture was 
cooled to room temperature, filtered and extract with ethyl acetate (300 mL) and water (30 
mL). The organic layer was washed with water (30 mL) and separated. The aqueous layer 
was extract twice more with ethyl acetate (20 mL). The combined organic layer were 
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washed with brine dried with anhydrous sodium sulfate, filtered, and evaporated under 
reduce pressure. The oily dark product was purified by flash chromatography (silica gel, 
petroleum ether/diethyl ether in gradient) to provide dimethyl 4-(3-methoxyphenoxy) 
isophthalate (114). Yield: 96%; m.p. 88-90 °C; IR max (cm-1) (KBr): 1724, 1719, 1613, 1488, 
1274, 1229, 1153, 948, 763; 1H NMR (CDCl3, 300MHz) δ: 8.58 (1H, d, J= 2.2 Hz, H-2), 8.07 
(1H, dd, J=8.7 and 2.2 Hz, H-6), 7.27 (1H, dd, J= 8.4 and 8.3 Hz, H-5’), 6.95 (1H, d, J=8.7 
Hz, H-5), 6.74 (1H, dd, J= 8.3 and 3.1 Hz, H-6’), 6.62 (1H, dd, J= 3.6 and 3.1 Hz, H-2’), 
6.61 (1H, dd, J= 8.4 and 3.6 Hz, H-4’), 3.93 (3H, s, C(1’)OOCH3), 3.89 (3H, s, 
C(1’’)OOCH3), 3.79 (3H, s, Ar-OCH3); 13C NMR (CDCl3, 75.47 MHz) δ: 165.7 (C-1’), 165.3 
(C-1’’), 161.1 (C-3), 160.4 (C-1), 156.9 (C-4), 134.6 (C-2), 133.6 (C-6), 130.4 (C-5), 124.6 
(C-3’), 122.0 (C-1’), 118.7 (C-5’), 111.6 (C-6’), 110.3 (C-4’), 105.6 (C-2’), 55.4 (Ar-OCH3), 
52.3 (C(1’)OOCH3), 52.2 (C(1’)OOCH3); MS (El) m/z (%): 316 [M]+. (100), 285 [M-OCH3]+. 
(55), 253 (54), 242 (10), 225 (16), 213 (12), 198 (25), 138 (15), 127 (10), 92 (15), 83 (14), 
64 (11). 
 
1.2.3. Hydrolysis of dimethyl ester. 4-(3-Methoxyphenoxy)isophthalic acid 
(115)  
 
Dimethyl 4-(3-methoxyphenoxy)isophthalate (114) (20.04 g, 63.35 mmol) was 
dissolved in methanol/tetrahydrofuran (1:1 v/v) and stirred at room temperature with 5M 
NaOH solution (67 mL) for 18 h. After evaporation of the organic solvents, water was added 
(400 mL) and the crude product was washed with ethyl acetate (2 x 200 mL). The organic 
layer was extracted with water (2 x 150 mL). The aqueous layer was acidified with 5M HCl 
solution resulting in the formation of a precipitate that was collected by filtration under 
reduced pressure and washed with cooled water, to provide 4-(3-
methoxyphenoxy)isophthalic acid (115) as a white solid. Yield: 92% m.p. 232-234°C;  IR 
max (cm-1) (KBr): 2907, 1694, 1680, 1601, 1486,1271,1265, 911, 758; 1HNMR (CDCl3, 
300.13 MHz) δ: 8.53 (1H, d, J= 2.2 Hz, H-2), 8.09 (1H, dd, J= 8.7 and 2.2 Hz, H-6), 7.29 
(1H, dd, J= 8.3 and 8.4 Hz, H-5’), 6.95 (1H, d, J= 8.7 Hz, H-5), 6.76 (1H, dd, J= 3.1 and 8.3 
Hz, H-6’), 6.62 (1H, dd, J= 3.1 and 3.3 Hz, H-2’), 6.59 (1H, dd, J= 3.3 and 8.3 Hz, H-4’), 
3.77 (3H, s, Ar-OCH3); 13C NMR (CDCl3, 75.47 MHz) δ: 179.3 (C-1’’), 179.3 (C-1’), 163.5 
(C-3), 162.5 (C-1), 159.2 (C-4), 145.3 (C-2), 136.6 (C-6), 135.5 (C-5), 132.3 (C-3’), 127.3 
(C-1’), 120.6 (C-5’), 113.4 (C-6’), 112.1 (C-4’), 107.5 (C-2’), 56.7(Ar-OCH3); MS (EI) m/z 
(%): 288[M]+. (100), 271 (10), 257[M-OCH3]+. (12), 227 (11), 199 (23), 165 (61), 124 (63), 92 
(23), 77 (20), 64 (19). 
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1.2.4. Intramolecular acilation. Xanthones formation 
 
To a solution of 4-(3’-methoxypenthoxy)isophthalic acid (115) (7.00 g, 14.40 mmol) 
in methane sulfonic acid (101.2 mL) was added phosphorus pentoxide (11.01 g,  45.99 
mmol) and the reaction mixture was stirred at room temperature for 22 h. The mixture was 
poured over ice, resulting in the formation of a cream-coloured solid that was collected by 
filtration under reduced pressure and dried at room temperature. The crude product was 
dissolved in methanol (1200 mL) and H2SO4 (24 mL) was added. The mixture was refluxed 
for approximately 19h. The products methyl 6-methoxy-9-oxo-9H-xanthene-2-carboxylate 
(116) and methyl 8-methoxy-9-oxo-9H-xanthene-2-carboxylate (117) were separated by 
flash column chromatography (silica gel, petrolium ether:ethyl acetate in gradient). After 
that, compound 116 (2.08 g) was dissolved in methanol/dichloromethane (670 mL, 1:1 v/v) 
and 5M NaOH solution (29 mL) was added. The mixture was stirred at room temperature 
for 22 h. After evaporation of the organic solvents, water was added (100 mL) and the 
solution was acidified with 5M HCl solution resulting in the formation of a white precipitate. 
The suspension was filtered under reduced pressure and the white solid was washed with 
water, to afford 6-methoxy-9-oxo-9H-xanthene-2-carboxylic acid (108). Yield: 93%. The 
same procedure was followed to hydrolyse the methyl 8-methoxy-9-oxo-9H-xanthene-2-
carboxylate (109) (37 mg, 0.14 mmol) to afford 8-methoxy-9-oxo-9H-xanthene-2-carboxylic 
acid (108). Yield: 1.5% 
 
1.2.4.1. Methyl 6-methoxy-9-oxo-9H-xanthene-2-carboxylate (116) m.p.: 
176-178 °C;  IR max (cm-1) (KBr): 1730, 1663, 1581, 1467, 1438, 1270, 1117, 764; 1HNMR 
(CDCl3, 300.13 MHz) δ: 8.98 (1H, d, J= 2.1 Hz, H-1), 8.32 (1H, dd, J= 2.1 and 8.7 Hz, H-3), 
8.24 (1H, d, J= 8.4 Hz, H-8), 7.48 (1H, d, J= 8.7 Hz, H-4), 6.96 (1H, dd, J= 2.3 and 8.4 Hz, 
H-7), 6.89 (1H, d, J= 2.3 Hz, H-5), 3.95 (3H, s, COOCH3), 3.93 (3H, s, Ar-OCH3); 13C NMR 
(CDCl3, 75.47 MHz) δ: 175.5 (C-9), 165.9 (COOCH3), 165.3 (C-6), 158.7 (C-10a), 157.8 (C-
4a), 134.8 (C-3), 129.1 (C-2), 128.3 (C-8), 125.9 (C-1), 121.5 (C-9a), 118.1 (C-4), 115.6 (C-
8a), 113.7 (C-7), 100.4 (C-5), 55.9 (Ar-OCH3), 52.3 (COOCH3); MS (EI) m/z (%): 284 [M]+. 
(89), 253 [M-OCH3]+. (100), 225 (32), 197 (14), 182 (30), 169 (17), 154 (16), 142 (14), 126 
(28), 111 (12), 75 (12), 63 (14). 
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1.2.4.2. Methyl 8-methoxy-9-oxo-9H-xanthene-2-carboxylate (117). m.p.: 
206-207 °C; IR max (cm-1) (KBr): 1726, 1668, 1611, 1480, 1431, 1264, 1079, 760; 1H NMR 
(CDCl3, 300.13 MHz) δ: 8.98 (1H, d, J= 2.1 Hz, H-1), 8.33 (1H, dd, J= 2.1 and 8.7 Hz, H-3), 
7.65 (1H, dd, J= 8.4 and 8.4 Hz, H-6), 7.47 (1H, d, J= 8.7 Hz, H-4), 7.09 (1H, dd, J= 0.8 and 
8.4 Hz, H-7), 6.86 (1H, dd, J= 0.8 and 8.4 Hz, H-5), 4.05 (3H, s, COOCH3), 3.98 (3H, s, Ar-
OCH3); 13C NMR (CDCl3,125.77 MHz) δ: 175.8 (C-9),166.0 (COOCH3), 160.8 (C-8), 157.9 
(C-10a), 157.8 (C-4a), 135.3 (C-3), 134.9 (C-6), 129.4 (C- 2), 126.0 (C-1), 122.6 (C-9a), 
117.7 (C-4), 112.5 (C-8a), 110.1 (C-7), 106.1 (C-5), 56.5 (Ar-OCH3), 52.4 (COOCH3); MS 
(EI) m/z (%): 284 [M]+. (100), 255 (56), 253 (30), 238 (56), 223 (47), 195 (27), 139 (33), 126 
(20), 112 (18), 70 (15), 63 (12). 
 
1.2.4.3. 6-Methoxy-9-oxo-9H-xanthene-2-carboxylic acid (108). m.p.: >300 
°C; IR max (cm-1) (KBr):  3411, 1687, 1610, 1575, 1500, 1433,1271, 766; 1H NMR (DMSO-
d6, 300.13 MHz) δ: 8.68 (1H, d, J= 2.1 Hz, H-1), 8.29 (1H, dd, J= 2.1 and 8.7 Hz, H-3), 8.09 
(1H, d, J= 8.4 Hz, H-8), 7.69 (1H, d, J= 8.7 Hz, H-4), 7.19 (1H, d, J= 2.3 Hz, H-5), 7.07 (1H, 
dd, J= 2.3 and 8.4 Hz, H-7), 3.93 (3H, s, Ar-OCH3); 13C NMR (DMSO-d6, 75.47 MHz) δ: 
175.3 (C-9), 167.6 (COOH), 164.9 (C-6), 157.6 (C-10a), 156.3 (C-4a), 135.7 (C-3), 127.6 
(C-2), 126.6 (C-8), 124.9 (C-1), 120.2 (C-9a), 116.7 (C-4), 115.0 (C-8a), 113.7 (C-7), 100.7 
(C-5), 56.2 (Ar-OCH3); MS (EI) m/z (%): 270 [M]+. (100), 253 [M-OH]+. (26), 226 (27), 199 
(15), 182 (15), 169 (8), 154 (7), 139 (7), 126 (17), 115 (10), 63 (16). 
 
1.2.4.4. 8-Methoxy-9-oxo-9H-xanthene-2-carboxylic acid (109). m.p.: 268-
270 °C; IR max (cm-1) (KBr):  3460, 1687, 1663, 1603, 1469, 1420, 1266, 763; 1H NMR 
(DMSO-d6, 300.13MHz) δ: 8.66 (1H, d, J= 2.1 Hz, H-1), 8.28 (1H, dd, J= 2.1 and 8.7 Hz, H-
3), 7.79 (1H, dd, J= 8.4 and 8.4 Hz, H-6), 7.67 (1H, d, J= 8.7 Hz, H-4), 7.20 (1H, dd, J= 0.7 
and 8.4 Hz, H-7), 7.06 (1H, dd, J= 0.7 and 8.4 Hz, H-5), 3.94 (3H, s, Ar-OCH3); 13C NMR 
(DMSO-d6, 125.77 MHz) δ: 174.3 (C-9), 166.2 (COOH), 160.2 (C-8), 157.2 (C-10a), 157.0 
(C-4a), 136.1 (C-3), 134.9 (C-6), 127.9 (C-2), 125.0 (C-1), 122.1 (C-9a), 118.2 (C-4), 111.6 
(C-8a), 109.7 (C-7), 107.0 (C-5), 56.3 (Ar-OCH3); HRMS (ESI) m/z: calcd for (C15H10O5 + 
H): 271.16994, found: 271.06010. 
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1.3. Synthesis of 5,7-dimethyl-9-oxo-9H-xanthene-2-carboxylic acid (XCar-5, 
110) 
 
1.3.1. Esterification of 4-bromoisophthalic acid (111). Dimethyl 4-
bromoisophthalate (112)    
 The dimethyl 4-bromoisophthalate (112) was synthesized (yield 90.7 %) and 
characterized according to the procedure described in 1.2.1. (page 102). 
1.3.2. Ullmann diaryl ether coupling. Dimethyl 4-(2,4-dimethylphenoxy) 
isophthalate (119) 
 
A mixture of dimethyl 4-bromoisophthalate (112) (9.94 g, 36.39 mmol), 2,4-
dimethylphenol (118) (8.0 mL, 54.59 mmol), CuI (0.35 g, 1.83 mmol), K3PO4 (15.53 g, 
73.17 mmol) picolinic acid (0.45 g, 3.65 mmol) the sealed flask was then evacuated and 
backfilled with nitrogen. The evacuation/backfill sequence was repeated two additional 
times. Under nitrogen atmosphere remaining liquid reagents were added, followed by 2,4-
dimethylphenol and dimethyl sulfoxide (73 mL). The sealed flask was placed in a preheated 
oil bath at 80 °C and the reaction mixture was stirred vigorously with a magnetic stirbar for 
28h.  The reaction mixture was cooled to room temperature, filtered and extracted with 
ethyl acetate (300 mL) and water (30 mL). The organic layer was washed with water (30 
mL) and separated. The aqueous layer was extracting twice more with ethyl acetate (20 
mL). The combined organic layer were washed with brine dried with anhydrous sodium 
sulfate, filtered, and evaporated under reduce pressure, the product dimethyl 4-(2,4-
dimethylphenoxy) isophthalate (119) is oily dark. Yield: 87 %; m.p. 97-99 °C; IR max (cm-1) 
(KBr): 1717, 1436, 1259; 1H NMR (DMSO-d6, 300.13MHz) δ: 8.35 (1H, d, J= 2.2 Hz, H-2), 
8.00 (1H, dd, J= 8.7 and 2.2 Hz, H-6), 7.17 (1H, s, H-3’), 7.08 (1H, d, J= 8.2 Hz, H-6’), 6.89 
(1H, d, J= 8.2 Hz, H-5’), 6.70 (1H, d, J= 8.7 Hz, H-5), 3.84 (3H, s, C(3)OOCH3), 3.84 (3H, s, 
C(1)OOCH3), 2.29 (3H, s, C-4’-CH3), 2.07 (3H, s, C-2’-CH3); 13C NMR (DMSO d6, 125.77 
MHz) δ: 166.1 (C(3)OOCH3), 166.0 (C(1)OOCH3), 165.1 (C-3), 164.9 (C-1), 160.3 (C-4), 
134.9 (C-6), 134.2 (C-2), 124.9 (C-1’), 124.4 (C-3’), 121.9 (C-5’), 120.3 (C-6’), 120.3 (C-5), 
116.3 (C-2’), 116.2 (C-4’), 52.3 (C(3)OOCH3), 52.2 (C(1)OOCH3), 21.0 (C-2’-CH3), 20.4 (C-
4’-CH3). 
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1.3.3. Hydrolysis of dimethyl ester. 4-(2,4-Dimethylphenoxy)isophthalic acid 
(120) 
 
Dimethyl 4-(2,4-dimethylphenoxy) isophthalate (119) (21.37 g, 68.05 mmol) was 
dissolved in methanol/tetrahydrofuran (1:1 v/v) and stirred at room temperature with 5M 
NaOH solution (72 mL) for 18 h. After evaporation of the organic solvents, water was added 
(400 mL) and the crude product was washed with ethyl acetate (2 x 200 mL). The organic 
layer was extracted with water (2 x 150 mL). The aqueous layer was acidified with 5M HCl 
solution resulting in the formation of a precipitate that was collected by filtration under 
reduced pressure and washed with cooled water, to provide 4-(2,4-
dimethylphenoxy)isophthalic acid (120) as a dark brown solid. Yield: 61 % m.p. 240-242 °C; 
IR max (cm-1) (KBr): 2923, 1613, 1604, 1491, 1257; 1H NMR (DMSO-d6, 300.13MHz) δ: 
8.33 (1H, d, J= 2.2 Hz, H-2), 7.97 (1H, dd, J= 8.7 and 2.2 Hz, H-6), 7.16 (1H, s, H-3’), 7.07 
(1H, d, J= 8.1 Hz, H-6’), 6.87 (1H, d, J= 8.1 Hz, H-5’), 6.67 (1H, d, J= 8.7 Hz, H-5), 2.29 
(3H, s, C-4’-CH3), 2.07 (3H, s, C-2’-CH3); 13C NMR (DMSO-d6, 125.77 MHz) δ: 166.3 
(C(3)OOH), 166.2 (C(1)OOH), 165.1 (C-3), 164.2 (C-1), 160.0 (C-4), 134.4 (C-2), 132.9 (C-
6), 128.2 (C-1’), 124.3 (C-3’), 122.0 (C-5’), 120.4 (C-6’), 120.3 (C-5), 118.1 (C-4’), 116.3 (C-
2’), 20.4 (C-2’-CH3), 15.5 (C-4’-CH3). 
 
1.3.4. Intramolecular acilation. Xanthone formation 
 
To a solution of 4-(2,4-dimethylphenoxy)isophthalic acid (120) (7.87 g, 14.49 mmol) 
in methane sulfonic acid (114 mL) was added phosphorus pentoxide (12.36 g,  45.99 
mmol) and the reaction mixture was stirred at room temperature for 22 h. The mixture was 
poured over ice, resulting in the formation of a cream-brown solid that was collected by 
filtration under reduced pressure and dried at room temperature to provide 5,7-dimethyl-9-
oxo-9H-xanthene-2-carboxylic acid (XCar-5, 110). Yield: 87%; m.p.  >300 °C; IR max (cm-1) 
(KBr): 2920, 1667, 1611, 1475, 1421, 768, 680; 1H NMR (DMSO-d6, 300.13 MHz) δ: 8.61 
(1H, d, J= 2.1 Hz, H-1), 8.23 (1H, dd, J= 8.7 and 2.1 Hz, H-3), 7.60 (1H, d, J= 8.7 Hz,  H-4), 
7.24 (1H, s, H-8), 7.02 (1H, s, H-6), 2.75 (3H, s, C-7-CH3), 2.50 (3H, s, C-5-CH3); 13C NMR 
(DMSO-d6, 125.77 MHz) δ: 176.8 (C-9), 166.2 (C=OOH), 157.1 (C-10a), 156.8 (C-4a), 
145.8 (C-7), 140.7 (C-5), 134.9 (C-3), 128.6 (C-6), 128.0 (C-1), 126.3 (C-2), 121.7 (C-9a), 
118.2 (C-4), 117.1 (C-8a), 116.0 (C-8), 22.6 (C-5-CH3), 21.2 (C-7-CH3). 
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1.4. General procedure for the synthesis of chiral derivatives of xanthones  
 
The 6-methoxy-9-oxo-9H-xanthene-2-carboxylic acid - XCar-2 (108) (100 mg, 0.37 
mmol) or 5,7-dimethyl-9-oxo-9H-xanthene-2-carboxylic acid - XCar-5 (110) (100 mg, 0.37 
mmol) was dissolved in dry THF (20 mL) and TEA (103 mL, 0.74 mmol) was added. 
Following, TBTU (120 mg, 0.37 mmol) and an appropriate chiral reagent (0.37 mmol) were 
added. The mixture was stirred at room temperature for 20 min or 1.5 h. After completion of 
the reaction, the solvent was evaporated under reduced pressure and the crude product 
(137-144) was dissolved in ethyl acetate, (145-156) in dichloromethane, or (157-160) in 
chloroform (50 mL). This solution was washed with 1M HCl solution (2 X 25 mL), saturated 
solution of NaHCO3 (2 X 30 mL) and water (3 X 50 mL). The organic layer was dried with 
anhydrous sodium sulphate, filtered and the solvent was evaporated under reduced 
pressure. The product was recrystallized from ethyl acetate/n-hexane (137-144) and from 
chloroform/n-hexane (145-160), to afford the CDX. 
 
(S)-6-methoxy-N-(1-(3-methoxyphenyl)ethyl)-9-oxo-9H-xanthene-2-carboxamide - (S)-
XEA-3-MET – (137) m.p.: 164-166°C (ethyl acetate/ n-hexane); [α]D25°C -36.4 (c = 5.5 x 10-3 
g/mL in acetone); IR max (cm-1) (KBr): 3319, 1663, 1631, 1533, 1482, 1469, 1440, 1270, 
833; 1H NMR (CDCl3, 300.13 MHz) δ: 8.58 (1H, d, J= 2.2 Hz, H-1), 8.32 (1H, dd, J= 2.3 and 
8.8 Hz, H-3), 8.26 (1H, d, J= 8.9 Hz, H-8), 7.54 (1H, d, J= 8.8 Hz, H-4), 7.30 (1H, d, J= 7.9 
Hz, H-2’’), 7.00-6.98 (2H, m, H-5’’ and H-6’’), 6.97 (1H, dd, J= 2.3 and 8.9 Hz, H-7), 6.93 
(1H, d, J= 2.3 Hz, H-5), 6.83 (1H, ddd, J= 0.7, 2.5 and 8.0 Hz, H-4’’), 6.59 (1H, d, J= 7.8 Hz, 
NH), 5.37-5.28 (1H, m, H-1’), 3.96 (3H, s, Ar-OCH3), 3.82 (3H, s, Ar-OCH3), 1.64 (3H, d, J= 
6.9 Hz, H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 175.9 (C-9), 165.5 (C=O amide), 164.8 (C-
6), 159.9 (C-3’’), 158.0 (C-10a), 157.9 (C-4a), 144.5 (C-1’'), 134.3 (C-3), 130.0 (C-2’’), 
129.8 (C-2), 128.4 (C-8), 124.0 (C-1), 121.1 (C-9a), 118.6 (C-6’’), 118.5 (C-4), 115.5 (C-
8a), 113.8 (C-7), 112.7 (C-4’’), 112.3 (C-5’’), 100.4 (C-5), 55.9 (Ar-OCH3), 55.2 (Ar-OCH3), 
49.6 (C-1’), 21.8 (C-2’). 
  
 (R)-6-methoxy-N-(1-(3-methoxyphenyl)ethyl)-9-oxo-9H-xanthene-2-carboxamide - (R)-
XEA-3-MET – (138) m.p.: 164-166°C (ethyl acetate/ n-hexane); [α]D25°C +39.2 (c = 5.5 x 10-3 
g/mL in acetone); IR max (cm-1)(KBr):  3319, 1666, 1633, 1533, 1482, 1470, 1440, 1271, 
833; 1H NMR (CDCl3, 300.13 MHz) δ: 8.58 (1H, d, J= 2.2 Hz, H-1), 8.32 (1H, dd, J= 2.3 and 
8.8 Hz, H-3), 8.26 (1H, d, J= 8.9 Hz, H-8), 7.54 (1H, d, J= 8.8 Hz, H-4), 7.30 (1H, d, J= 7.9 
Hz, H-2’’), 7.00-6.98 (2H, m, H-5’’ and H-6’’), 6.97 (1H, dd, J= 2.3 and 8.9 Hz, H-7), 6.93 
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(1H, d, J= 2.3 Hz, H-5), 6.83 (1H, ddd, J= 0.7, 2.5 and 8.0 Hz, H-4’’), 6.58 (1H, d, J= 7.8 Hz, 
NH), 5.37-5.28 (1H, m, H-1’), 3.96 (3H, s, Ar-OCH3), 3.82 (3H, s, Ar-OCH3), 1.64 (3H, d, J= 
6.9 Hz, H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 175.9 (C-9), 165.5 (C=O amide), 164.6 (C-
6), 159.9 (C-3’’), 158.0 (C-10a), 157.9 (C-4a), 144.5 (C-1’'), 134.3 (C-3), 130.0 (C-2’’), 
129.9 (C-2), 128.4 (C-8), 124.0 (C-1), 121.1 (C-9a), 118.6 (C-6’’), 118.6 (C-4), 115.5 (C-
8a), 113.8 (C-7), 112.7 (C-4’’), 112.3 (C-5’’), 100.4 (C-5), 55.9 (Ar-OCH3), 55.2 (Ar-OCH3), 
49.6 (C-1’), 21.8 (C-2’). 
 
(S)-6-methoxy-N-(1-(4-methoxyphenyl)ethyl)-9-oxo-9H-xanthene-2-carboxamide - (S)-
XEA-4-MET – (139) m.p.: 210-212°C (ethyl acetate/ n-hexane); [α]D25°C +26.5 (c = 5.6 x 10-3 
g/mL in acetone); IR max (cm-1) (KBr): 3318, 1655, 1629, 1539, 1513, 1478, 1443, 1272, 
831; 1H NMR (CDCl3, 300.13 MHz) δ: 8.56 (1H, d, J= 2.3 Hz, H-1), 8.32 (1H, dd, J= 2.3 and 
8.8 Hz, H-3), 8.26 (1H, d, J= 8.9 Hz, H-8), 7.54 (1H, d, J= 8.8 Hz, H-4), 7.35 (2H, d, J= 8.5 
Hz, H-2’’ and H-6’’), 6.99 (1H, dd, J= 2.4 and 8.9 Hz, H-7), 6.93 (1H, d, J= 2.7 Hz, H-5), 
6.89 (2H, d, J= 2.1 Hz, H-3’’ and H-5’’), 6.59 (1H, d, J= 7.8 Hz, NH), 5.37-5.28 (1H, m, H-
1’), 3.96 (3H, s, Ar-OCH3), 3.81 (3H, s, Ar-OCH3), 1.63 (3H, d, J= 7.0 Hz, H-2’). 13C NMR 
(CDCl3,125.77 MHz) δ: 175.9 (C-9), 165.5 (C=O amide), 164.8 (C-6), 159.0 (C-4’’), 158.0 
(C-10a), 157.9 (C-4a), 135.0 (C-1’'), 134.3 (C-3), 130.0 (C-2), 128.3 (C-8), 127.5 (C-2’’ and 
C-6’’), 124.0 (C-1), 121.1 (C-9a), 118.5 (C-4), 115.5 (C-8a), 114.1(C-3’’ and C-5’’), 113.8 
(C-7), 100.3 (C-5), 55.9 (Ar-OCH3), 55.3 (Ar-OCH3), 49.0 (C-1’), 21.6 (C-2’). 
 
(R)-6-methoxy-N-(1-(4-methoxyphenyl)ethyl)-9-oxo-9H-xanthene-2-carboxamide - (R)-
XEA-4-MET – (140) m.p.: 212-214°C (ethyl acetate/ n-hexane); [α]D25°C -28.5 (c = 5.6 x 10-3 
g/mL in acetone);  IR max (cm-1) (KBr):  3319, 1658, 1636, 1537, 1479, 1443, 1272, 831; ; 
1H NMR (CDCl3, 300.13 MHz) δ: 8.56 (1H, d, J= 2.3 Hz, H-1), 8.32 (1H, dd, J= 2.3 and 8.8 
Hz, H-3), 8.26 (1H, d, J= 8.9 Hz, H-8), 7.54 (1H, d, J= 8.8 Hz, H-4), 7.35 (2H, d, J= 8.5 Hz, 
H-2’’ and H-6’’), 6.99 (1H, dd, J= 2.4 and 8.9 Hz, H-7), 6.93 (1H, d, J= 2.7 Hz, H-5), 6.89 
(2H, d, J= 2.1 Hz, H-3’’ and H-5’’), 6.59 (1H, d, J= 7.8 Hz, NH), 5.37-5.28 (1H, m, H-1’), 
3.96 (3H, s, Ar-OCH3), 3.81 (3H, s, Ar-OCH3), 1.63 (3H, d, J= 7.0 Hz, H-2’). 13C NMR 
(CDCl3,125.77 MHz) δ: 175.9 (C-9), 165.6 (C=O amide), 164.8 (C-6), 159.0 (C-4’’), 158.0 
(C-10a), 157.9 (C-4a), 135.0 (C-1’'), 134.3 (C-3), 130.1 (C-2), 128.3 (C-8), 127.5 (C-2’’ and 
C-6’’), 124.0 (C-1), 121.0 (C-9a), 118.5 (C-4), 115.5 (C-8a), 114.1(C-3’’ and C-5’’), 113.8 
(C-7), 100.3 (C-5), 55.9 (Ar-OCH3), 55.3 (Ar-OCH3), 49.0 (C-1’), 21.6 (C-2’). 
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(S)-N-(1-(4-chlorophenyl)ethyl)-6-methoxy-9-oxo-9H-xanthene-2-carboxamide - (S)-
XEA-4-CLO – (141) m.p.: 190-192 °C (ethyl acetate/ n-hexane); [α]D25°C +136.7 (c = 5.3 x 
10-3 g/mL in chloroform);  IR max (cm-1) (KBr):  3290, 1651, 1635, 1589, 1540, 1480, 1445, 
1275, 826; 1H NMR (CDCl3, 300.13 MHz) δ: 8.59 (1H, d, J= 2.2 Hz, H-1), 8.30 (1H, dd, J= 
2.3 and 8.8 Hz, H-3), 8.24 (1H, d, J= 8.9 Hz, H-8), 7.53 (1H, d, J= 8.8 Hz, H-4), 7.36-7.26 
(4H, m, H-2’’, H-3’’, H-5’’ and H-6’’), 6.98 (1H, dd, J= 2.4 and 8.9 Hz, H-7), 6.91 (1H, d, J= 
2.3 Hz, H-5), 6.71 (1H, d, J= 7.4 Hz, NH), 5.37-5.28 (1H, m, H-1’), 3.95 (3H, s, Ar-OCH3), 
1.62 (3H, d, J= 7.0 Hz, H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 175.9 (C-9), 165.5 (C=O 
amide), 165.0 (C-6), 158.0 (C-10a), 157.9 (C-4a), 141.6 (C-4’’), 134.3 (C-3), 133.1 (C-1’'), 
129.8 (C-2), 128.3 (C-8), 127.6 (C-2’’ and C-6’’), 124.0 (C-1), 121.0 (C-9a), 118.6 (C-4), 
117.8(C-3’’ and C-5’’), 115.5 (C-8a), 113.8 (C-7), 100.3 (C-5), 55.9 (Ar-OCH3), 49.0 (C-1’), 
21.8 (C-2’). 
 
(R)-N-(1-(4-chlorophenyl)ethyl)-6-methoxy-9-oxo-9H-xanthene-2-carboxamide - (R)-
XEA-4-CLO – (142) m.p.: 190-192 °C (ethyl acetate/ n-hexane); [α]D25°C -135.9 (c = 5.3 x 
10-3 g/mL in chloroform);   IR max (cm-1)(KBr):  3296, 1652, 1635, 1590, 1540, 1481, 1445, 
1274, 827; 1H NMR (CDCl3, 300.13 MHz) δ: 8.59 (1H, d, J= 2.2 Hz, H-1), 8.30 (1H, dd, J= 
2.3 and 8.8 Hz, H-3), 8.24 (1H, d, J= 8.9 Hz, H-8), 7.53 (1H, d, J= 8.8 Hz, H-4), 7.36-7.26 
(4H, m, H-2’’, H-3’’, H-5’’ and H-6’’), 6.98 (1H, dd, J= 2.4 and 8.9 Hz, H-7), 6.91 (1H, d, J= 
2.3 Hz, H-5), 6.67 (1H, d, J= 7.4 Hz, NH), 5.37-5.28 (1H, m, H-1’), 3.95 (3H, s, Ar-OCH3), 
1.62 (3H, d, J= 7.0 Hz, H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 175.9 (C-9), 165.5 (C=O 
amide), 164.9 (C-6), 158.0 (C-10a), 157.9 (C-4a), 141.6 (C-4’’), 134.3 (C-3), 133.1 (C-1’'), 
129.8 (C-2), 128.3 (C-8), 127.6 (C-2’’ and C-6’’), 124.0 (C-1), 121.0 (C-9a), 118.6 (C-4), 
117.8(C-3’’ and C-5’’), 115.5 (C-8a), 113.8 (C-7), 100.3 (C-5), 55.9 (Ar-OCH3), 49.0 (C-1’), 
21.8 (C-2’). 
 
(S)-N-(1-(4-fluorophenyl)ethyl)-6-methoxy-9-oxo-9H-xanthene-2-carboxamide - (S)-
XEA-4-FLU – (143) m.p.: 170-172 °C (ethyl acetate/ n-hexane); [α]D25°C +45.5 (c = 5.7 x 10-
3 g/mL in acetone); IR max (cm-1) (KBr):  3316, 1665, 1634, 1511, 1478, 1443, 1274, 833; 
1H NMR (CDCl3, 300.13 MHz) δ: 8.57 (1H, d, J= 2.3 Hz, H-1), 8.32 (1H, dd, J= 2.3 and 8.8 
Hz, H-3), 8.26 (1H, d, J= 8.9 Hz, H-8), 7.55 (1H, d, J= 8.8 Hz, H-4), 7.41–7.37 (2H, m, H-2’’ 
and H-6’’), 7.08-7.03 (2H, m, H-3’’and H-5’’ ), 6.99 (1H, dd, J= 2.3 and 8.9 Hz, H-7), 6.93 
(1H, d, J= 2.3 Hz, H-5), 6.58 (1H, d, J= 7.4 Hz, NH), 5.37-5.28 (1H, m, H-1’), 3.96 (3H, s, 
Ar-OCH3), 1.63 (3H, d, J= 7.0 Hz, H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 175.9 (C-9), 
165.5 (C=O amide), 164.8 (C-6), 161.1 (C-4’’), 158.0 (C-10a), 157.9 (C-4a), 138.7 (C-1’'), 
134.4 (C-3), 129.8 (C-2), 128.4 (C-8), 127.9 (C-2’’ and C-6’’), 123.9 (C-1), 121.0 (C-9a), 
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118.7 (C-4), 115.5 (C-3’’ and C-5’’), 115.6 (C-8a), 113.9 (C-7), 100.4 (C-5), 55.9 (Ar-OCH3), 
48.9 (C-1’), 21.8 (C-2’). 
 
(R)-N-(1-(4-fluorophenyl)ethyl)-6-methoxy-9-oxo-9H-xanthene-2-carboxamide - (R)-
XEA-4-FLU – (144) m.p.: 170-172 °C (ethyl acetate/ n-hexane); [α]D25°C -52.5 (c = 5.7 x 10-3 
g/mL in acetone); IR max (cm-1) (KBr):  3317, 1665, 1630, 1539, 1443, 1274, 834; 1H NMR 
(CDCl3, 300.13 MHz) δ: 8.57 (1H, d, J= 2.3 Hz, H-1), 8.32 (1H, dd, J= 2.3 and 8.8 Hz, H-3), 
8.26 (1H, d, J= 8.9 Hz, H-8), 7.55 (1H, d, J= 8.8 Hz, H-4), 7.41–7.37 (2H, m, H-2’’ and H-
6’’), 7.08-7.03 (2H, m, H-3’’and H-5’’ ), 6.99 (1H, dd, J= 2.3 and 8.9 Hz, H-7), 6.93 (1H, d, 
J= 2.3 Hz, H-5), 6.58 (1H, d, J= 7.4 Hz, NH), 5.37-5.28 (1H, m, H-1’), 3.96 (3H, s, Ar-
OCH3), 1.63 (3H, d, J= 7.0 Hz, H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 175.9 (C-9), 165.5 
(C=O amide), 164.8 (C-6), 161.1 (C-4’’), 158.0 (C-10a), 157.9 (C-4a), 138.7 (C-1’'), 134.4 
(C-3), 129.8 (C-2), 128.3 (C-8), 127.9 (C-2’’ and C-6’’), 123.9 (C-1), 121.0 (C-9a), 118.7 (C-
4), 115.5 (C-3’’ and C-5’’), 115.6 (C-8a), 113.9 (C-7), 100.4 (C-5), 55.9 (Ar-OCH3), 48.9 (C-
1’), 21.8 (C-2’). 
 
(S)-N-(1-(3-methoxyphenyl)ethyl)-5,7-dimethyl-9-oxo-9H-xanthene-2-carboxamide- 
(S)-XEA5-3-MET – (145) m.p.: 195-197 °C (chloroform/ n-hexane); [α]D25°C +183.7 (c = 3.7 
x 10-3 g/mL in chloroform);  IR max (cm-1) (KBr): 3289, 1664, 1633, 1606, 1540, 1473,  837, 
791;  1H NMR (CDCl3, 300.13 MHz) δ: 8.60 (1H, d, J= 2.3 Hz, H-1), 8.33 (1H, dd, J= 2.3 
and 8.8 Hz, H-3), 7.95 (1H, d, J= 0.8 Hz, H-8), 7.59 (1H, d, J= 8.8 Hz, H-4), 7.43 (1H, d, J= 
0.8 Hz, H-6), 7.27 (1H, d, J= 7.9 Hz, H-2’’), 7.02–6.96 (2H, m, H-5’’ and H-6’’), 6.82 (1H, 
ddd, J= 0.8, 2.6 and 8.0 Hz H-4’’), 6.63 (1H, d, J= 7.6 Hz, NH), 5.37-5.27 (1H, m, H-1’), 
3.81 (3H, s, Ar-OCH3), 2.54 (3H, s, C5-CH3), 2.44 (3H, s, C7-CH3), 1.64 (3H, d, J= 6.9 Hz, 
H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 177.3 (C-9), 164.9 (C=O amide), 159.8 (C-3’’), 
157.7 (C-4a), 152.7 (C-10a), 144.6 (C-1’'), 137.6 (C-6), 134.5 (C-3), 133.8 (C-7), 129.8 (C-
2), 127.1 (C-5), 124.2 (C-1), 123.6 (C-8), 121.1 (C-8a), 120.6 (C-9a), 118.9 (C-4), 118.5 (C-
5’’), 112.7 (C-6’’), 112.3 (C-2’’), 112.3 (C-4’’), 55.2 (Ar-OCH3), 49.5 (C-1’), 21.7 (C-2’), 20.8 
(C7-CH3), 15.7 (C5-CH3). 
 
(R)-N-(1-(3-methoxyphenyl)ethyl)-5,7-dimethyl-9-oxo-9H-xanthene-2-carboxamide - 
(R)-XEA5-3-MET – (146) m.p.: 195-197 °C (chloroform/ n-hexane); [α]D25°C -173.5 (c = 3.7 x 
10-3 g/mL in chloroform); IR max (cm-1) (KBr): 3297, 1664, 1633, 1606, 1540, 1473, 837, 
791;  1H NMR (CDCl3, 300.13 MHz) δ: 8.59 (1H, d, J= 2.3 Hz, H-1), 8.33 (1H, dd, J= 2.3 
and 8.8 Hz, H-3), 7.95 (1H, d, J= 0.8 Hz, H-8), 7.59 (1H, d, J= 8.8 Hz, H-4), 7.43 (1H, d, J= 
0.8 Hz, H-6), 7.27 (1H, d, J= 7.9 Hz, H-2’’), 7.02–6.96 (2H, m, H-5’’ and H-6’’), 6.82 (1H, 
112 
 
ddd, J= 0.8, 2.6 and 8.0 Hz H-4’’), 6.63 (1H, d, J= 7.6 Hz, NH), 5.37-5.27 (1H, m, H-1’), 
3.81 (3H, s, Ar-OCH3), 2.54 (3H, s, C5-CH3), 2.44 (3H, s, C7-CH3), 1.64 (3H, d, J= 6.9 Hz, 
H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 177.3 (C-9), 164.9 (C=O amide), 159.8 (C-3’’), 
157.7 (C-4a), 152.7 (C-10a), 144.6 (C-1’'), 137.6 (C-6), 134.5 (C-3), 133.8 (C-7), 129.8 (C-
2), 127.1 (C-5), 124.1 (C-1), 123.6 (C-8), 121.1 (C-8a), 120.6 (C-9a), 118.9 (C-4), 118.5 (C-
5’’), 112.7 (C-6’’), 112.3 (C-2’’), 112.3 (C-4’’), 55.2 (Ar-OCH3), 49.5 (C-1’), 21.7 (C-2’), 20.8 
(C7-CH3), 15.7 (C5-CH3). 
 
(S)-N-(1-(4-methoxyphenyl)ethyl)-5,7-dimethyl-9-oxo-9H-xanthene-2-carboxamide – 
(S)-XEA5-4-MET – (147) m.p.: 188-190 °C (chloroform/ n-hexane); [α]D25°C +179.3 (c = 4.3 
x 10-3 g/mL in chloroform); IR max (cm-1) (KBr): 3303, 1662, 1634, 1614, 1539, 1515, 1466, 
829, 792; ;  1H NMR (CDCl3, 300.13 MHz) δ: 8.57 (1H, d, J= 2.3 Hz, H-1), 8.33 (1H, dd, J= 
2.3 and 8.8 Hz, H-3), 7.96 (1H, d, J= 0.8 Hz, H-8), 7.59 (1H, d, J= 8.8 Hz, H-4), 7.43 (1H, d, 
J= 0.8 Hz, H-6), 7.35 (2H, d, J= 8.7 Hz, H-2’’ and H-6’’), 6.90 (2H, d, J= 8.7 Hz H-3’’ and H-
5’’), 6.60 (1H, d, J= 7.5 Hz, NH), 5.37-5.27 (1H, m, H-1’), 3.80 (3H, s, Ar-OCH3), 2.54 (3H, 
s, C5-CH3), 2.44 (3H, s, C7-CH3), 1.64 (3H, d, J= 6.9 Hz, H-2’). 13C NMR (CDCl3,125.77 
MHz) δ: 177.3 (C-9), 164.8 (C=O amide), 158.9 (C-4’’), 157.7 (C-4a), 152.7 (C-10a), 137.6 
(C-6), 135.0 (C-1’'), 134.5 (C-3), 133.7 (C-7), 129.8 (C-2), 127.5 (C-2’’ and C-6’’), 127.1 (C-
5), 124.1 (C-1), 123.6 (C-8), 121.1 (C-8a), 120.6 (C-9a), 118.9 (C-4), 114.1 (C-3’’ and C-
5’’), 55.3 (Ar-OCH3), 49.0 (C-1’), 21.6 (C-2’), 20.8 (C7-CH3), 15.7 (C5-CH3). 
 
(R)-N-(1-(4-methoxyphenyl)ethyl)-5,7-dimethyl-9-oxo-9H-xanthene-2-carboxamide – 
(R)-XEA5-4-MET – (148) m.p.: 188-190 °C (chloroform/ n-hexane); [α]D25°C -177.6 (c = 4.4 x 
10-3 g/mL in chloroform); IR max (cm-1) (KBr): 3300, 1662, 1633, 1610, 1550, 1467, 829, 
793; ;  1H NMR (CDCl3, 300.13 MHz) δ: 8.57 (1H, d, J= 2.3 Hz, H-1), 8.33 (1H, dd, J= 2.3 
and 8.8 Hz, H-3), 7.96 (1H, d, J= 0.8 Hz, H-8), 7.59 (1H, d, J= 8.8 Hz, H-4), 7.43 (1H, d, J= 
0.8 Hz, H-6), 7.35 (2H, d, J= 8.7 Hz, H-2’’ and H-6’’), 6.90 (2H, d, J= 8.7 Hz H-3’’ and H-5’’), 
6.60 (1H, d, J= 7.5 Hz, NH), 5.37-5.27 (1H, m, H-1’), 3.80 (3H, s, Ar-OCH3), 2.54 (3H, s, 
C5-CH3), 2.44 (3H, s, C7-CH3), 1.64 (3H, d, J= 6.9 Hz, H-2’). 13C NMR (CDCl3,125.77 MHz) 
δ: 177.3 (C-9), 164.8 (C=O amide), 158.9 (C-4’’), 157.7 (C-4a), 152.7 (C-10a), 137.6 (C-6), 
135.0 (C-1’'), 134.5 (C-3), 133.7 (C-7), 129.8 (C-2), 127.5 (C-2’’ and C-6’’), 127.1 (C-5), 
124.0 (C-1), 123.6 (C-8), 121.1 (C-8a), 120.6 (C-9a), 118.9 (C-4), 114.1 (C-3’’ and C-5’’), 
55.3 (Ar-OCH3), 49.0 (C-1’), 21.6 (C-2’), 20.8 (C7-CH3), 15.7 (C5-CH3). 
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(S)-N-(1-(4-chlorophenyl)ethyl)-5,7-dimethyl-9-oxo-9H-xanthene-2-carboxamide – (S)-
XEA5-4-CLO – (149) m.p.: 215-217 °C (chloroform/ n-hexane); [α]D25°C +204.2 (c = 4.7 x 
10-3 g/mL in chloroform); IR max (cm-1) (KBr): 3297, 1667, 1629, 1611, 1536, 1474, 825, 
791; 1H NMR (CDCl3, 300.13 MHz) δ: 8.60 (1H, d, J= 2.3 Hz, H-1), 8.33 (1H, dd, J= 2.3 and 
8.8 Hz, H-3), 7.95 (1H, d, J= 0.7 Hz, H-8), 7.60 (1H, d, J= 8.8 Hz, H-4), 7.43 (1H, d, J= 0.8 
Hz, H-6), 7.36  (2H, d, J= 8.8 Hz, H-2’’ and H-6’’), 7.31 (2H, d, J= 8.8 Hz H-3’’ and H-5’’), 
6.65 (1H, d, J= 7.5 Hz, NH), 5.37-5.27 (1H, m, H-1’), 2.54 (3H, s, C5-CH3), 2.44 (3H, s, C7-
CH3), 1.63 (3H, d, J= 6.9 Hz, H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 177.3 (C-9), 165.0 
(C=O amide), 157.8 (C-4a), 152.7 (C-10a), 141.6 (C-4’’), 137.7 (C-6), 134.5 (C-3), 133.8 
(C-7), 133.2 (C-1’'), 129.6 (C-2), 128.8 (C-2’’ and C-6’’), 127.7 (C-3’’ and C-5’’), 127.2 (C-5), 
124.1 (C-1), 123.6 (C-8), 121.1 (C-8a), 120.6 (C-9a), 119.0 (C-4), 49.0 (C-1’), 21.8 (C-2’), 
20.8 (C7-CH3), 15.7 (C5-CH3). 
 
(R)-N-(1-(4-chlorophenyl)ethyl)-5,7-dimethyl-9-oxo-9H-xanthene-2-carboxamide – (R)-
XEA5-4-CLO – (150) m.p.: 215-217 °C (chloroform/ n-hexane); [α]D25°C -203.4 (c = 4.7 x 10-
3 g/mL in chloroform); IR max (cm-1) (KBr): 3299, 1666, 1631, 1611, 1540, 1470, 828, 791; 
1H NMR (CDCl3, 300.13 MHz) δ: 8.60 (1H, d, J= 2.3 Hz, H-1), 8.33 (1H, dd, J= 2.3 and 8.8 
Hz, H-3), 7.95 (1H, d, J= 0.7 Hz, H-8), 7.60 (1H, d, J= 8.8 Hz, H-4), 7.43 (1H, d, J= 0.8 Hz, 
H-6), 7.36  (2H, d, J= 8.8 Hz, H-2’’ and H-6’’), 7.31 (2H, d, J= 8.8 Hz H-3’’ and H-5’’), 6.65 
(1H, d, J= 7.5 Hz, NH), 5.37-5.27 (1H, m, H-1’), 2.54 (3H, s, C5-CH3), 2.44 (3H, s, C7-CH3), 
1.63 (3H, d, J= 6.9 Hz, H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 177.3 (C-9), 164.9 (C=O 
amide), 157.8 (C-4a), 152.7 (C-10a), 141.6 (C-4’’), 137.7 (C-6), 134.5 (C-3), 133.8 (C-7), 
133.2 (C-1’'), 129.5 (C-2), 128.8 (C-2’’ and C-6’’), 127.7 (C-3’’ and C-5’’), 127.2 (C-5), 124.1 
(C-1), 123.6 (C-8), 121.1 (C-8a), 120.6 (C-9a), 119.0 (C-4), 49.0 (C-1’), 21.8 (C-2’), 20.8 
(C7-CH3), 15.7 (C5-CH3). 
 
(S)-N-(1-(4-fluorophenyl)ethyl)-5,7-dimethyl-9-oxo-9H-xanthene-2-carboxamide - (S)-
XEA5-4-FLU – (151) m.p.: 186-188 °C (chloroform/ n-hexane); [α]D25°C +167.4 (c = 4.3 x 10-
3 g/mL in chloroform); IR max (cm-1) (KBr): 3304, 1673, 1637, 1609, 1555, 1473, 824, 790; 
1H NMR (CDCl3, 300.13 MHz) δ: 8.58 (1H, d, J= 2.3 Hz, H-1), 8.33 (1H, dd, J= 2.3 and 8.8 
Hz, H-3), 7.98 (1H, d, J= 0.7 Hz, H-8), 7.60 (1H, d, J= 8.8 Hz, H-4), 7.43 (1H, d, J= 0.8 Hz, 
H-6), 7.41  (2H, d, J= 8.7 Hz, H-2’’ and H-6’’), 7.07 (2H, d, J= 8.7 Hz H-3’’ and H-5’’), 6.58 
(1H, d, J= 7.5 Hz, NH), 5.38-5.28 (1H, m, H-1’), 2.54 (3H, s, C5-CH3), 2.44 (3H, s, C7-CH3), 
1.64 (3H, d, J= 6.9 Hz, H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 177.3 (C-9), 165.0 (C=O 
amide), 157.8 (C-4a), 152.7 (C-10a), 138.8 (C-4’’), 137.7 (C-6), 135.0 (C-1’'), 134.5 (C-3), 
133.9 (C-7), 129.7 (C-2), 128.0 (C-2’’ and C-6’’), 127.2 (C-5), 124.1 (C-1), 123.6 (C-8), 
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121.1 (C-8a), 120.6 (C-9a), 119.0 (C-4), 115.6 (C-3’’ and C-5’’), 48.9 (C-1’), 21.8 (C-2’), 
20.8 (C7-CH3), 15.7 (C5-CH3). 
 
(R)-N-(1-(4-fluorophenyl)ethyl)-5,7-dimethyl-9-oxo-9H-xanthene-2-carboxamide - (R)-
XEA5-4-FLU – (152) m.p.: 186-188 °C (chloroform/ n-hexane); [α]D25°C -166.7 (c = 4.2 x 10-3 
g/mL in chloroform); IR max (cm-1) (KBr): 3303, 1672, 1637, 1608, 1555, 1473, 829, 792; 1H 
NMR (CDCl3, 300.13 MHz) δ: 8.58 (1H, d, J= 2.3 Hz, H-1), 8.33 (1H, dd, J= 2.3 and 8.8 Hz, 
H-3), 7.98 (1H, d, J= 0.7 Hz, H-8), 7.60 (1H, d, J= 8.8 Hz, H-4), 7.43 (1H, d, J= 0.8 Hz, H-
6), 7.41  (2H, d, J= 8.7 Hz, H-2’’ and H-6’’), 7.07 (2H, d, J= 8.7 Hz H-3’’ and H-5’’), 6.58 
(1H, d, J= 7.5 Hz, NH), 5.38-5.28 (1H, m, H-1’), 2.54 (3H, s, C5-CH3), 2.44 (3H, s, C7-CH3), 
1.64 (3H, d, J= 6.9 Hz, H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 177.3 (C-9), 165.0 (C=O 
amide), 157.8 (C-4a), 152.7 (C-10a), 138.8 (C-4’’), 137.7 (C-6), 135.0 (C-1’'), 134.5 (C-3), 
133.9 (C-7), 129.7 (C-2), 128.0 (C-2’’ and C-6’’), 127.2 (C-5), 124.1 (C-1), 123.6 (C-8), 
121.1 (C-8a), 120.6 (C-9a), 119.0 (C-4), 115.6 (C-3’’ and C-5’’), 48.9 (C-1’), 21.8 (C-2’), 
20.8 (C7-CH3), 15.7 (C5-CH3). 
 
(S)-5,7-dimethyl-9-oxo-N-(1-(p-tolyl)ethyl)-9H-xanthene-2-carboxamide – (S)-XEA5 - 
(153) m.p.: 210-212 °C (chloroform/ n-hexane); [α]D25°C +130.7 (c = 3.9 x 10-3 g/mL in 
chloroform); IR max (cm-1) (KBr): 3298, 1667, 1632, 1609, 1547, 1466, 834, 790; 1H NMR 
(CDCl3, 300.13 MHz) δ: 8.58 (1H, d, J= 2.3 Hz, H-1), 8.33 (1H, dd, J= 2.3 and 8.8 Hz, H-3), 
7.97 (1H, d, J= 0.9 Hz, H-8), 7.60 (1H, d, J= 8.8 Hz, H-4), 7.43 (1H, d, J= 0.9 Hz, H-6), 7.33  
(2H, d, J= 8.0 Hz, H-2’’ and H-6’’), 7.18 (2H, d, J= 8.0 Hz H-3’’ and H-5’’), 6.60 (1H, d, J= 
7.6 Hz, NH), 5.37-5.27 (1H, m, H-1’), 2.54 (3H, s, C5-CH3), 2.44 (3H, s, C7-CH3), 2.34 (3H, 
s, amine-CH3), 1.64 (3H, d, J= 6.9 Hz, H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 177.3 (C-9), 
164.8 (C=O amide), 157.7 (C-4a), 152.7 (C-10a), 139.9 (C-4’’), 137.6 (C-6), 137.2 (C-1’'), 
134.5 (C-3), 133.8 (C-7), 129.9 (C-2), 129.4 (C-2’’ and C-6’’), 127.1 (C-5), 126.2 (C-3’’ and 
C-5’’), 124.1 (C-1), 123.6 (C-8), 121.1 (C-8a), 120.6 (C-9a), 118.9 (C-4), 49.4 (C-1’), 21.7 
(amine-CH3), 21.1 (C-2’), 20.8 (C7-CH3), 15.7 (C5-CH3). 
 
(R)-5,7-dimethyl-9-oxo-N-(1-(p-tolyl)ethyl)-9H-xanthene-2-carboxamide – (R)-XEA5 – 
(154) m.p.: 210-212 °C (chloroform/ n-hexane); [α]D25°C -125.8 (c = 3.9 x 10-3 g/mL in 
chloroform); IR max (cm-1) (KBr): 3300, 1667, 1634, 1612, 1542, 1466, 832, 791; 1H NMR 
(CDCl3, 300.13 MHz) δ: 8.58 (1H, d, J= 2.3 Hz, H-1), 8.33 (1H, dd, J= 2.3 and 8.8 Hz, H-3), 
7.97 (1H, d, J= 0.9 Hz, H-8), 7.60 (1H, d, J= 8.8 Hz, H-4), 7.43 (1H, d, J= 0.9 Hz, H-6), 7.33  
(2H, d, J= 8.0 Hz, H-2’’ and H-6’’), 7.18 (2H, d, J= 8.0 Hz H-3’’ and H-5’’), 6.60 (1H, d, J= 
7.6 Hz, NH), 5.37-5.27 (1H, m, H-1’), 2.54 (3H, s, C5-CH3), 2.44 (3H, s, C7-CH3), 2.34 (3H, 
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s, amine-CH3), 1.64 (3H, d, J= 6.9 Hz, H-2’). 13C NMR (CDCl3,125.77 MHz) δ: 177.3 (C-9), 
164.8 (C=O amide), 157.9 (C-4a), 152.7 (C-10a), 139.9 (C-4’’), 137.6 (C-6), 137.2 (C-1’'), 
134.5 (C-3), 133.8 (C-7), 129.9 (C-2), 129.4 (C-2’’ and C-6’’), 127.1 (C-5), 126.2 (C-3’’ and 
C-5’’), 124.4 (C-1), 123.6 (C-8), 121.1 (C-8a), 120.6 (C-9a), 118.9 (C-4), 49.4 (C-1’), 21.7 
(amine-CH3), 21.1 (C-2’), 20.8 (C7-CH3), 15.7 (C5-CH3). 
 
(S)-5,7-dimethyl-9-oxo-N-(1-phenylethyl)-9H-xanthene-2-carboxamide – (S)-XEA5-DES 
– (155) m.p.: 199-201 °C (chloroform/ n-hexane); [α]D25°C +132.5 (c = 4.0 x 10-3 g/mL in 
chloroform); IR max (cm-1) (KBr): 3303, 1666, 1630, 1611, 1536, 1475, 833, 791; 1H NMR 
(CDCl3, 300.13 MHz) δ: 8.59 (1H, d, J= 2.3 Hz, H-1), 8.33 (1H, dd, J= 2.3 and 8.8 Hz, H-3), 
7.97 (1H, d, J= 0.9 Hz, H-8), 7.60 (1H, d, J= 8.8 Hz, H-4), 7.43-7.27  (6H, d, J= 8.0 Hz, H-6, 
H-2’’, H-3’’, H-4’’, H-5’’ and H-6’’), 6.65 (1H, d, J= 7.6 Hz, NH), 5.41-5.32 (1H, m, H-1’), 2.54 
(3H, s, C5-CH3), 2.44 (3H, s, C7-CH3), 1.66 (3H, d, J= 6.9 Hz, H-2’). 13C NMR 
(CDCl3,125.77 MHz) δ: 177.3 (C-9), 164.9 (C=O amide), 157.7 (C-4a), 152.7 (C-10a), 
142.9 (C-1’'), 137.6 (C-6), 134.5 (C-3), 133.8 (C-7), 129.8 (C-2), 128.7 (C-3’’ and C-5’’), 
127.5 (C-4’’),127.1 (C-5), 126.3 (C-2’’ and C-6’’), 124.1 (C-1), 123.6 (C-8), 121.1 (C-8a), 
120.6 (C-9a), 118.9 (C-4), 49.5 (C-1’), 21.7 (C-2’), 20.8 (C7-CH3), 15.7 (C5-CH3). 
 
(R)-5,7-dimethyl-9-oxo-N-(1-phenylethyl)-9H-xanthene-2-carboxamide – (R)-XEA5-
DES – (156) m.p.: 199-201 °C (chloroform/ n-hexane); [α]D25°C -131.5 (c = 4.0 x 10-3 g/mL in 
chloroform); IR max (cm-1) (KBr): 3304, 1665, 1632, 1612, 1536, 1475, 837, 791; 1H NMR 
(CDCl3, 300.13 MHz) δ: 8.59 (1H, d, J= 2.3 Hz, H-1), 8.33 (1H, dd, J= 2.3 and 8.8 Hz, H-3), 
7.97 (1H, d, J= 0.9 Hz, H-8), 7.60 (1H, d, J= 8.8 Hz, H-4), 7.43-7.27  (6H, d, J= 8.0 Hz, H-6, 
H-2’’, H-3’’, H-4’’, H-5’’ and H-6’’), 6.65 (1H, d, J= 7.6 Hz, NH), 5.41-5.32 (1H, m, H-1’), 2.54 
(3H, s, C5-CH3), 2.44 (3H, s, C7-CH3), 1.66 (3H, d, J= 6.9 Hz, H-2’). 13C NMR 
(CDCl3,125.77 MHz) δ: 177.3 (C-9), 164.9 (C=O amide), 157.7 (C-4a), 152.7 (C-10a), 
142.9 (C-1’'), 137.6 (C-6), 134.5 (C-3), 133.8 (C-7), 129.8 (C-2), 128.7 (C-3’’ and C-5’’), 
127.5 (C-4’’),127.1 (C-5), 126.3 (C-2’’ and C-6’’), 124.1 (C-1), 123.6 (C-8), 121.1 (C-8a), 
120.6 (C-9a), 118.9 (C-4), 49.5 (C-1’), 21.7 (C-2’), 20.8 (C7-CH3), 15.7 (C5-CH3). 
 
N-((1S,2S)-2-hydroxy-1,2-diphenylethyl)-5,7-dimethyl-9-oxo-9H-xanthene-2-
carboxamide – (S,S)-X2ADF5 – (157) m.p.: 243-245 °C (chloroform/ n-hexane); [α]D25°C     
-30.2 (c = 4.3 x 10-3 g/mL in chloroform); IR max (cm-1) (KBr): 3421, 3320, 1669, 1634, 
1613, 1529, 1475, 792, 701; 1H NMR (CDCl3, 300.13 MHz) δ: 9.01 (1H, d, J= 8.3 Hz, NH), 
8.55 (1H, d, J= 2.1 Hz, H-1), 8.09 (1H, dd, J= 2.1 and 8.8 Hz, H-3), 7.82 (1H, d, J= 0.8 Hz, 
H-8), 7.68 (1H, d, J= 8.8 Hz, H-4), 7.59 (1H, d, J= 0.8 Hz, H-6),  7.33-7.16  (10H, m, H-2’’, 
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H-3’’, H-4’’, H-5’’, H-6’’, H-2’’’, H-3’’’, H-4’’', H-5’’’ and H-6’’’), 5.70 (1H, d, J= 5.1 Hz, OH), 
5.21-5.15 (1H, m, H-1’), 4.99 (3H, d, J= 5.1 Hz, H-2’), 2.51 (3H, s, C5-CH3), 2.48 (3H, s, 
C7-CH3). 13C NMR (CDCl3,125.77 MHz) δ: 176.1 (C-9), 163.8 (C=O amide), 156.9 (C-4a), 
152.7 (C-10a), 143.6 (C-1’'), 141.3 (C-1’'’), 137.6 (C-6), 134.0 (C-3), 133.5 (C-7), 130.2 (C-
2), 128.4 (C-3’’ and C-5’’), 127.7 (C-2’’ and C-6’’), 127.7 (C-3’’’ and C-5’’’),  127.0 (C-2’’’ and 
C-6’’’), 127.0 (C-5), 126.9 (C-4’’), 126.6 (C-4’’’), 125.5 (C-1), 122.9 (C-8), 120.6 (C-8a), 
120.1 (C-9a), 118.5 (C-4), 74.5 (C-2’), 59.2 (C-1’), 20.3 (C7-CH3), 15.2 (C5-CH3). 
 
N-((1R,2R)-2-hydroxy-1,2-diphenylethyl)-5,7-dimethyl-9-oxo-9H-xanthene-2-
carboxamide – (R,R)-X2ADF5 – (158) m.p.: 243-245 °C (chloroform/ n-hexane); [α]D25°C     
+52.8 (c = 4.3 x 10-3 g/mL in chloroform); IR max (cm-1) (KBr): 3389, 3302, 1668, 1635, 
1533, 1489, 1475, 801, 702; 1H NMR (CDCl3, 300.13 MHz) δ: 9.18 (1H, d, J= 8.3 Hz, NH), 
8.76 (1H, d, J= 2.1 Hz, H-1), 7.86 (1H, d, J= 0.8 Hz, H-8), 7.76 (1H, dd, J= 2.1 and 8.8 Hz, 
H-3), 7.76 (1H, d, J= 8.8 Hz, H-4), 7.61 (1H, d, J= 0.8 Hz, H-6),  7.32-7.14  (10H, m, H-2’’, 
H-3’’, H-4’’, H-5’’, H-6’’, H-2’’’, H-3’’’, H-4’’', H-5’’’ and H-6’’’), 5.70 (1H, d, J= 5.1 Hz, OH), 
5.26-5.21 (1H, m, H-1’), 4.99 (3H, d, J= 5.1 Hz, H-2’), 2.51 (3H, s, C5-CH3), 2.48 (3H, s, 
C7-CH3). 13C NMR (CDCl3,125.77 MHz) δ: 176.2 (C-9), 164.6 (C=O amide), 156.9 (C-4a), 
152.7 (C-10a), 143.0 (C-1’'), 141.3 (C-1’'’), 137.6 (C-6), 134.2 (C-3), 133.5 (C-7), 130.2 (C-
2), 127.8 (C-3’’ and C-5’’), 127.7 (C-2’’ and C-6’’), 127.7 (C-3’’’ and C-5’’’),  127.0 (C-2’’’ and 
C-6’’’), 127.0 (C-5), 126.9 (C-4’’), 126.6 (C-4’’’), 125.5 (C-1), 122.9 (C-8), 120.7 (C-8a), 
120.1 (C-9a), 118.5 (C-4), 75.5 (C-2’), 59.2 (C-1’), 20.3 (C7-CH3), 15.2 (C5-CH3). 
 
N-((1S,2R)-2-hydroxy-1,2-diphenylethyl)-5,7-dimethyl-9-oxo-9H-xanthene-2-
carboxamide – (S,R)-X2ADF5 – (159) m.p.: 240-242 °C (chloroform/ n-hexane); [α]D25°C     
+32.2 (c = 4.3 x 10-3 g/mL in chloroform); IR max (cm-1) (KBr): 3385, 3311, 1673, 1635, 
1533, 1474, 755, 701; 1H NMR (CDCl3, 300.13 MHz) δ: 9.18 (1H, d, J= 8.3 Hz, NH), 8.64 
(1H, d, J= 2.1 Hz, H-1), 8.20 (1H, dd, J= 2.1 and 8.8 Hz, H-3), 7.97 (1H, d, J= 0.8 Hz, H-8), 
7.56 (1H, d, J= 8.8 Hz, H-4), 7.44 (1H, d, J= 0.8 Hz, H-6),  7.38-7.24  (10H, m, H-2’’, H-3’’, 
H-4’’, H-5’’, H-6’’, H-2’’’, H-3’’’, H-4’’', H-5’’’ and H-6’’’), 5.70 (1H, d, J= 5.1 Hz, OH), 5.46-
5.42 (1H, m, H-1’), 5.16 (3H, d, J= 5.1 Hz, H-2’), 2.53 (3H, s, C5-CH3), 2.45 (3H, s, C7-
CH3). 13C NMR (CDCl3,125.77 MHz) δ: 177.2 (C-9), 166.0 (C=O amide), 157.8 (C-4a), 
152.7 (C-10a), 140.7 (C-1’'), 139.4 (C-1’'’), 137.6 (C-6), 134.4 (C-3), 133.8 (C-7), 129.6 (C-
2), 127.9 (C-2’’ and C-6’’), 127.8 (C-3’’ and C-5’’), 127.8 (C-2’’’ and C-6’’’), 127.4 (C-3’’’ and 
C-5’’’),  127.1 (C-5), 127.0 (C-4’’), 126.1 (C-4’’’), 125.5 (C-1), 123.6 (C-8), 121.1 (C-8a), 
120.6 (C-9a), 118.9 (C-4), 74.9 (C-2’), 60.2 (C-1’), 20.8 (C7-CH3), 15.7 (C5-CH3). 
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N-((1R,2S)-2-hydroxy-1,2-diphenylethyl)-5,7-dimethyl-9-oxo-9H-xanthene-2-
carboxamide – (R,S)-X2ADF5 – (160) m.p.: 241-243 °C (chloroform/ n-hexane); [α]D25°C     
-39.0 (c = 4.3 x 10-3 g/mL in chloroform); IR max (cm-1) (KBr): 3418, 3311, 1674, 1636, 
1614, 1540, 1474, 754, 700; 1H NMR (CDCl3, 300.13 MHz) δ: 9.18 (1H, d, J= 8.3 Hz, NH), 
8.64 (1H, d, J= 2.1 Hz, H-1), 8.29 (1H, dd, J= 2.1 and 8.8 Hz, H-3), 7.97 (1H, d, J= 0.8 Hz, 
H-8), 7.59 (1H, d, J= 8.8 Hz, H-4), 7.44 (1H, d, J= 0.8 Hz, H-6),  7.38-7.24  (10H, m, H-2’’, 
H-3’’, H-4’’, H-5’’, H-6’’, H-2’’’, H-3’’’, H-4’’', H-5’’’ and H-6’’’), 5.70 (1H, d, J= 5.1 Hz, OH), 
5.53-5.49 (1H, m, H-1’), 5.16 (3H, d, J= 5.1 Hz, H-2’), 2.53 (3H, s, C5-CH3), 2.45 (3H, s, 
C7-CH3). 13C NMR (CDCl3,125.77 MHz) δ: 177.2 (C-9), 165.6 (C=O amide), 157.8 (C-4a), 
152.7 (C-10a), 140.7 (C-1’'), 139.7 (C-1’'’), 137.6 (C-6), 134.4 (C-3), 133.8 (C-7), 129.6 (C-
2), 128.2 (C-3’’ and C-5’’), 128.2 (C-3’’’ and C-5’’’),  128.1 (C-2’’ and C-6’’), 128.0 (C-2’’’ and 
C-6’’’), 127.8 (C-4’’), 127.1 (C-5), 126.5 (C-4’’’), 124.5 (C-1), 123.6 (C-8), 121.1 (C-8a), 
120.6 (C-9a), 118.9 (C-4), 74.9 (C-2’), 59.8 (C-1’), 20.8 (C7-CH3), 15.7 (C5-CH3). 
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2. Enantiomeric Purity 
 
2.1. Instrumentation and chromatographic conditions 
 
Liquid chromatography analysis was performed in Laboratory of Organic and 
Medicinal Chemistry of the Faculty of Pharmacy of the University of Porto. Analytical HPLC 
analyses were performed on a SpectraSYSTEM (Thermo Fisher Scientific, Inc, USA) 
equipped with a P4000 pump, an AS3000 autosampler and a diode array detector UV8000. 
The separation was carried out on (S,S)-Whelk-O1 CSP (150 x 4.6 mm i.d. column) 
obtained from Regis Technologies, Inc. (Morton Grove, Illinois, USA). Ethanol (EtOH), 
methanol (MeOH), acetonitrile (ACN) for HPLC were purchased from Sigma-Aldrich Co (St. 
Louis, Missouri, USA).  
The polar organic mode LC evaluation was carried out using a mixture of MeOH and 
ACN.  The mobile phase was prepared in a volume/volume (50:50 v/v) relation and 
degassed in an ultrasonic bath for 15 min before use. The flow rate used was 1 mL/min and 
the chromatograms were monitored by UV detection at a wavelength of 254 nm. The 
sample injections (25 μL) were carried out in triplicate. The dead time (t0) was considered to 
be equal to the peak of the solvent front and was taken from each particular run. The stock 
solutions of CDXs in EtOH at the concentration of 1 mg/mL were prepared and further 
diluted in the same solvent to a concentration of 0.1 mg/mL. Working solutions of 
enantiomeric mixtures of CDXs were prepared mixing equal aliquots of each enantiomer. 
The elution order and e.e determinations were carried out with the stock solutions of each 
enantiomer of CDXs diluted at the concentration of 20 μg/mL. Solutions of 50 μg/mL of 
each enantiomer spiked with 0.5% of the opposite enantiomer were also prepared. The 
analyses were performed at room temperature.  
The retention factor (k) was calculated using the equation (k = [tR - t0] / t0). The 
separation factor (α) was calculated as (α = k2/k1). The resolution factor (Rs) was calculated 
using the equation (Rs = 1.18 [tR2 - tR1]/[W1 0.5+W2 0.5]) where tR1 and tR2 are the retention 
times of the first and second enantiomers, respectively, and W1 0.5 and W2 0.5 are the 
corresponding peak width measured on half height.111 
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3. Biological activity 
 
3.1. Cell Cultures 
 
The three human tumor cell lines, A375-C5 (melanoma), MCF-7 (breast 
adenocarcinoma), and NCI-H460 (non-small cell lung cancer), were grown as monolayer 
and routinely maintained in cell culture medium RPMI-1640 (with Glutamax, Lonza) 
supplemented with 5% heat-inactivated fetal bovine serum (FBS), and incubated in a 
humidified incubator at 37 °C with 5% CO2 (Hera Cell, Heraeus). Cell number and viability 
were routinely determined with Trypan Blue (Sigma) exclusion assay. All experiments were 
performed with cells in exponential growth with viabilities over 90% and repeated at least 
three times. 
 
3.2. Cell growth assay inhibitory assay 
 
The effects of compounds on the growth of human tumor cell lines were evaluated 
according to the procedure adopted by the NCI in the ‘In vitro Anticancer Drug Discovery 
Screen’ that uses the protein-binding dye sulforhodamine B (SRB) to assess cell growth.110 
The optimal plating density of each cell line, that ensures exponential growth throughout all 
the experimental period, was 5 X 105 cells/mL for MCF-7 and NCI-H460 and 7.5 X 105 
cells/mL for A375-C5. Cells in 96-well plates were allowed to attach overnight and then 
exposed for 48h to five dilutions, starting from maximum concentration of 150 μM. 
Following this incubation period, the adherent cells were fixed in situ, washed and stained 
with SRB. The bound stain was solubilized and the absorbance was measured at 515 ηm in 
a plate reader (Biotek Synergy 2). For each tested compound and for each cell line a dose–
response curve was obtained and the growth inhibition of 50% (GI50), corresponding to the 
concentration of compound that inhibited 50% of the net cell growth, was calculated as 
described.110 Doxorubicin, used as a positive control, was tested in the same manner. The 
effect of the vehicle solvent (DMSO) was also evaluated by exposing untreated control cells 
to the maximum concentration of DMSO used in each assay (0.25%). 
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Currently, chirality is considered one of major driving forces in design, discovery, and 
development, launching and marketing of new drugs, especially when dealing with single 
enantiomeric drugs. Xanthones (9H-xanthon-9-ones) are privileged structures and many 
have proved to be important building blocks for synthesis of new compounds. Among them, 
chiral derivatives of xanthones (CDXs) represent an attractive area of Pharmaceutical 
Medicinal Chemistry research concerning their broad spectrum of 
biological/pharmacological activities. 
This work described the synthesis of a library of twenty four CDXs in 
enantiomerically pure form by an efficient and mild methodology. The CDXs were 
synthesized by coupling two suitable functionalized xanthone derivatives as chemical 
substrates with a variety of commercially available chiral building blocks, namely amines 
and amino alcohols. The coupling reactions were carried out with the coupling reagent O-
(benzotriazol-1-yl)-N-N-N’-N’-tetramethyluronium tetrafluoroborate (TBTU). 
Three carboxyxanthone derivatives (XCars) were also successfully synthesized by a 
multi-step synthetic pathway, via diaryl ether intermediate (Ullman synthesis).  
On the basis of our current state of knowledge all the synthesized CDXs and one of 
the XCar are describe here for the first time. 
The evaluation of enantiomeric purity of all synthesised CDXs was determined by 
enantioselective LC method using the (S,S)-Whelk-O1 chiral stationary phase (CSP) under 
polar organic mode elution conditions. 
Considering growth inhibitory effects on human tumor cell lines, some CDXs 
exhibited interesting results, with some cases of enantioselectivity. Furthermore, the nature 
and positions of substituents on the xanthonic scaffold of CDXs demonstrate to have great 
influence on the growth inhibitory effects. 
 Taking in consideration the results obtained and described in this work it can be 
saying that the main objectives of this dissertation were accomplished. 
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Table 24: Chemical structures and biological/pharmacological activities of CDXs. 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
(1) 
 
Sterigmatocystin 
 
Natural and 
Synthetic 
 
Antitumor 50,51,53,54 
 
(2) 
 
Dihydrosterigmatocystin 
 
Natural and 
Synthetic 
 
Antitumor 50,52,53 
 
 
(3) 
 
Secosterigmatocystin 
 
Natural and 
Synthetic 
 
Antitumor 50,52,53 
 
(4) 
 
Asperxanthone 
 
Natural and 
Synthetic 
 
Tabacco mosaic virus 
inhibition 50,55 
 
(5) 
 
Chaetoxanthone A 
 
Natural and 
Synthetic 
 
Antiprotozoal 50,56 
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Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
(6) 
 
Chaetoxanthone B 
 
Natural and 
Synthetic 
 
Antiprotozoal 50,56 
 
 
(7) 
 
Chaetoxanthone C 
 
Natural and 
Synthetic 
 
Antiprotozoal 50,56 
 
(8) 
 
Psorospermin 
 
Natural and 
Synthetic 
 
Antitumor 39,57,58,60 
 
(9) 
 
Psorofebrin 
 
Natural and 
Synthetic 
 
Antitumor 60 
 
(10) 
 
Isohydroxyisopsorofebrin 
 
Natural and 
Synthetic 
 
Antitumor 60 
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Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
(11) 
 
(8aR,8bS,9aS,10aS)-6-
hydroxy-1-methoxy-8b-
methyl-8a,8b,9a,10a-
tetrahydro-5H-
oxireno[2'',3'':4',5']furo[2',
3':4,5]furo[2,3-c]xanthen-
5-one 
 
Natural and 
Synthetic 
 
Antitumor 60 
 
(12) 
 
(3R,3aR,12cS)-6-
hydroxy-11-methoxy-
3a,12c-dihydro-2H,7H-
spiro[furo[2',3':4,5]furo[2,
3-c]xanthene-3,2'-
oxiran]-7-one 
 
Natural and 
Synthetic 
 
Antitumor 60 
 
(13) 
 
Chlorohydrin 
 
Natural and 
Synthetic 
 
Antitumor 60 
 
(14) 
 
 
 
 
(2R,3R) O-5-methyl 
psorospermin 
 
Natural and 
Synthetic 
 
Antitumor 61 
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Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
(15) 
 
(2R,3R)-3-(4-hydroxy-3-
methoxyphenyl)-2-
(hydroxymethyl)-2,3-
dihydro-7H-
[1,4]dioxino[2,3-
c]xanthen-7-one 
 
Synthetic 
 
 
Antitumor, 
PKC and cellular 
proliferation  inhibition 
39,65 
 
 
(16) 
 
(2S,3S)-3-(4-hydroxy-3-
methoxyphenyl)-2-
(hydroxymethyl)-2,3-
dihydro-12H-
[1,4]dioxino[2,3-
a]xanthen-12-one 
 
Synthetic 
 
 
Antitumor, 
PKC and cellular 
proliferation  inhibition 
39,65 
 
 
(17) 
 
 
(2R,3R)-2-(4-hydroxy-3-
methoxyphenyl)-3-
(hydroxymethyl)-2,3-
dihydro-12H-
[1,4]dioxino[2,3-
a]xanthen-12-one 
 
Synthetic 
 
 
Antitumor, 
PKC and cellular 
proliferation  inhibition 
39,65 
 
(18) 
 
(2S,3S)-3-(4-hydroxy-3-
methoxyphenyl)-2-
(hydroxymethyl)-2,3-
dihydro-11H-
[1,4]dioxino[2,3-
b]xanthen-11-one 
 
Synthetic 
 
 
Antitumor, 
PKC and cellular 
proliferation  inhibition 
39,65 
 
(19) 
 
 
(2R,3S)-3-(4-hydroxy-3-
methoxyphenyl)-2-
(hydroxymethyl)-2,3-
dihydro-7H-
[1,4]dioxino[2,3-
c]xanthen-7-one 
 
 
 
 
Synthetic 
 
 
Antitumor, 
PKC and cellular 
proliferation  inhibition 
39,65 
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Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
(20) 
 
Tajixanthone 
 
Natural and 
Synthetic 
 
Antitumor 50,68-71 
 
(21) 
 
Shamixanthone 
 
Natural and 
Synthetic 
 
Antitumor 50,68-71 
 
 
 
(22) 
 
2-(5-methyl-9-oxo-9H-
xanthen-4-yl)propanoic 
acid 
 
Synthetic 
 
Antitumor 74 
 
 
 
(22a) 
 
(R)-2-(5-methyl-9-oxo-
9H-xanthen-4-
yl)propanoic acid 
 
Synthetic 
 
Antitumor 74 
 
 
 
(22b) 
 
(S)-2-(5-methyl-9-oxo-
9H-xanthen-4-
yl)propanoic acid 
 
Synthetic 
 
Antitumor 74 
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Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
(23) 
 
2-(9-oxo-9H-xanthen-4-
yl)propanoic acid 
 
Synthetic 
 
Antitumor 
and 
Antiinflammatory 74 
 
 
 
 
(24a) 
 
e.e. (%)  > 99 % 
 
Column amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: EtOH/ACN (50:50 v:v), 0.5 mL/min, 
λmax 254 nm) 
29. 
 
(R)-6-methoxy-9-oxo-N-
(1-(p-tolyl)ethyl)-9H-
xanthene-2-carboxamide 
 
Synthetic 
 
 
 
Growth of human tumor 
cell lines inhibition 
29,80 
 
 
 
 
(24b) 
e.e. (%)  > 99% 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: EtOH/ACN (50:50 v:v), 0.5 mL/min, 
λmax 254 nm) 
29 
 
(S)-6-methoxy-9-oxo-N-
(1-(p-tolyl)ethyl)-9H-
xanthene-2-carboxamide 
 
 
Synthetic 
 
 
 
Local anaesthetic, 
and  growth of human 
tumor cell lines 
inhibition 
29,77,80 
 
 
 
 
(25a) 
 
e.e. (%)  > 99 % 
 
Column: Chirobiotic T, Mobile phase: n-
hexane/EtOH (80:20 v:v), 0.5 mL/min, λmax 
254 nm) 29 
 
 
 
(R)-N-(1-hydroxy-3-
methylbutan-2-yl)-6-
methoxy-9-oxo-9H-
xanthene-2-carboxamide 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29,80 
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Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
(25b) 
 
e.e. (%)  > 99 % 
 
Column: Chirobiotic T, Mobile phase: n-
hexane/EtOH (80:20 v:v), 0.5 mL/min, λmax 
254 nm) 29. 
 
(S)-N-(1-hydroxy-3-
methylbutan-2-yl)-6-
methoxy-9-oxo-9H-
xanthene-2-carboxamide 
 
 
Synthetic 
 
 
 
Local anaesthetic, 
and  growth of human 
tumor cell lines 
inhibition 
 
29,77,80 
 
 
 
(26a) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: EtOH/ACN (50:50 v:v), 0.5 mL/min, 
λmax 254 nm)29 
 
 
(R)-N-(1-hydroxy-4-
methylpentan-2-yl)-6-
methoxy-9-oxo-9H-
xanthene-2-carboxamide 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
 
29,80 
 
 
 
(26b) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: EtOH/ACN (50:50 v:v), 0.5 mL/min, 
λmax 254 nm) 29 
 
 
(S)-N-(1-hydroxy-4-
methylpentan-2-yl)-6-
methoxy-9-oxo-9H-
xanthene-2-carboxamide 
 
Synthetic 
 
 
 
Local anaesthetic, 
and  growth of human 
tumor cell lines 
inhibition 
29,77,80 
 
 
 
 
(27a) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: EtOH/ACN (50:50 v:v)29 
 
(R)-N-(2-hydroxy-1-
phenylethyl)-6-methoxy-
9-oxo-9H-xanthene-2-
carboxamide 
 
Synthetic 
 
 
 
Growth of human tumor 
cell lines inhibition 
29,80 
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Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
 
(27b) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-dimethylphe- 
nylcarbamate coated onto APS-Nucleosil 
(500 Å, 7 lm, 20% w/w), Mobile phase: 
EtOH/ACN (50:50 v:v), 0.5 mL/min, λmax 254 
nm) 29. 
 
 
(S)-N-(2-hydroxy-1-
phenylethyl)-6-methoxy-
9-oxo-9H-xanthene-2-
carboxamide 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29,80 
 
 
 
 
 
 
 
 
(28a) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: EtOH/ACN (50:50 v:v), 0.5 mL/min, 
λmax 254 nm) 
 
 
(R)-N-(1-hydroxypropan-
2-yl)-6-methoxy-9-oxo-
9H-xanthene-2-
carboxamide 
 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
 
29,80 
 
 
 
 
(28b) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: EtOH/ACN (50:50 v:v), 0.5 mL/min, 
λmax 254 nm)29. 
 
(S)-N-(1-hydroxypropan-
2-yl)-6-methoxy-9-oxo-
9H-xanthene-2-
carboxamide 
 
 
Synthetic 
 
 
 
Growth of human tumor 
cell lines inhibition 
 
29,80 
 
 
 
 
(29a) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-dimethylphe- 
nylcarbamate coated onto APS-Nucleosil 
(500 Å, 7 lm, 20% w/w), Mobile phase: n-
hexane/2-PrOH (50:50 v:v), 0.5mL/min, λmax 
254 nm)29. 
 
(R)-N-(2-hydroxypropyl)-
6-methoxy-9-oxo-9H-
xanthene-2-carboxamide 
 
 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29,80 
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Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
 
(29b) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: n-hexane/ 2-PrOH (50:50 v:v), 0.5 
mL/min, λmax 254 nm)29. 
 
(S)-N-(2-hydroxypropyl)-
6-methoxy-9-oxo-9H-
xanthene-2-carboxamide 
 
 
 
Synthetic 
 
 
 
Growth of human tumor 
cell lines inhibition 
 
29,80 
 
 
 
(30c) 
 
e.e. (%)  > 97 % 
 
 
Column: (S,S)-Whelk-O1, Mobile phase: 
ACN/ MeOH (50:50 v:v), 1.0 mL/min, λmax 
254 nm)29. 
 
N-((1R,2S)-2-hydroxy-
1,2-diphenylethyl)-6-
methoxy-9-oxo-9H-
xanthene-2-carboxamide 
 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29 
 
(30d) 
 
e.e. (%)  > 98 % 
 
Column: (S,S)-Whelk-O1, Mobile phase: 
ACN/MeOH (50:50 v:v), 1.0 mL/min, λmax 254 
nm)29. 
 
N-((1S,2R)-2-hydroxy-
1,2-diphenylethyl)-6-
methoxy-9-oxo-9H-
xanthene-2-carboxamide 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29 
 
 
 
(31a) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: MeOH, 0.5 mL/min, λmax 254 nm)29 
 
 
(R)-tert-butyl 2-(6-
methoxy-9-oxo-9H-
xanthene-2-
carboxamido) 
propanoate 
 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29 
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Biological/ 
pharmacological 
activity 
 
 
 
 
(31b) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: MeOH 0.5 mL/min, λmax 254 nm)29. 
 
 
(S)-tert-butyl 2-(6-
methoxy-9-oxo-9H-
xanthene-2-
carboxamido) 
propanoate 
 
 
 
 
 
Synthetic 
 
Growth of human tumor 
cell lines inhibition 
29 
 
 
 
 
(32a) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucle- osil (500 Å, 7 lm, 20% w/w), Mobile 
phase: ACN, 0.5 mL/min, λmax 254 nm)29. 
 
(R)-2-((9-oxo-9H-
xanthen-3-yl)oxy)-N-(1-
(p-tolyl)ethyl) 
acetamide 
 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29 
 
 
 
 
 
(32b) 
 
e.e. (%)  > 98 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: ACN, 0.5 mL/min, λmax 254 nm)29. 
 
(S)-2-((9-oxo-9H-
xanthen-3-yl)oxy)-N-(1-
(p-tolyl)ethyl) 
acetamide 
 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29 
 
 
 
(33a) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: MeOH, 0.5 mL/min, λmax 254 nm)29. 
 
 
(R)-N-(1-hydroxy-3-
methylbutan-2-yl)-2-((9-
oxo-9H-xanthen-3-
yl)oxy) 
acetamide 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29 
149 
 
Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
 
(33b) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: MeOH, 0.5 mL/min, λmax 254 nm)29. 
 
 
 
 
 
 
(S)-N-(1-hydroxy-3-
methylbutan-2-yl)-2-((9-
oxo-9H-xanthen-3-
yl)oxy) 
acetamide 
 
 
 
 
 
 
Synthetic 
 
 
 
 
 
 
 
Growth of human tumor 
cell lines inhibition 29 
 
 
(34a) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase:  ACN 0.5 mL/min, λmax 254 nm)29. 
 
(R)-N-(1-hydroxy-4-
methylpentan-2-yl)-2-((9-
oxo-9H-xanthen-3-
yl)oxy) 
acetamide 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29 
 
(34b) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: ACN, 0.5 mL/min, λmax 254 nm)29. 
 
(S)-N-(1-hydroxy-4-
methylpentan-2-yl)-2-((9-
oxo-9H-xanthen-3-
yl)oxy) 
acetamide 
 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29 
 
(35a) 
 
e.e. (%)  > 99 % 
 
Column: cellulose tris-3,5-dimethyl- 
phenylcarbamate coated onto APS-Nucleosil 
(500 Å, 7 lm, 20% w/ w), Mobile phase: n-
hexane/EtOH (70:30 v:v), 0.5 mL/min, λmax 
254 nm)29 
 
(R)-N-(2-hydroxy-1-
phenylethyl)-2-((9-oxo-
9H-xanthen-3-yl)oxy) 
acetamide 
 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29,80 
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(35b) 
 
e.e. (%)  > 99 % 
 
Column: cellulose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: n-hexane/ EtOH (70:30 v:v), 0.5 
mL/min, λmax 254 nm)29. 
 
 
(S)-N-(2-hydroxy-1-
phenylethyl)-2-((9-oxo-
9H-xanthen-3-yl)oxy) 
acetamide 
 
 
 
 
Synthetic 
 
 
 
 
Growth of human tumor 
cell lines inhibition 
29,80 
 
 
(36a) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarba- mate coated onto 
APS-Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: ACN, 0.5 mL/min, λmax 254 nm)29. 
 
(R)-N-(1-hydroxypropan-
2-yl)-2-((9-oxo-9H-
xanthen-3-yl)oxy) 
acetamide 
 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29 
 
 
(36b) 
 
e.e. (%)  >99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarba- mate coated onto 
APS-Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: ACN, 0.5 mL/min, λmax 254 nm)29. 
 
(S)-N-(1-hydroxypropan-
2-yl)-2-((9-oxo-9H-
xanthen-3-yl)oxy) 
acetamide 
 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29 
 
 
 
(37a) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: ACN, 0.5 mL/min, λmax 254 nm)29. 
 
(R)-N-(2-hydroxypropyl)-
2-((9-oxo-9H-xanthen-3-
yl)oxy) 
acetamide 
 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29 
 
 
151 
 
Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
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(37b) 
 
e.e. (%)  > 99 % 
 
Column: amylose tris-3,5-
dimethylphenylcarbamate coated onto APS-
Nucleosil (500 Å, 7 lm, 20% w/w), Mobile 
phase: ACN, 0.5 mL/min, λmax 254 nm)29. 
 
 
 
(S)-N-(2-hydroxypropyl)-
2-((9-oxo-9H-xanthen-3-
yl)oxy) 
acetamide 
 
 
Synthetic 
 
 
 
Growth of human tumor 
cell lines inhibition 
29 
 
 
(38c) 
 
e.e. (%)  > 98 % 
 
Column: (S,S)- Whelk-O1, Mobile phase: 
ACN/MeOH (50:50 v:v), 1.0 mL/min, kmax 254 
nm)29. 
 
N-((1R,2S)-2-hydroxy-
1,2-diphenylethyl)-2-((9-
oxo-9H-xanthen-3-
yl)oxy) 
acetamide 
 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29 
 
 
(38d) 
 
e.e. (%)  > 99 % 
 
Column: (S,S)-Whelk-O1, Mobile phase: 
ACN/MeOH (50:50 v:v), 1.0 mL/min, λmax 254 
nm)29. 
 
N-((1S,2R)-2-hydroxy-
1,2-diphenylethyl)-2-((9-
oxo-9H-xanthen-3-
yl)oxy) 
acetamide 
 
 
Synthetic 
 
 
Growth of human tumor 
cell lines inhibition 
29 
 
 
 
 
 
 
 
 
(39) 
 
2-(((1-hydroxypropan-2-
yl)amino)methyl)-6-
methoxy-9H-xanthen-9-
one hydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antiplatelets, 
Antimutagenic and 
Antiarrhythmic 
40,91,96,97 
 
 
HCl 
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(39a) 
 
(R)-2-(((1-
hydroxypropan-2-
yl)amino)methyl)-6-
methoxy-9H-xanthen-9-
one hydrochloride 
 
Synthetic 
 
Anticonvulsant 40,89 
 
 
 
                   (39b) 
 
(S)-2-(((1-
hydroxypropan-2-
yl)amino)methyl)-6-
methoxy-9H-xanthen-9-
one hydrochloride 
 
Synthetic 
 
Anticonvulsant 40 
 
 
 
 
(40) 
 
2-(((2-
hydroxypropyl)amino)me
thyl)-6-methoxy-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant and 
Antiplatelets 
40,89,91,96 
 
 
(40a) 
 
(R)-2-(((2-
hydroxypropyl)amino)me
thyl)-6-methoxy-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant 
40 
 
 
 
                   (40b) 
 
(S)-2-(((2-
hydroxypropyl)amino)me
thyl)-6-methoxy-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant 40 
 
 
 
 
                 (41) 
 
2-(((2-
hydroxypropyl)(methyl)a
mino)methyl)-6-methoxy-
9H-xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant and 
Antiplatelets 
40,91,96 
 
 
 
 
                        (42) 
 
2-(((2-
hydroxybutyl)amino)met
hyl)-6-methoxy-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant 40,97 
HCl 
HCl 
HCl 
HCl 
HCl 
HCl 
HCl 
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(43) 
 
 
6-chloro-2-(((1-
hydroxypropan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
 
Synthetic 
 
 
Anticonvulsant and 
Antimutagenic 
40,92,97 
 
 
 
(43a) 
 
e.e. (%) > 99,9 % 
 
 
(R)-6-chloro-2-(((1-
hydroxypropan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
 
Synthetic 
 
 
Anticonvulsant 85,92 
 
 
 
(43b) 
 
e.e. (%) = > 99,0% 
 
 
(S)-6-chloro-2-(((1-
hydroxypropan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
 
Synthetic 
 
 
 
Anticonvulsant 85,92 
 
 
 
(44) 
 
 
6-chloro-2-(((2-
hydroxypropyl)amino)me
thyl)-9H-xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant 40 
 
 
(44a) 
 
 
(R)-6-chloro-2-(((2-
hydroxypropyl)amino)me
thyl)-9H-xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant 85 
 
 
 
(44b) 
 
 
(S)-6-chloro-2-(((2-
hydroxypropyl)amino)me
thyl)-9H-xanthen-9-one 
 
Synthetic 
 
Anticonvulsant 85 
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Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
 
 
(45) 
 
 
6-chloro-2-(((1-
hydroxybutan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant, Local 
anesthetic 
and Hemodynamic 
activity 
40,93 
 
 
 
(45a) 
 
 
(R)-6-chloro-2-(((1-
hydroxybutan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
 
Synthetic 
 
Anticonvulsant, Local 
anesthetic 
and Hemodynamic 
activity 
85,93 
 
 
 
(45b) 
 
 
(S)-6-chloro-2-(((1-
hydroxybutan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
 
Synthetic 
 
Anticonvulsant, Local 
anesthetic 
and Hemodynamic 
activity 
 
 
 
(46) 
 
 
5-chloro-2-(((1-
hydroxybutan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant 40 
 
 
 
(46b) 
 
 
(S)-5-chloro-2-(((1-
hydroxybutan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant 40 
 
 
 
(47) 
 
 
2-(((2-
hydroxybutyl)amino)met
hyl)-9H-xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant 83 
HCl 
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Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
 
(48) 
 
 
2-chloro-7-(((1-
hydroxybutan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
 
Synthetic 
 
Anticonvulsant, Local 
anesthetic 
and Hemodynamic 
activity 83,93 
 
 
 
                     (48a) 
 
 
(R)-2-chloro-7-(((1-
hydroxybutan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant, Local 
anesthetic 
and Hemodynamic 
activity 83,93 
 
 
 
(48b) 
 
 
(S)-2-chloro-7-(((1-
hydroxybutan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
 
Synthetic 
 
Anticonvulsant, Local 
anesthetic 
and Hemodynamic 
activity 83,93 
 
 
 
(49) 
 
 
N-(1-hydroxybutan-2-yl)-
2-(9-oxo-9H-xanthen-2-
yl)acetamide 
 
Synthetic 
 
Anticonvulsant 
 
 
 
 
(50) 
 
 
(S)-N-(1-hydroxybutan-
2-yl)-2-(9-oxo-9H-
xanthen-2-yl)acetamide 
 
Synthetic 
 
Anticonvulsant 83 
 
 
 
 
(51) 
 
 
2-(((1-hydroxybutan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
 
Anticonvulsant 83 
HCl 
HCl 
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Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
(52) 
 
4-(((1-hydroxybutan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
 
Synthetic 
 
Anticonvulsant, Local 
anesthetic 
and Hemodynamic  93 
 
 
 
(52a) 
 
(R)-4-(((1-hydroxybutan-
2-yl)amino)methyl)-9H-
xanthen-9-one 
 
Synthetic 
 
Anticonvulsant, Local 
anesthetic 
and Hemodynamic 
activity 93 
 
 
 
(52b) 
 
(S)-4-(((1-hydroxybutan-
2-yl)amino)methyl)-9H-
xanthen-9-one 
 
Synthetic 
 
Anticonvulsant, Local 
anesthetic 
and Hemodynamic 
activity 93 
 
 
 
 
(53) 
 
2-chloro-7-(((1-
hydroxybutan-2-
yl)(methyl)amino)methyl)
-9H-xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant 83,93 
 
 
 
 
 
(53a) 
 
(R)-2-chloro-7-(((1-
hydroxybutan-2-
yl)(methyl)amino)methyl)
-9H-xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant and 
Antiplatelets 83,91,93 
 
 
 
 
(53b) 
 
 
(S)-2-chloro-7-(((1-
hydroxybutan-2-
yl)(methyl)amino)methyl)
-9H-xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant 83,93 
HCl 
HCl 
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Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
HCl 
(54a) 
 
 
(R)-2-chloro-7-(((1-
hydroxypropan-2-
yl)(methyl)amino)methyl)
-9H-xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant 91 
 
 
 
 
 
HCl 
(55) 
 
 
2-(3-(tert-butylamino)-2-
hydroxypropoxy)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antipiletic, Antiplatelets 
and Antimycobacterial  
84,91,96,99 
 
 
 
 
HCl 
(56) 
 
 
2-(2-hydroxy-3-((1-
hydroxy-2-methylpropan-
2-yl)amino)propoxy)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antipiletic and 
Antiplatelets 84,86,96 
 
 
 
(57) 
 
2-(3-(tert-
butyl(methyl)amino)-2-
hydroxypropoxy)-9H-
xanthen-9-one 
 
Synthetic 
 
Anticonvulsant, 
Antipiletic and 
Antimycobacterial 84,99 
 
 
HCl 
 
(58) 
 
 
3-(2-hydroxy-3-((1-
hydroxy-2-methylpropan-
2-yl)amino)propoxy)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant and 
Antiarrhythmic 86 
 
 
 
 
HCl 
 
(59) 
 
 
6-(2-hydroxy-3-((1-
hydroxy-2-methylpropan-
2-yl)amino)propoxy)-2-
methyl-9H-xanthen-9-
one hydrochloride 
 
Synthetic 
 
Anticonvulsant and 
Antiarrhythmic 86 
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Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
 
HCl 
 
(60) 
 
6-(2-hydroxy-3-((1-
hydroxy-2-methylpropan-
2-
yl)(methyl)amino)propox
y)-2-methyl-9H-xanthen-
9-one hydrochloride 
 
Synthetic 
 
Anticonvulsant and 
Antiarrhythmic 86 
 
 
 
(61) 
 
 
6-(2-hydroxy-3-
(isopropylamino)propoxy
)-2-methyl-9H-xanthen-
9-one 
 
Synthetic 
 
Anticonvulsant and 
Antimutagenic 86,97 
 
 
HCl 
 
(62) 
 
 
6-(2-hydroxy-3-
(isopropyl(methyl)amino)
propoxy)-2-methyl-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant 86 
 
 
HCl 
 
(63) 
 
 
6-(3-(2,6-
dimethylpiperidin-1-yl)-2-
hydroxypropoxy)-2-
methyl-9H-xanthen-9-
one hydrochloride 
 
Synthetic 
 
Anticonvulsant 86 
 
 
 
HCl 
 
(64) 
 
 
6-chloro-2-(((1-
hydroxypropan-2-
yl)(methyl)amino)methyl)
-9H-xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antiarrhythmic and 
Antimutagenic 89,97 
 
 
 
HCl 
 
(64b) 
 
 
(S)-6-chloro-2-(((1-
hydroxypropan-2-
yl)(methyl)amino)methyl)
-9H-xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant 85 
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Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
 
(65) 
 
 
N-(1-hydroxypropan-2-
yl)-9-oxo-9H-xanthene-
2-carboxamide 
 
Synthetic 
 
Anticonvulsant 85 
 
 
HCl 
 
(66) 
 
 
2-(((1-hydroxypropan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant and 
Antiarrhythmic 89 
 
 
HCl 
 
(67) 
 
 
4-(((1-hydroxypropan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant and 
Antiarrhythmic 89 
 
 
 
 
(68) 
 
 
6-Chloro-2-((2-
hydroxybutylamino)meth
yl)-9H-xanthen-9-one 
 
Synthetic 
 
 
Anticonvulsant 85 
 
 
 
 
(69) 
 
6-Chloro-N-(1-
hydroxypropan-2-yl)-9-
oxo-9H-xanthene-2-
carboxiamide 
 
Synthetic 
 
 
Anticonvulsant 85 
 
 
 
 
 
(70) 
 
 
2-(((1-hydroxybutan-2-
yl)amino)methyl)-6-
methoxy-9H-xanthen-9-
one 
 
 
 
 
Synthetic 
 
Anticonvulsant 90,93 
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Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
 
 
(70a) 
 
(R)-2-(((1-hydroxybutan-
2-yl)amino)methyl)-6-
methoxy-9H-xanthen-9-
one 
 
Synthetic 
 
Anticonvulsant 90,93 
 
 
 
 
(70b) 
 
(S)-2-(((1-hydroxybutan-
2-yl)amino)methyl)-6-
methoxy-9H-xanthen-9-
one 
 
 
Synthetic 
 
Anticonvulsant 90,93 
 
 
(71) 
 
5-(((2-
hydroxypropyl)amino)me
thyl)-3-methoxy-9H-
xanthen-9-one 
 
Synthetic 
 
Anticonvulsant 90 
 
 
 
(72) 
 
5-(((1-hydroxypropan-2-
yl)amino)methyl)-3-
methyl-9H-xanthen-9-
one hydrochloride 
 
 
 
 
Synthetic 
 
Anticonvulsant 90 
 
 
(72a) 
 
(R)-5-(((1-
hydroxypropan-2-
yl)amino)methyl)-3-
methyl-9H-xanthen-9-
one hydrochloride 
 
 
 
Synthetic 
 
Anticonvulsant 90 
 
 
 
(72b) 
 
(S)-5-(((1-
hydroxypropan-2-
yl)amino)methyl)-3-
methyl-9H-xanthen-9-
one hydrochloride 
 
Synthetic 
 
Anticonvulsant 90 
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Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
 
(73) 
 
 
5-(((1-hydroxybutan-2-
yl)amino)methyl)-3-
methoxy-9H-xanthen-9-
one 
 
Synthetic 
 
Anticonvulsant 90 
 
 
 
(73a) 
 
 
(R)-5-(((1-hydroxybutan-
2-yl)amino)methyl)-3-
methoxy-9H-xanthen-9-
one 
 
Synthetic 
 
Anticonvulsant 90 
 
 
 
(73b) 
 
 
(S)-5-(((1-hydroxybutan-
2-yl)amino)methyl)-3-
methoxy-9H-xanthen-9-
one 
 
Synthetic 
 
Anticonvulsant 90 
 
 
(74) 
 
 
5-(((1-hydroxybutan-2-
yl)(methyl)amino)methyl)
-3-methoxy-9H-xanthen-
9-one 
 
Synthetic 
 
Anticonvulsant 90 
 
 
 
(75) 
 
 
2-chloro-7-(((1-
hydroxypropan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
 
Synthetic 
 
Anticonvulsant 90 
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Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
 
(75a) 
 
(R)-2-chloro-7-(((1-
hydroxypropan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
 
Synthetic 
 
Anticonvulsant 90 
 
 
 
(75b) 
 
(S)-2-chloro-7-(((1-
hydroxypropan-2-
yl)amino)methyl)-9H-
xanthen-9-one 
 
Synthetic 
 
Anticonvulsant 90 
 
 
 
2 HCl 
(76) 
 
2-(2-hydroxy-3-
morpholinopropoxy)-9H-
xanthen-9-one 
dihydrochloride 
 
Synthetic 
 
Antiplatelets 
and 
Antimycobacterial 96,99 
 
 
 
HCl 
(77) 
2-(3-(2,6-
dimethylmorpholino)-2-
hydroxypropoxy)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Antiplatelets 
and 
Antimycobacterial 96,99 
 
 
 
 
HCl 
(78) 
 
2-(2-hydroxy-3-(4-
methylpiperazin-1-
yl)propoxy)-9H-xanthen-
9-one hydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antipiletic 
and Antimycobacterial  
84,99 
 
 
 
 
2HCl 
 
(79) 
 
2-(3-(4-benzylpiperazin-
1-yl)-2-hydroxypropoxy)-
9H-xanthen-9-one 
dihydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antipiletic 
and Antimycobacterial 
84,99 
 
 
 
2HCl 
 
(80) 
 
2-(2-hydroxy-3-(4-(2-
hydroxyethyl)piperazin-
1-yl)propoxy)-9H-
xanthen-9-one 
dihydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antipiletic, Antiplatelets 
and Antimycobacterial  
84,96,99 
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Table 24: Chemical structures and biological/pharmacological activities of CDXs (Continuation) 
Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
 
(81) 
 
Ethyl 4-(2-hydroxy-3-((9-
oxo-9H-xanthen-
2yl)oxy)propyl)piperazin
e-1-carboxylate 
 
Synthetic 
 
Anticonvulsant, 
Antipiletic 
and Antimycobacterial  
84,99 
 
 
2HCl 
 
(82) 
 
2-(2-hydroxy-3-((3-
morpholinopropyl)amino)
propoxy)-9H-xanthen-9-
one dihydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antipiletic 
And 
Antiplatelets 84,86,96 
 
 
 
(83) 
 
2-(2-hydroxy-3-(4-
phenylpiperazin-1-
yl)propoxy)-9H-xanthen-
9-one 
 
Synthetic 
 
Anticonvulsant, 
Antipiletic 
and Antimycobacterial 
84,99 
 
 
 
(84) 
 
2-(2-hydroxy-3-
(piperazin-1-yl)propoxy)-
9H-xanthen-9-one 
 
Synthetic 
 
Anticonvulsant, 
Antipiletic 
and Antimycobacterial  
84,99 
 
 
 
HCl 
(85) 
 
6-(2-hydroxy-3-(4-(2-
hydroxyethyl)piperazin-
1-yl)propoxy)-2-methyl-
9H-xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant  86 
 
 
 
(86) 
 
2-(2hydroxy-3-(4-(2-
phenoxyethyl)piperazin-
1-yl)propoxy)-9H-
xanthen-9-one 
dihydrochloride 
 
 
 
Synthetic 
 
 
 
Arrhythmic 
and Antihypertensive  
98 
 
 
 
 
(87) 
 
2-(3-(4-(2-(2,6-
dimethylphenoxy)ethyl)pi
perazin-1-yl)-2-
hydroxypropoxy)-9H-
xanthen-9-one 
dihydrochloride 
 
Synthetic 
 
 
 
Arrhythmic 98 
 
 
 
(88) 
2-(2-hydroxy-3-(4-(4-
methoxyphenethyl)piper
azin-1-yl)propoxy)-9H-
xanthen-9-one 
dihydrochloride 
 
 
Synthetic 
 
 
 
Arrhythmic 98 
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Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
2HCl 
 
(89) 
 
4-(2-hydroxy-3-(4-(2-
phenoxyethyl)piperazin-
1-yl)propoxy)-9H-
xanthen-9-one 
dihydrochloride 
 
Synthetic 
 
 
 
Arrhythmic 
and Antihypertensive 98 
 
 
 
2HCl 
 
(90) 
4-(2-hydroxy-3-(4-(2-(4-
methoxyphenoxy)ethyl)pi
perazin-1-yl)propoxy)-
9H-xanthen-9-one 
dihydrochloride 
 
Synthetic 
 
 
 
Arrhythmic 98 
 
 
 
2HCl 
 
(91) 
 
4-(3-(4-
(benzo[d][1,3]dioxol-5-
ylmethyl)piperazin-1-yl)-
2-hydroxypropoxy)-9H-
xanthen-9-one 
dihydrochloride 
 
Synthetic 
 
 
 
Arrhythmic 98 
 
 
 
2HCl 
 
(92) 
 
6-(2-hydroxy-3-(4-
(pyridin-2-yl)piperazin-1-
yl)propoxy)-2-methyl-9H-
xanthen-9-one 
dihydrochloride 
 
Synthetic 
 
 
 
Arrhythmic 98 
 
 
 
2HCl 
 
(93) 
 
4-(2-hydroxy-3-(4-(2-
hydroxyethyl)piperazin-
1-yl)propoxy)-9H-
xanthen-9-one 
dihydrochloride 
 
Synthetic 
 
 
Antiarrhythmic, and 
Antihypertensive 
41 
 
 
HCl 
(94) 
 
Ethyl 4-(2-hydroxy-3-((9-
oxo-9H-xanthen-4-
yl)oxy)propyl)piperazine-
1-carboxylate 
hydrochloride 
 
Synthetic 
 
 
Antiarrhythmic and 
Antihypertensive 
41 
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Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
2HCl 
 
(95) 
 
4-(3-(4-benzylpiperazin-
1-yl)-2-hydroxypropoxy)-
9H-xanthen-9-one 
dihydrochloride 
 
Synthetic 
 
 
Anticonvulsant, 
Antiarrhythmic and 
Antihypertensive 
41 
 
 
 
(96) 
 
4-(2-hydroxy-3-(4-(3-
methoxyphenyl)piperazin
-1-yl)propoxy)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
 
Antiarrhythmic and 
Antihypertensive 
100 
 
 
 
(97) 
 
1-(4-(3-
methoxyphenyl)piperazin
-1-yl)-3-((9-oxo-9H-
xanthen-4-
yl)oxy)propan-2-yl 
acetate hydrochloride 
 
Synthetic 
 
 
Antiarrhythmic and 
Antihypertensive 
100 
 
 
 
(98) 
 
 
4-(2-hydroxy-3-(4-
styrylpiperazin-1-
yl)propoxy)-9H-xanthen-
9-one dihydrochloride 
 
Synthetic 
 
 
Antiarrhythmic and 
Antihypertensive 
100 
 
 
 
 
(99) 
 
 
3-chloro-5-(2-hydroxy-3-
(4-styrylpiperazin-1-
yl)propoxy)-9H-xanthen-
9-one dihydrochloride 
 
Synthetic 
 
 
Antiarrhythmic and 
Antihypertensive 
100 
 
 
 
 
 
 
(100) 
 
3-chloro-5-(2-hydroxy-3-
(4-
(phenoxymethyl)piperazi
n-1-yl)propoxy)-9H-
xanthen-9-one 
dihydrochloride 
 
Synthetic 
 
 
Antiarrhythmic and 
Antihypertensive 
100 
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Structure Name Origin 
Biological/ 
pharmacological 
activity 
 
 
(101) 
 
3-chloro-5-(2-hydroxy-3-
(4-phenylpiperazin-1-
yl)propoxy)-9H-xanthen-
9-one dihydrochloride 
 
Synthetic 
 
 
Antiarrhythmic and 
Antihypertensive 
100 
 
 
 
 
(102) 
 
2-(3-(allylamino)-2-
hydroxypropoxy)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antiarrhythmic, 
Antihypertensive  and 
Antifungal 87,88 
 
 
 
 
(103) 
 
 
3-(3-(allylamino)-2-
hydroxypropoxy)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antiarrhythmic and 
Antihypertensive 88 
 
 
 
 
(104) 
 
4-(3-(allylamino)-2-
hydroxypropoxy)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antiarrhythmic and 
Antihypertensive 88 
 
 
 
HCl 
(105) 
 
4-(3-((1,3-Dihydroxy-2-
methylpropan-2-
yl)amino)-2-
hydroxypropoxy)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antiarrhythmic and 
Antihypertensive 88 
 
 
 
(106) 
 
3-Chloro-5-(2-hydroxy-3-
((1-hydroxy-2-
methylpropan-2-
yl)amino)propoxy)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antiarrhythmic and 
Antihypertensive 88 
 
 
 
 
(107) 
 
3-Chloro-5-(3-((1,3-
dihydroxy-2-
methylpropan-2-
yl)amino)-2-
hydroxypropoxy)-9H-
xanthen-9-one 
hydrochloride 
 
Synthetic 
 
Anticonvulsant, 
Antiarrhythmic and 
Antihypertensive 
88 
(a)–(R)-enantiomer;  (b)–(S)-enantiomer; (c)–(R,S)-enantiomer;  (d)–(S,R)- enantiomer. 
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Table 25: Structures of carboxyxanthones derivatives and chiral derivatives of xanthones 
 
Structure Name Code 
 
 
 
 
6-methoxy-9-oxo-9H-
xanthene-2-carboxylic 
acid 
XCar – 2 
(108) 
 
 
 
 
8-methoxy-9-oxo-9H-
xanthene-2-carboxylic 
acid 
XCar-3 
(109) 
 
 
 
 
5,7-dimethyl-9-oxo-9H-
xanthene-2-carboxylic 
acid 
XCar- 5 
(110) 
 
 
 
(S)-6-methoxy-2-(3-(3-
methoxyphenyl)butanoyl
)-9H-xanthen-9-one 
(S)-XEA-3-MET 
(137) 
 
 
 
(R)-6-methoxy-2-(3-(3-
methoxyphenyl)butanoyl
)-9H-xanthen-9-one 
(R)-XEA-3-MET 
(138) 
 
 
 
(S)-6-methoxy-2-(3-(4-
methoxyphenyl)butanoyl
)-9H-xanthen-9-one 
(S)-XEA-4-MET 
(139) 
 
 
 
 
(R)-6-methoxy-2-(3-(4-
methoxyphenyl)butanoyl
)-9H-xanthen-9-one 
(R)-XEA-4-MET 
(140) 
 
 
 
 
 
(S)-2-(3-(4-
chlorophenyl)butanoyl)-
6-methoxy-9H-xanthen-
9-one 
 
(S)-XEA-4-CLO 
(141) 
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(R)-2-(3-(4-
chlorophenyl)butanoyl)-
6-methoxy-9H-xanthen-
9-one 
(R)-XEA-4-CLO 
(142) 
 
 
 
(S)-2-(3-(4-
fluorophenyl)butanoyl)-6-
methoxy-9H-xanthen-9-
one 
(S)-XEA-4-FLU 
(143) 
 
 
 
(R)-2-(3-(4-
fluorophenyl)butanoyl)-6-
methoxy-9H-xanthen-9-
one 
(R)-XEA-4-FLU 
(144) 
 
 
(S)-N-(1-(3-
methoxyphenyl)ethyl)-
5,7-dimethyl-9-oxo-9H-
xanthene-2-carboxamide 
(S)-XEA5-3-MET 
(145) 
 
 
(R)-N-(1-(3-
methoxyphenyl)ethyl)-
5,7-dimethyl-9-oxo-9H-
xanthene-2-carboxamide 
(R)-XEA5-3-MET 
(146) 
 
 
(S)-N-(1-(4-
methoxyphenyl)ethyl)-
5,7-dimethyl-9-oxo-9H-
xanthene-2-carboxamide 
(S)-XEA5-4-MET 
(147) 
 
 
(R)-N-(1-(4-
methoxyphenyl)ethyl)-
5,7-dimethyl-9-oxo-9H-
xanthene-2-carboxamide 
(R)-XEA5-4-MET 
(148) 
 
 
(S)-N-(1-(4-
chlorophenyl)ethyl)-5,7-
dimethyl-9-oxo-9H-
xanthene-2-carboxamide 
(S)-XEA5-4-CLO 
(149) 
 
 
 
 
(R)-N-(1-(4-
chlorophenyl)ethyl)-5,7-
dimethyl-9-oxo-9H-
xanthene-2-carboxamide 
(R)-XEA5-4-CLO 
(150) 
 
 
 
(S)-N-(1-(4-
fluorophenyl)ethyl)-5,7-
dimethyl-9-oxo-9H-
xanthene-2-carboxamide 
(S)-XEA5-4-FLU 
(151) 
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(R)-N-(1-(4-
fluorophenyl)ethyl)-5,7-
dimethyl-9-oxo-9H-
xanthene-2-carboxamide 
(R)-XEA5-4-FLU 
(152) 
 
 
 
 
(S)-5,7-dimethyl-9-oxo-
N-(1-(p-tolyl)ethyl)-9H-
xanthene-2-carboxamide 
(S)-XEA5 (153) 
 
 
 
 
(R)-5,7-dimethyl-9-oxo-
N-(1-(p-tolyl)ethyl)-9H-
xanthene-2-carboxamide 
(R)-XEA5 (154) 
 
 
 
 
(S)-5,7-dimethyl-9-oxo-
N-(1-phenylethyl)-9H-
xanthene-2-carboxamide 
(S)-XEA5-DES 
(155) 
 
 
 
(R)-5,7-dimethyl-9-oxo-
N-(1-phenylethyl)-9H-
xanthene-2-carboxamide 
(R)-XEA5-DES 
(156) 
 
 
 
 
N-((1S,2S)-2-hydroxy-
1,2-diphenylethyl)-5,7-
dimethyl-9-oxo-9H-
xanthene-2-carboxamide 
(S,S)-X2ADF5 
(157) 
 
 
N-((1R,2R)-2-hydroxy-
1,2-diphenylethyl)-5,7-
dimethyl-9-oxo-9H-
xanthene-2-carboxamide 
(R,R)-X2ADF5 
(158) 
 
 
N-((1S,2R)-2-hydroxy-
1,2-diphenylethyl)-5,7-
dimethyl-9-oxo-9H-
xanthene-2-carboxamide 
(S,R)-X2ADF5 
(159) 
170 
 
 
 
 
N-((1R,2S)-2-hydroxy-
1,2-diphenylethyl)-5,7-
dimethyl-9-oxo-9H-
xanthene-2-carboxamide 
(R,S)-X2ADF5 
(160) 
 
 
 
 
 
 
 
 
 
 
 
 
 
